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Thesis Abstract 
The TRPV4 channel is a member of the Transient Receptor Potential family of ion channels 
and is known to be expressed on airway smooth muscle, macrophages and epithelial cells 
within the lung. Whilst it has been reported that TRPV4 is present on sensory nerves, its role 
in modulating the function of airway sensory nerves and the cough reflex remains unexplored. 
The aim of this thesis was therefore to determine a role for TRPV4 in sensory nerve activity 
and the cough reflex. 
Using an in vitro model of vagal sensory nerve activation and an in vivo guinea pig cough 
model, it was established that activation of TRPV4 by selective ligands activates airway 
sensory nerves and cause cough. Calcium imaging of isolated neurons and airway single fibre 
recordings determined that this was through activation of a different population of nerve fibres 
than those activated by TRPV1 and TRPA1 ligands, which are both known to activate sensory 
nerves and cause cough.   
Calcium flux and fibre firing demonstrated a delay prior to activation by a TRPV4 agonist, 
suggesting an indirect mechanism of action.  Activation of TRPV4 has been linked to ATP 
release in several cell types, and therefore it was hypothesised that activation of TRPV4 on 
the nerves leads to ATP release and subsequently activation of airway sensory nerves.  The 
purine receptor P2X3, which is activated by ATP, is expressed on airway sensory nerves, and 
a selective P2X1/3 agonist caused depolarisation of the vagus nerve and firing of Aδ single 
fibres in vivo. Further, TRPV4 induced activation of sensory nerves in vitro and cough in vivo 
was inhibited following the administration of a selective P2X3 antagonist.  
This data would suggest that the activation of airway sensory nerves by TRPV4 ligands causes 
ATP release which then activates P2X3 possibly present on the same subset of sensory 
nerves, to cause cough. The work within my thesis has therefore uncovered TRPV4 as a 
modulator of airway sensory nerves and associated functions such as cough, which exerts its 
actions via a novel mechanism of action and as such is a good candidate for possible anti-
tussive therapies. 
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1.1: Cough  
Cough is a troublesome symptom, and is the most common reason for patients to visit a doctor 
in the UK (Schappert and Burt, 2006; Schappert and Rechtsteiner, 2011).  Under normal 
circumstances, cough is a vital defensive reflex; protecting the airways from inhalation of 
foreign materials and harmful substances and also aids in immune defence (Irwin et al., 1998; 
Fontana et al., 1999; Widdicombe, 1995).  However, in certain conditions which can occur in 
disease, the cough response can become excessive which can dramatically impact quality of 
life of sufferers.  Despite this, there are currently no safe and effective treatments for cough.   
Cough is a reflex response driven by sensory nerve fibres housed within the vagus nerve, 
which are tailored to detect changes in the physical and chemical environment (Brouns et al., 
2012). These fibres express a number of ion channels which detect and respond to a diverse 
range of stimuli, a number of which have been implicated in the cough response and can be 
activated by a number of exogenous and endogenous mediators. There is a large body of 
data outlining the role of the Transient Receptor Potential (TRP) family of ion channels in the 
cough reflex, where activation of two channels; TRPA1 and TRPV1 have been shown to cause 
cough in both animals and man (Wortley et al., 2014; Andrè et al., 2009; Birrell et al., 2009; 
Grace et al., 2012). Furthermore, an antagonist of the ionotropic purinoceptor P2X3 has been 
shown to inhibit the objective cough frequency in patients suffering from treatment resistant 
chronic cough (Abdulqawi et al., 2014). Further investigation into the mechanism of action of 
ion channels present on the afferent arm of the cough reflex may help to increase our 
understanding of the cough reflex, and uncover potential novel therapeutics.  
1.1.1: Physiology of the cough reflex 
The cough reflex is a forced event used to clear the larynx, trachea and large bronchi from 
foreign material and secretions and prevent asphyxiation (Chung and Pavord, 2008). 
Physiologically, cough can be separated into three phases, beginning with a rapid deep 
inspiration, followed by a compressive phase where the intrathoracic pressure builds up 
following closure of the glottis.  The reflex ends with an expiratory phase; a rapid expulsion of 
air, which can reach 500mph (Bianco et al., 1988), and the lungs and airways are cleared of 
irritant materials. This release of air results in a characteristic cough sound that all are familiar 
with (Smith, 2010). Cough itself can occur singly, or in bouts where repetitive coughs occur in 
succession (Nasra and Belvisi, 2009).  
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1.1.2: Prevalence of cough 
A persistent cough is currently the most common reason for patients to visit a doctor in the UK 
(Schappert and Burt, 2006; Schappert and Rechtsteiner, 2011). The clinical aetiology of cough 
can be defined as either acute (under 3 weeks in duration (Irwin et al., 1998)), or chronic (over 
8 weeks in duration). Acute cough occurs mainly as a result of viral or bacterial respiratory 
tract infections (Curley et al., 1988; Irwin et al., 1998) or viral infections (common cold) (Irwin 
et al., 1990) and often resolves itself a few weeks following treatment and clearance of the 
infection (Irwin, 2006). Chronic cough is a common symptom of the inflammatory diseases 
asthma and Chronic Obstructive Pulmonary Disease (COPD) (Fuller and Choudry, 1987; Irwin 
et al., 1998; Morice et al., 2007), where presenting with chronic cough often is a key feature 
leading to diagnosis of both diseases (McGarvey et al., 2008, Vestbo et al., 2013). Chronic 
cough can also arise in pulmonary fibrosis (Irwin et al., 1998), Post Nasal Drip (PND), Gastro-
Esophageal Reflux Disease (GERD), as a side effect of medications such as ACE inhibitors 
(Sesoko and Kaneko, 1985; Lalloo et al., 1996; Fahim et al., 2011; Faruqi et al., 2014), or it 
can also be idiopathic in origin. Idiopathic chronic cough can be triggered by normally 
innocuous stimuli and lead to unproductive bouts of coughing, which are not consciously 
suppressed (Pratter, 2006). Epidemiological studies have revealed that chronic cough can 
affect up to 40% of the population at any one time (Cullinan, 1992; Janson et al., 2001; Morice 
et al., 2001).  This disease can affect patients for months or years at a time ultimately impacting 
on their quality of life (French, 1998). Long term excessive coughing can lead to excessive 
sweating, cough syncope, sleep disturbance, nausea and urinary incontinence (Irwin and 
Curley, 1991; French, 1998; French et al., 2002). In addition, chronic cough can also have a 
negative impact on social relationships with friends and family (Brignall et al., 2008), and many 
patients suffer from high levels of anxiety and depression (McGarvey and Morice, 2006). 
Despite this, success rates of treating chronic cough have been reported to be as low as 58% 
(Haque et al., 2005).   
1.2. Causes of Chronic Cough 
1.2.1: Asthma 
Asthma is a chronic inflammatory disease of the airways characterised by bronchoconstriction, 
which is mostly reversible, airway hyperresponsiveness (AHR) and symptoms such as 
dyspnoea, chest tightness, wheezing and cough (Lemanske and Busse, 2003). The World 
Health Organisation (WHO) has estimated that over 300 million people worldwide suffer from 
asthma, and the prevalence and mortality are increasing (Lemanske and Busse, 2003; 
Bateman et al., 2008). Asthma is often associated with allergy, when an individual is exposed 
to an allergen, this leads to the production of allergen specific Immunoglobulin E (IgE). When 
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the individual is re-exposed to the allergen, this produces an asthmatic response, which leads 
to bronchoconstriction, AHR and an inflammatory response involving Th2 cells, eosinophils, 
mast cells and CD4+ cells (Barnes, 2008).  
Almost all asthmatic patients present with cough as a symptom (Niimi, 2011), and the 
symptom of cough is key in the management and diagnosis of asthma (Global Strategy for 
Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007). In addition, 
some asthmatic patients suffer from cough variant asthma (CVA) (Corrao et al., 1979). Here, 
patients present with cough as the predominant symptom, and classical symptoms of asthma 
such as wheeze, chest tightness and apnoea may be absent (Morice, 2004). Patients are 
often treated successfully with asthma therapeutics (Dicpinigaitis, 2006). Cough as a symptom 
was reported to have the greatest impact on the quality of life of patients, worse than both 
wheeze and sleep disturbance (Osman et al., 2001). Furthermore, a 9 year study indicated 
that the worsening of cough has been shown to have the highest predictive weight for a poor 
outcome in asthma (de Marco et al., 2006). The cough rate of asthmatics has been shown to 
be significantly greater than for healthy volunteers (Smith, 2010). 
Asthma is associated with eosinophilic inflammation, which is demonstrated by increased 
levels in the sputum and from airway biopsies (Smith, 2010). In the majority of cases, cough 
responds well to anti-inflammatory agents (Dicpinigaitis, 2006) which reduce eosinophilic 
counts, suggesting that this eosinophilic inflammation may help to promote the increased 
cough response seen in asthma, and could affect airway sensory nerves which drive the cough 
response (Smith, 2010). Furthermore, there are also increased amounts of Prostaglandin E2 
(PGE2) (Chaudhuri et al., 2004) and bradykinin (Abe et al., 1967) in the airways of asthmatic 
patients, which alongside adding to the inflammatory response, have also been shown to 
cause a tussive response themselves in both animals and humans (Choudry et al., 1989; 
Maher et al., 2009; Grace et al., 2012).  ATP, which is released during inflammation 
(Adriaensen et al., 2004), has also been shown to be increased in the BAL of mice following 
allergen challenge compared to saline controls (Idzko et al., 2007), and asthmatics have been 
shown to experience bronchoconstriction, cough and dyspnea following aerosolised ATP 
challenge (Basoglu et al., 2005). Anti-inflammatory agents have been shown to successfully 
treat cough in CVA (Pavord, 2004) and the majority of chronic cough in asthmatics, suggesting 
that there is potentially a causative effect between inflammation and chronic cough in asthma.  
1.2.2: COPD 
COPD is associated with chronic airway inflammation and encompasses a number of 
pathologies including chronic bronchitis, bronchiolitis and emphysema (Bateman et al., 2008). 
This disease is a global health problem and it is estimated that it will be the third leading cause 
1. Introduction 
 
19 
 
of death worldwide by 2020 (Vestbo et al., 2013). COPD is characterised by airflow limitation, 
which is both progressive and not fully reversible and persistent inflammation which can lead 
to functional changes in the airways from repeated tissue injury and repair (Di Stefano et al., 
2009). The chronic airflow limitation in COPD can be caused by a number of factors including 
small airways disease caused by obstructive bronchiolitis and emphysema, along with 
parenchymal destruction. Chronic inflammation can also lead to the narrowing of the small 
airways (Vestbo et al., 2013). The key risk factor for the development of COPD is cigarette 
smoking (Sethi and Rochester, 2000), where chronic cigarette smoke exposure leads to a 
positive feedback loop of inflammation (Barnes, 2008).  The Lung Health Survey showed that 
patients with COPD exhibiting chronic cough had a greater number of pack years smoking, a 
worse lung function and are more likely to be current smokers (Kanner et al., 1999), Despite 
this, stopping smoking reduced the prevalence of chronic cough by over 80% after 5 years 
(Kanner et al., 1999). 
Chronic cough is one of the first complaints that patients with COPD present with and it is the 
key to diagnosis (Vestbo et al., 2013). A survey uncovered that cough was experienced by 
70% of COPD sufferers, and was reported to occur on a daily basis in 40% (Rennard et al., 
2002). Similarly to asthma, a defining feature of COPD is lung inflammation characterised by 
macrophages, neutrophils and CD8+ T-lymphocytes (Keatings et al., 1996; Keatings et al., 
1997). Unlike asthma, the abnormal inflammation seen is resistant to anti-inflammatory agents 
such as glucocorticoids (Barnes, 2013).  
COPD is associated with substantial airway inflammation; the bronchoalveolar lavage fluid 
(BALF), sputum and exhaled breath condensates of patients show an increase in inflammatory 
mediators and cellular components of inflammatory disease (Bhowmik et al., 2000; Gompertz 
et al., 2001; Biernacki et al., 2003; Montuschi et al., 2003), and this may help to contribute to 
the enhanced cough response seen. Furthermore, similarly to asthma, some mediators such 
as prostaglandins are known to cause cough themselves (Choudry et al., 1989; Maher et al., 
2009), and others, such as tachykinins, are indirectly involved in the cough response (Joos et 
al., 2003). ATP levels have also been shown to be increased in COPD (Mohnesin et al., 2006; 
Mortaz et al., 2010) and a recent study has indicated that ATP induced more dyspnea, cough 
and throat irritation in patients with COPD following aerosolised ATP (Basoglu et al., 2015). 
Chronic cough in COPD can also occur due to the mechanical stimulation of excessive mucus 
production, where an accumulation of mucus is associated with disease progression (Hogg et 
al., 2004), and epidemiological studies have shown that chronic cough and mucus secretion 
lead to a decline in lung function (Løkke et al., 2006).  
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Although normal clinical practice would be to target the underlying cause of chronic cough 
(Irwin et al., 2006), in the case of COPD, unlike asthma, this is not possible as the disease is 
progressive and anti-inflammatory agents do not show any efficacy, and therefore specific 
targeted treatments may show greater efficacy in treatment of chronic cough in COPD. 
1.2.3: Unexplained Chronic Cough 
Unexplained, or idiopathic, chronic cough, is the diagnosis given to patients who present with 
chronic cough with no known underlying disease cause (McGarvey et al., 2013). Initial 
diagnosis of chronic cough involves systematic evaluation to outline a suspected underlying 
cause, after which most can be identified (Irwin et al., 1990; Morice, 2004, Morice et al., 2006; 
Shields et al., 2008). However when no underlying cause is found, and the cough response is 
unresponsive to treatment, cough is defined as idiopathic, or unexplained and this can account 
for 18-42% of patients in specialist cough clinics (Polley et al., 2008, Haque et al., 2005). 
Clinical examination, chest radiography and spirometry of these patients is normal (Birring, 
2011), and this condition is found predominantly in female patients (up to 80% in some cases) 
where cough begins around the menopause, suggesting a hormonal link (Birring et al., 2003; 
Mund et al., 2005).  
Although the underlying cause is unknown, chronic cough has been associated with airway 
inflammation, where increased levels of cysteinyl leukotrienes, histamine, PGE2 and 
Prostaglandin D2 (PGD2) are found in the airways of patients with chronic cough compared to 
healthy controls (Birring et al., 2004). Furthermore, an increased number of mast cells have 
been found in the BALF (McGarvey et al., 1999). Chronic dry coughing has also been linked 
with hypothyroidism in post-menopausal women, as idiopathic coughers were shown to have 
mild chronic lymphocytic airway inflammation which was associated with organ specific auto-
immune disease (Birring et al., 2003), and a subset of post-menopausal women have also 
been shown to have elevated CD4+ lymphocytes (Mund et al., 2005). However, treatment of 
unexplained chronic cough with traditional anti-inflammatories has been shown to be 
unsuccessful, indicating that there are further mechanisms underlying this condition.  
Similar to chronic cough associated with asthma and COPD, chronic coughers show an 
elevated response to capsaicin cough challenge (Sumner et al., 2013; Ternesten-Hasséus et 
al., 2013). It has therefore been proposed that chronic coughers experience airway sensory 
hyperreactivity syndrome (Chung, 2011; Millqvist, 2011) due to patients experiencing a lower 
threshold to common tussive stimuli with no known underlying cause. The mechanisms 
underlying this hypersensitivity of the cough reflex are currently unknown (Pratter, 2006; 
Chung, 2011; Millqvist, 2011).  
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1.2.4: Current therapies 
Other than medications that aim to treat the underlying cause of chronic cough, there is a lack 
of successful, specific targeted therapies for cough. In the UK, over £100 million a year is 
spent on antitussive therapies (Dicpinigaitis, 2011) and in the USA, this figure is $3 billion 
(Footitt and Johnston, 2009). Antitussive medications account for large number of over the 
counter medications (OTCs) taken and in the USA, a survey taken revealed that over half of 
all preschool children had been given OTCs, and 67% of these comprised of antitussive 
medications (Kogan et al., 1994). This is despite the fact that a recent systematic review of 
over 2100 participants failed to support the efficacy of OTCs for the treatment of cough 
(Schroeder and Fahey, 2002), and a study has revealed that cough syrup has no 
pharmacological effect and instead acts as a lubricant to coat the throat (Eccles, 2006). 
Recently the American College of Chest Physicians (ACCP) has begun to advise against the 
use of antitussives with children suffering from an URTI (Bolser, 2006). In addition some 
children’s antitussive medications have been withdrawn from public use because of the lack 
of therapeutic potential and also the emergence of some life threatening side effects in children 
under 2 (Centers for Disease Control and Prevention, 2007; Vassilev et al., 2009).  
Currently, the only cough therapeutics that show any efficacy are those which act via the 
Central Nervous System (CNS) such as opiates.  A clinical study in patients with chronic cough 
revealed that morphine sulphate was efficacious in treating patients who did not respond to 
other antitussive medications (Morice et al., 2007).  Codeine is currently the reference 
antitussive of choice, despite a study indicating that codeine was no more effective in treating 
cough in patients with COPD than placebo (Smith et al., 2006). Furthermore, opiates have 
wide ranging, potentially dangerous side effects such as respiratory depression, sedation and 
gastro-intestinal problems (Belvisi and Geppetti, 2004), revealing an urgent need for new, safe 
and effective medications for chronic cough. Peripherally acting drugs, which target the 
afferent arm of the airway sensory nerve pathway and receptors and ion channels present on 
the vagus nerve could show greater specificity and efficacy. These could act through reducing 
the efficacy of synaptic transmission, or by inhibiting action potential frequency which may 
show improved therapeutic potential with fewer side effects (Canning and Mori, 2011).  
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1.3. The Cough Reflex and Airway Sensory Nerves 
Sensory nerves within the airways detect changes in the physical and chemical environment 
and relay pulmonary sensory information to the CNS, which leads to reflex responses such as 
cough (Belvisi, 2002; Brouns et al., 2012). Regardless of cause, animal studies have revealed 
that cough is initiated following activation of afferent fibres in the vagus nerve (Cranial nerve 
X) (Canning et al., 2006b), which innervates other midline organs and tissues along with the 
airways (Standring, 2005). Vagal afferents have termini in and under the airway epithelium, 
and have cell bodies in the jugular and nodose ganglia, which project peripherally to the 
airways and centrally to the Nucleus Tractus Solitarius (NTS) in the brainstem (Belvisi, 2002). 
The jugular and nodose ganglia have different embryological origins; the jugular is neural crest 
derived and the nodose is epibranchial placode derived (Nasra and Belvisi, 2009), and as a 
result house different populations of nerve fibres. The cell bodies of the vagus then branch 
into the superior laryngeal nerve (SLN) and recurrent laryngeal nerves (RLN) which carry 
airway fibres to the trachea and bronchi (Belvisi, 2003; Canning, 2004).  
The cough reflex is a neural circuit, which connects the periphery to the CNS. It differs to other 
respiratory and airway reflexes as it occurs in a discontinuous, threshold dependent manner 
(Canning and Mori, 2011). There are three phases to the cough reflex; the first involves the 
initiation of the reflex through activation of sensory nerves, the second occurs in the CNS 
where the reflex is processed and involves a complex neuronal network and thirdly, efferent 
motor neurons are stimulated leading to cough (Pacheco, 2014) (Figure 1.1). 
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Figure 1.1: The cough reflex 
1: An exogenous (e.g. cigarette smoke) or endogenous (e.g. PGE2) stimulus activates receptors on 
vagal sensory nerve endings located in and under the epithelium.  If this stimulus reaches a certain 
threshold, then an action potential is produced which is carried up the vagus nerve to the CNS. 
2: The vagus nerve synapses with 2nd order interneurons within the Nucleus Tractus Solitarius (NTS) 
in the brainstem and the reflex is processed. 
3: The signal is relayed via efferent motor neurons to the diaphragm, respiratory muscles and larynx to 
cause cough.   
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Mechanical disturbance, inflammatory mediators, environmental stimuli, changes in pH, 
osmolarity, chemicals, and temperature can all activate airway sensory nerves and cause 
cough through activation of receptors present on the cell surface (Lowry et al., 1988; 
McGarvey et al., 1998; Wong et al., 1999; Undem, 2004; Koskela et al., 2005; Canning et al., 
2006a; Maher et al., 2009; Belvisi et al., 2011; Grace et al., 2012). Activation of a receptor by 
a stimulus causes a change in ionic conductance across the membrane, depolarising the cell 
membrane. This initial depolarisation is known as a generator potential. This generator 
potential then has to reach a sufficient magnitude before an action potential can be produced 
(Brouns et al., 2012). An action potential involves a rapid change in membrane potential which 
is propagated without decrement along the length of the cell and is triggered when the 
depolarisation is sufficient enough for the membrane potential to reach a critical value. The 
critical threshold of an action potential is dependent upon the gating potential of voltage gated 
sodium channels (VGSCs), which when opened trigger an influx of Na+. The normal resting 
potential of a membrane is -70mV, however following an influx of Na+ ions after the generator 
potential has reached a threshold value, the membrane becomes less negative and 
depolarises, which generates an action potential. This wave of depolarisation can then be 
propagated along the nerve fibre as action potentials to neuronal terminals within the CNS.  
Once opened, the VGSCs become inactivated at a depolarised potential, which prevents 
further depolarisation of the cell membrane. Voltage gated potassium channels (VGKCs) then 
open, causing an efflux of positive K+ ions, and repolarisation of the membrane (Figure 1.2). 
The magnitude of an action potential is fixed and remains the same size and shape as it is 
propagated along the axon. Cough requires a sustained high frequency activation of afferent 
nerves for initiation (Canning and Mori, 2011), which leads to an urge to cough sensation 
preceding the reflex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
The mechanisms by which the afferent signals are processed in the CNS and cause cough 
are complex and not fully understood (Fong et al., 2004). Anatomical and functional studies 
have revealed that the vagal afferents synapse on 2nd order interneurons in the NTS in the 
dorsomedial region of the medulla (Mazzone and Canning, 2002; Kubin et al., 2006). 
Furthermore, it is thought that the region of CNS involved in processing the reflex is likely to 
be linked to the respiratory centre as a change in breathing pattern is an integral part of the 
cough response (Karlsson and Fuller, 1999). The major neurotransmitter involved in the cough 
reflex is likely to be glutamate as physiological and pharmacological investigations have 
revealed that N-methyl-D-aspartate (NMDA) glutamate receptors play a role in the central 
synapses of vagal nerves (Mutolo et al., 2007, 2010; Canning, 2009, 2011).  
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However interestingly, the cough reflex is under some level of conscious control, as coughs 
can be produced without stimulation, the cough reflex can be consciously enhanced, and 
cough can also be supressed under certain circumstances (Canning and Mori, 2011).  
Finally, the signal is sent via respiratory bulbospinal pre-motor neurons (I-Aug and E-Aug) to 
inspiratory and expiratory laryngeal motor neurons which cause a large contraction of the 
abdominal muscles and larynx which expels air and causes the characteristic cough sound 
(Bongianni et al., 1998; Haji et al., 2008).    
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Figure 1.2: The Action Potential 
1. The nerve cell is at a resting state, maintained by sodium and potassium pumps.  A stimulus 
may be added to the cell but it has yet to reach the threshold potential  
2. Threshold potential has been reached and VGSCs open leading to an influx of Na+ ions into 
the cell, causing rapid depolarisation of the cell. At this point the cell is unable to fire another 
action potential regardless of how strong the stimulus. This stage is known as the absolute 
refractory period. 
3. Action potential peak is reached and the VGSCs begin to inactivate, and the delayed rectifier 
VGKCs activate. 
4. Activation of VGKCs causes a movement of K+ out of the cell, causing rapid repolarisation of 
the cell. During this latter part of the action potential the cell is now capable of firing a second 
action potential, however a stronger than normal stimulus is required.  This is known as the 
relative refractory period.  
5. Closure of the VGKC is also delayed, causing hyperpolarisation of the cell. 
6. The cell returns to resting potential. 
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1.3.1: Sensory nerves subtypes and cough 
Sensory nerves can be activated by a wide variety of stimuli, and can broadly be categorised 
into mechanoreceptors which respond to mechanical forces in the lung including those caused 
by inflation and deflation during respiration, and chemoreceptors which respond to both 
exogenous chemicals and inflammatory mediators which may potentially pose a threat of 
tissue damage (Brouns et al., 2012). According to current understanding, there are five 
different subtypes of sensory nerve receptor within the airways; three of which are 
mechanically sensitive (and are all Aδ-fibres, as in transmit action potentials in the Aδ range); 
the rapidly adapting stretch receptors (RARs), slowly adapting stretch receptors (SARs) and 
the cough receptors, and two which are more chemically sensitive; C-fibres (which are further 
sub-divided into pulmonary and bronchial and/or jugular and nodose derived fibres) and Aδ 
nociceptors (Figure 1.3). These fibres can be characterised according to a large number of 
properties including adaptation indices, physiochemical sensitivity, neurochemistry, origin, 
myelination, sites of termination and conduction velocities (CVs) (Canning et al., 2006b). The 
properties of these fibre types have been discerned using studies in animals, and translational 
studies are yet to be undertaken in human tissue, therefore findings should be interpreted with 
some caution.   
Rapidly Adapting Receptors (RARs) 
RARs, which are also known as classical RARs, irritant receptors and Aδ-fibres (Adcock et 
al., 2014; Adcock et al., 2003), are so named because they adapt rapidly (cease action 
potential propagation) to a maintained mechanical stimulus (Sant’Ambrogio and Widdicombe, 
2001). These fast conducting, myelinated fibres occur throughout the respiratory tract from 
the nose to bronchi, but are mostly found in the larger airways where are thought to play a 
defensive role and respond to stimuli such as lung hyperinflation/deflation and light touch 
alongside citric acid (Mortola et al., 1975; Sant’Ambrogio et al., 1978; Adcock et al., 2003; 
Canning et al., 2006a; Ricco et al., 1996; Sant’Ambrogio and Widdicombe, 2001).  RARs 
conduct action potentials in the Aδ range, with conduction velocities of over 3m/s (Canning et 
al., 2006b). The cell bodies of RARs are thought to be mostly housed in the nodose ganglia, 
(Ricco et al., 1996; Canning et al., 2006b) and the receptors are not thought to be directly 
activated by chemical stimuli such as bradykinin and capsaicin, although these stimuli can 
indirectly activate these fibres following mucus production and bronchoconstriction 
(Widdicombe, 2003). However, recent work has suggested that a subset of RAR Aδ fibres 
respond to capsaicin regardless of conduction velocity (Adcock et al., 2014).  RARs are 
capable of causing a cough response even under anaesthesia, and therefore thought to 
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provide the defensive cough reflex which clears lungs of harmful particles (Nasra and Belvisi, 
2009; Dicpinigaitis et al., 2014).   
Slowly Adapting Receptors (SARs) 
SARs are also fast conducting, nodose derived myelinated fibres, conducting action potentials 
at approximately 18m/s (Canning et al., 2006a), but in comparison to RARs they adapt more 
slowly to a maintained stimulus. They are also less sensitive than RARs to sustained lung 
inflation (Schelegle and Green, 2001). Termini are found in and within the smooth muscle of 
the airways (Bartlett et al., 1976), and the receptors are involved in tidal breathing. SARs are 
especially important in the Hering Breur reflex, a stretch reflex stimulated by vagal fibres that 
when stimulated causes the cessation of inspiration and the start of expiration (Schelegle, 
2003). SARs are not thought to play a direct effect in the cough response. 
Cough Receptors 
The ‘cough receptor’ was first described by Canning and colleagues in 2004 as a fibre type 
similar to RARs in that it is derived from the nodose, and found in the larynx, trachea and 
bronchi. Additionally, these receptors respond to acid, pH and low threshold mechanical 
stimulation including punctate light touch, and are unresponsive to capsaicin, bradykinin and 
hypertonic saline (Canning, 2004; Mazzone, 2004). However, the cough receptors are more 
slowly conducting than RARs (transmit action potentials at ~5m/s) and are insensitive to 
stretch, pressure and bronchoconstriction which do activate RARs (Canning, 2004; Mazzone, 
2004). However, as all research into this fibre has been carried out in animals, the relevance 
of this fibre type to the human cough response is yet to be determined (Canning, 2004; 
Mazzone, 2004; Nasra and Belvisi, 2009). Much of the characterisation of the Aδ-fibres has 
been carried out in vitro. 
Aδ nociceptors                                  
Aδ nociceptors are fast conducting myelinated fibres which conduct action potentials ~4-6m/s 
with termini in the intra and extrapulmonary airways (Canning et al., 2006a).  They differ from 
RARs as they are less responsive to mechanical stimulation, originate in the jugular ganglia 
and express TRPV1, and so as a result they are responsive to capsaicin and PGE2 (Riccio et 
al., 1996; Kajekar et al., 1999; Yu, 2005). Although these fibres are similar pharmacologically 
to C-fibres, their effect on cough has not yet been fully elucidated.  
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C-fibres 
C-fibres are slower conducting, unmyelinated fibres which transmit action potentials at around 
~1m/s (Fox et al., 1993; Riccio et al., 1996; Mazzone, 2004; Canning et al., 2006a). This fibre 
type make up the majority of afferent nerves which innervate the airways (Coleridge and 
Coleridge 1984, Lee and Pisarri 2001), and can originate from both the nodose and jugular 
ganglia. C-fibres innervate the epithelium and other structures within the airway wall in both 
intrapulmonary and extrapulmonary airways. The central reflex induced following activation of 
C-fibres is blocked by anaesthesia and they are therefore thought to be responsible for the 
conscious perception of airway irritation (Mazzone, 2004). 
C-fibre endings, although responsive to mechanical stimuli, have a much higher threshold of 
activation than RARs/SARs (Coleridge and Coleridge, 1984; Ho et al., 2001). They are 
however activated by a large number of chemical stimuli including agonists of the TRPV1 (e.g. 
capsaicin) and TRPA1 (e.g. acrolein) ion channels, along with endogenous stimuli such as 
PGE2 and bradykinin, which are capable of causing a cough response in both animal models 
and man (Coleridge and Coleridge, 1984; Lalloo et al., 1995; Canning, 2004; Dicpinigaitis and 
Alva, 2005; Birrell et al., 2009; Grace et al., 2012; Dicpinigaitis et al., 2014; Adcock et al., 
2014). The expression of both TRPV1 and TRPA1 receptors have been confirmed in animal 
C fibres using single cell polymerase chain reaction (PCR) of airway ganglia (Nassenstein et 
al., 2008; Brozmanova et al., 2012), and furthermore TRPV1 has been shown to be expressed 
on human nerves (Groneberg et al., 2004). The activation of C fibres by these chemical stimuli 
is a direct effect as the fibres are not responsive to changes in airway pressure and 
bronchoconstriction (Coleridge and Coleridge, 1984; Undem, 2004). However, this may differ 
on non C fibres. 
C fibres can be further differentiated from Aδ nociceptors and RARs as they are capable of 
synthesising neuropeptides which are transported to the central and peripheral nerve termini 
(Lundberg et al., 1985; Baluk et al., 1992; Hunter and Undem, 1999; Myers et al., 2002) and 
can evoke reflex responses such as bronchoconstriction and mucus production (Nasra and 
Belvisi, 2009). However although this has been confirmed to occur in guinea pig and murine 
airways, it is not yet determined if this occurs in human airways.  
There are two distinct populations of C fibres, termed ‘bronchial’ and ‘pulmonary’ C fibres 
according to their sites of termination. Bronchial C fibres are thought to innervate the 
extrapulmonary airways, are mostly derived from the jugular ganglia and are stimulated by 
chemicals in the bronchial and systemic circulation (Coleridge and Coleridge, 1984). These 
fibres also express neurokinins such as substance P and calcitonin gene-related peptide 
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(CGRP) and is thought that these fibres are responsible for mediating the cough response 
because of their position within the airways (Undem, 2002a). In contrast, pulmonary C fibres 
are thought to innervate the lower airways, mostly do not express substance P or CGRP 
(Coleridge and Coleridge, 1984; Carr and Undem, 2003; Undem, 2004) and have been shown 
to inhibit cough in animal models (Tatar et al., 1994; Widdicombe and Undem, 2002; Chou et 
al., 2008).This inhibition is thought to be through inhibition of the respiratory centres in the 
CNS which cause cough rather than a direct inhibition of the cough reflex (Karlsson and Fuller, 
1999).  
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Figure 1.3: Summary of different vagal nerve fibre subtype properties in the airways 
Information from (Sant’Ambrogio et al., 1978; Riccio, Kummer, et al., 1996; Widdicombe, 2003; Canning, 2004; Canning et al., 2006a; Nasra and Belvisi, 
2009; Schelegle, 2003; Adcock et al., 2014)
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1.4 Assessment of the cough reflex 
1.4.1: Animal Models of Cough 
The neural pathways, physiology and pharmacology of the cough reflex have been investigated 
using animal models in a number of species including guinea pigs, dogs, cats, rabbits, mice and 
rats (Gardiner and Browne, 1984; Hanácek et al., 1984; Kamei et al., 1993; Tatar et al., 1994; 
Patel et al., 2003). However, the anatomy and physiology of the guinea pig airways is the most 
similar to man, the lungs are innervated similarly (Canning, 2006a), and guinea pigs show similar 
sensitivity to the tussive stimuli capsaicin and citric acid (Karlsson and Fuller, 1999). Therefore it 
is widely agreed that the guinea pig provides the most suitable model system (Belvisi and Hele, 
2003). The guinea pig can therefore be used in a number of in vitro and in vivo systems to 
investigate the cough reflex pre-clinically, many of which are used in this thesis and are described 
in greater detail in Chapter 2. Briefly;  
 Cells from guinea pig nodose and vagal ganglia can be isolated and investigated.  By 
administering a retrograde tracer dye DiIC18(3),1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiI) to the airways, 12-14 days prior to 
analysis, airway specific neurons can be isolated (Undem, 2002a; Kwong et al., 2008; 
Lieu et al., 2012). Once isolated, the cells can be loaded with a Ca2+ specific dye and 
intracellular calcium levels monitored in the presence of agonists and antagonists to 
determine activation (Grace et al., 2012; Dubuis et al., 2013). The cells can also be 
used for target expression at the mRNA level and electrophysiological assessment 
(e.g. patch clamp) (Nassenstein et al., 2008; Dubuis et al., 2013). 
 The vagus nerve can also be isolated and placed into a grease gap recording 
chamber, where compounds can be applied to one end of the nerve trunk and 
compound membrane depolarisation recorded as a measure of activation (Birrell et 
al.; 2008; Fox et al., 1995; Grace and Belvisi, 2011). It has been shown that many 
compounds which induce depolarisation of the isolated nerves in this preparation also 
induce a cough response in vivo (Patel et al., 2003; Maher et al., 2009).  Alongside 
guinea pig tissue, translational data can be acquired using donor human vagal tissue, 
which is a major advantage of this technique.  
 In vivo electrophysiology can be utilised to investigate the effects of pro-tussive or anti-
tussive compounds on action potential firing of airway specific afferent fibres (Adcock 
et al., 2003; Canning, 2004). The fibre type is identified using a range of criteria 
(pattern of spontaneous activity, response to hyper-inflation or deflation, adaptation 
1. Introduction 
 
33 
 
indices, response to capsaicin and citric acid and conduction velocity), and the effects 
of compounds can be investigated on nerve termini in the whole animal, making the 
system more physiologically relevant.  
 Finally, the guinea pig can be used as a model system for studying cough responses. 
This involves placing guinea pigs into individual Perspex chambers, and the effects of 
aerosolised compounds on the cough reflex measured. Studies have indicated that 
cough responses in animals are very similar to those seen in man (Laude et al., 1993; 
Lee, 2006; Birrell et al., 2009). 
1.4.2: Clinical Assessment of Cough 
Use of the guinea pig model in the investigation of airway sensory nerves and cough has 
uncovered a great deal regarding the mechanisms and triggers for cough.  In order to translate 
these findings to the clinic, three main methods exist which monitor cough, and also help to 
evaluate the efficacy of novel antitussives, outlined below.   
Cough questionnaires 
Cough questionnaires provide a subjective, qualitative measurement of the impact of cough 
severity on daily life (Bonvini et al., 2015). Currently, there are 3 validated and comparable 
questionnaires in use which measure cough as their end point. The Leicester Cough 
Questionnaire (LCQ) contains 19 items in 3 domains consisting of physical, psychological and 
social attributes and utilises a 17 point Likert Response scale (Birring 2003). Responses have 
been shown to correlate with cough visual analogue scores, and cough frequency measured 
using objective cough counters (Birring et al., 2003; Birring et al., 2006). The remaining 2 
questionnaires are the Cough Quality of Life Questionnaire (CQLQ), which has 28 items in 6 
domains (Simpson, 1999; French et al., 2002) and Chronic Cough Impact Questionnaire (CCIQ) 
(Baiardini et al., 2005). Using a specialised scoring system, these questionnaires evaluate the 
physical, psychological and social impact of coughing and are comparable in ascertaining the 
severity and impact of the cough response. However, an obvious disadvantage of this method is 
that it is reliant upon patient recall and is subjective. 
Ambulatory cough counting 
Ambulatory cough counting allows a non-invasive objective cough count to be taken in a patient’s 
natural environment (Smith, 2010). The patient wears a cough monitor, which is a a discrete 
recording device which can be worn under clothing, and is equipped with a microphone which 
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measures cough over a defined time period, for up to 24 hours (Smith and Woodcock, 2008; 
Smith, 2010; Kelsall et al., 2011).   
Cough monitors are currently not commercially available, however there are several in use in 
cough clinics. A well known and widely published monitor is the Leicester Cough Monitor, however 
this is yet to become fully automated (Birring et al., 2008; McGuinness et al., 2008). It has been 
shown to have a high sensitivity in both patients and healthy individuals (around 82-83%) (Yousaf 
et al., 2013). Another cough monitor in use is the Hull Automated Cough Counter which uses 
neual based technology to recognize sounds (Barry et al., 2006), however it is still in development. 
The Vitalojak (Vitalograph Limited, Buckinghamshire, UK) is a custom made digital recording 
device which records cough through a microphone placed on the chest wall and on clothing (Smith 
and Woodcock, 2008). This system removes silences and non cough sounds from the recording 
using a specialised compression algorithm, and no longer requires calibration (McGuinness et al., 
2012; Smith, 2010) and has been shown to be highly selective in measuring cough from patients 
with chronic cough, asthma, COPD, lung cancer and healthy controls (McGuinness et al., 2012). 
The key advantage of using this technique is that it is a more representative measure of the cough 
reflex as it is not carried out in a laboratory environment, and is not reliant upon patient recall.  
Cough reflex sensitivity 
A cough challenge to certain pro tussive compounds, commonly capsaicin and citric acid, can be 
carried out in a laboratory environment to assess cough sensitivity between different patient 
subgroups. Capsaicin is commonly used as it induces cough in a dose dependable, reproducible 
manner (Dicpinigaitis, 2006) and is also safe to use, with no reported adverse effects (Dicpinigaitis 
and Alva, 2005). Sensitivity is commonly measured using C2 and C5 parameters; the 
concentration of tussive stimulus which is required to reach 2 or 5 coughs (Doherty et al., 2000; 
Dicpinigaitis, 2006; Morice et al., 2007). This is both easy to perform (Morice et al., 2007) and 
also produces reproducible results (Dicpinigaitis, 2006) and is achieved by patients inhaling single 
doubling concentrations of cough stimulus, most commonly capsaicin (Hilton et al., 2013). In 
addition, a key advantage of this technique is that clinicians are able to discern differences in 
cough sensitivity across difference diseases, including asthma, COPD and chronic cough with the 
caveat that capsaicin challenge will only detect changes in TRPV1 pathway sensitivity.  
However, several disadvantages of the use of C2 and C5 parameters have recently come to light.  
When compared to ambulatory cough counts, the results found that sensitivity testing only weakly 
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correlates (Birring et al., 2006; Decalmer et al., 2007; Hilton et al., 2013). Instead it has been 
suggested to use non linear dose response modeling, which utilises the EMax and ED50 from a 
capsaicin challenge instead of C2 and C5, and has been shown to be able to distinguish between 
disease subgroups and healthy controls, and also correlates well with ambulatory cough counts, 
and also cough studies in animals (Hilton et al., 2013; Smith et al., 2012).  
1.5: Ion channels implicated in the cough reflex 
Airway sensory nerves express a number of ion channels which are activated by and respond to 
a wide range of mechanical, chemical and thermal stimuli. When these ion channels encounter 
potentially noxious stimuli they act as cellular sensors, to induce protective mechanisms in the 
airways such as cough and bronchoconstriction. A role of a number of these ion channels that 
have been implicated in the cough reflex are outlined below. 
1.5.1: P2X3 receptors  
The ubiquitous signalling molecule Adenosine Triphosphate (ATP) is found in every cell in the 
body where it plays a critical role in cellular metabolism and energy provision. It is released from 
cells under both physiological and pathophysiological requirements and plays a role as a local 
regulator and mediator in disease (Pelleg and Schulman, 2002). ATP activates the ionotropic P2X 
receptors and the metabotropic P2Y receptors (Burnstock and Kennedy, 1985), and is known to 
activate airway sensory nerves (Brouns et al., 2000) where receptors containing P2X3 subunits 
have been shown to play a crucial role (Burnstock, 2001; Jarvis, 2003; Ford et al., 2006). P2X3 
receptors are members of the purinergic P2X family of ion channels, of which there are 7 
members, which function as homo or heterotrimers formed of proteins subunits encoded by genes 
for P2X1-P2X7 (North and Surprenant, 2000; Gever et al., 2006). P2X receptors show preference 
for ATP over breakdown products such as Adenosine Monophosphate (AMP) (Burnstock and 
Verkhratsky, 2010). P2X3 forms homotrimeric P2X3 receptors (consisting of 3 P2X3 subunits) or 
heterotrimeric P2X2/P2X3 receptors (consisting of 2 P2X3 subunits and 1 P2X2 subunit) (Ford, 
2012).  
ATP and P2X3 have been implicated in a number of respiratory diseases, and ATP levels in the 
BALF of COPD and asthmatic patients has been shown to be enhanced (Mohsenin and 
Blackburn, 2006; Polosa and Holgate, 2006; Idzko et al., 2007; Lommatzsch et al., 2010; Mortaz 
et al., 2010). Furthermore, a recent clinical study has outlined a possible role for receptors 
containing the P2X3 subunit in the pathogenesis of chronic cough (Abdulqawi et al., 2014). In this 
study, a selective P2X3 antagonist AF-219 was shown to significantly inhibit daytime objective 
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cough frequency in patients with chronic cough (Abdulqawi et al., 2014). This is the first antagonist 
that targets the afferent arm of the reflex which has shown any efficacy, and indicates that ATP 
and P2X3 could play a role in the cough reflex.  
Expression 
Although the majority of P2X receptors are widely expressed in neuronal, epithelial, muscular and 
immune cells (Burnstock and Knight, 2004), P2X3 expression is much more limited and although 
it can be found in epithelial cells and enteric neurons, receptors are mostly localised on sensory 
neurons (Chen et al., 1995; Lewis et al., 1995; Vulchanova et al., 1996; Jin et al., 2004; Wang et 
al., 2005; Burnstock, 2008). P2X3 is predominantly expressed in the airways on small to medium 
diameter C or Aδ fibres originating from the jugular and nodose ganglia (Kwong et al., 2008; 
Undem and Nassenstein, 2009).  
Activation 
As mentioned previously, P2X3 is predominantly activated by ATP and the ATP derivative αβ-
Methylene ATP (αβ-MeATP) is a potent agonist. αβ-MeATP is a more stable ligand selective for 
P2X1 and P2X3 containing receptors. For activation to occur, three molecules of ATP are bound 
to extracellular portions of open P2X channels (Jiang et al., 2003). P2X3 receptors are rapidly 
desensitised, the channel opens milliseconds following activation, and deactivates within tens of 
milliseconds (North and Jarvis, 2013).  
When activated, P2X3 can then cause a variety of effects within the lung (Figure 1.3). 
Administration of ATP in the guinea pig, although did not cause cough alone, did significantly 
enhance the number of coughs to citric acid, and this enhancement was inhibited following 
application of a P2X1/P2X3 inhibitor TNP-ATP (Kamei et al., 2005). ATP has also been shown to 
activate sensory fibres from the nodose and jugular ganglia, which was blocked by the selective 
P2X3 antagonist A-317492 (Kwong et al., 2008). In humans, ATP was shown to cause cough and 
bronchoconstriction in asthmatic subjects, smokers and patients with COPD (Basoglu et al., 2005; 
Basoglu et al., 2015), and aerosolised ATP has also been shown to cause bronchoconstriction in 
normal subjects (Pellegrino et al., 1996). Taken together this would suggest a role for ATP and 
P2X3 in the activation of airway sensory nerves and cough (Figure 1.4).  
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Figure 1.4: P2X3 activation 
P2X3 present on airway sensory nerves is activated primarily by ATP (North and Jarvis, 2013; North and 
Jarvis 2010). This causes a variety of intracellular responses, including sensory nerve activation and firing 
in the guinea pig (Kwong et al., 2008), an increased tussive response to citric acid in guinea pigs (Kamei 
et al., 2005) and cough and bronchoconstriction in man (Pellegrino et al., 1996; Basoglu et al., 2005). 
 
P2X3 antagonists as antitussives 
To date, one small molecule inhibitor of P2X3 has advanced into clinic trials for chronic idiopathic 
cough. In a recent, placebo controlled clinical trial, AF-219 administered twice daily was shown to 
inhibit objective cough frequency by 75% in patients with chronic cough (Abdulqawi et al., 2014). 
There was also a significant improvement in all end point measurements compared to placebo 
(Abdulqawi et al., 2014). These results indicate that P2X3 may represent a promising new anti 
tussive treatment.  
1.5.2: Transient Receptor Potential family of ion channels 
A number of members of the TRP family of ion channels have been implicated in the afferent arm 
of the cough reflex (reviewed in (Grace et al., 2013)).  TRP channels are a superfamily of ion 
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channels which respond to a variety of stimuli present in the cellular environment including 
changes in temperature, stretch, chemicals, oxidation, osmolarity and pH (Moran et al., 2011; 
Picazo-Juárez et al., 2011). These channels show a preference for Ca2+ and acquired their name 
from the original discovery in the Drosophila fly where they were shown to have a transient 
response to bright light (Montell and Rubin, 1989; Ramsey et al., 2006; Caterina et al., 1997). 
There are 28 members in 6 subfamilies; the caninocal TRPC, vanilloid TRPV, melastatin TRPM, 
ankyrin TRPA, polycistin TRPP and mucolipin TRPML which are categorised according to 
sequence homology and amino acid sequences (Clapham, 2003).  All TRP channels share the 
same basic structure, with intracellular N and C termini, variable number of ankyrin repeats and 
6 transmembrane domains with the cation pore present between domains 5 and 6 (Caterina et 
al., 1997; Ramsey et al., 2006). When TRP channels are activated, this causes an influx of cations 
and depolarises the membrane. If the stimulus reaches a critical threshold then an action potential 
is produced causing a wide range of cellular responses (Kaneko and Szallasi, 2014). Further 
investigation into the mechanism of action of these channels may lead to the development of 
novel therapeutics for the treatment of conditions such as chronic cough  
Transient Receptor Potential Vanilloid 1 (TRPV1)  
The polymodal ion channel TRPV1 has been heavily implicated in the cough response in both 
animals and man.  It was the first TRP receptor to be identified as a key regulator of the cough 
reflex (Lalloo 1995). Furthermore, the potent TRPV1 agonist capsaicin is one of the most 
commonly used tussive stimuli in the clinic (Szallasi and Blumberg, 1990; Caterina et al., 1997).  
Expression of TRPV1 in the airway  
TRPV1 is highly expressed in a population of sensory neurons where it has been shown to 
mediate excitation and desensitisation to specific agonists (Szallasi and Blumberg, 1999). It was 
initially thought that expression of TRPV1 was confined to sensory neurons (Szallasi and 
Blumberg, 1999; Caterina et al., 1997), but it has since been shown to be expressed in a variety 
of neuronal and non-neuronal tissues and organs, albeit at lower levels than that found in sensory 
ganglia (reviewed in (Tominaga and Tominaga, 2005)). Single cell PCR of airway ganglia has 
confirmed that TRPV1 mRNA is present in airway specific neurons (Nassenstein et al., 2008; Lieu 
et al., 2012). Selective antibodies for many of the TRP channel family are yet to be found, and 
therefore protein expression has not been confirmed. Instead, functional experiments involving 
changes in intracellular Ca2+ signal in ganglia, and in vitro and in vivo nerve depolarisation and 
isolated airway fibre firing studies have been utilised to determine the functional presence of 
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TRPV1 on the vagus nerve. Utilising this approach, it has been shown that TRPV1 is functionally 
expressed on guinea pig airway jugular ganglia, where agonists cause intracellular Ca2+ flux, 
however, in normal healthy conditions, TRPV1 agonists have less of an effect on the nodose 
(Grace et al., 2012; Hu et al., 2014). In addition, capsaicin has been shown to induce firing of both 
C fibres and a population of RAR Aδ fibres (Adcock et al., 2014), suggesting the presence of the 
TRPV1 receptors on these fibres. 
Activation of TRPV1 
The TRPV1 ion channel is activated by a wide range of exogenous and endogenous mediators, 
including irritant chemicals, acid, noxious heat (temperatures above 43oC), and endogenous 
mediators such as anandamide and HPETE (Caterina et al., 1997; Zygmunt et al., 1999; Smart 
et al., 2000; Jia et al., 2002; Kagaya et al., 2002; Moriyama et al., 2005a; Jordt et al., 2000; Zhou 
et al., 2011). Both capsaicin and resinoferotoxin (RTX) directly open the channel, whereas other 
agonists such as low pH and increased temperature are thought to sensitise the channel and 
lower the activation threshold for opening as well as directly opening the channel (Caterina et al., 
1997; Trevisani et al., 2007; Tominaga, 2008). TRPV1 can also be indirectly activated by agonists 
of G Protein Coupled Receptors (GPCRs), which bind to GPCRs and initiate a signalling cascade 
which activates TRPV1. These agonists including bradykinin (Grace et al., 2012), PGE2 
(Moriyama et al., 2005; Grace, et al., 2012) and activators of the Protease Activated Receptors 
(PARs) (Amadesi et al., 2004). 
Activation of TRPV1 present on airway afferents causes a wide range of effects in the airways. It 
is well known that capsaicin causes a cough response in both animals and man (Fox et al., 1995c; 
Lalloo et al., 1995; Caterina et al., 1997; Nasra and Belvisi, 2009; Ricco et al., 1996), and both 
direct agonists such as capsaicin and RTX and indirect agonists such as PGE2 have been shown 
to functionally activate guinea pig and mouse vagal tissue (Fox et al., 1995c; Maher et al., 2009; 
Grace et al., 2012; Birrell et al., 2014). These agonists also activate donor human vagal tissue, 
thereby producing translational results (Birrell et al., 2009; Birrell et al., 2014; Usmani et al., 2005).  
TRPV1 ligands have also been shown to cause firing of single afferent C fibres (Adcock, 2009; 
Adcock et al., 2014) and a subset of Aδ fibres (Adcock et al., 2014). Other agonists which cause 
cough such as PGE2, citric acid, low pH and bradykinin do so through activation, at least partially, 
through the TRPV1 ion channel (Fuller and Choudry, 1987; Karlsson and Fuller, 1999; Doherty 
et al., 2000; Morice et al., 2007; Laude et al., 1993; Lalloo et al., 1995; Morice et al., 2001; Kollarik 
and Undem, 2002; Maher et al., 2009; Grace et al., 2012). Capsaicin is also capable of indirectly 
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causing bronchconstriction, via the release of sensory neuropeptides such as  substance P and 
neurokinin A from C fibre terminals, which activates receptors on airway smooth muscle (Lalloo 
et al., 1995; Lundberg et al., 1985; Belvisi, 2002) and can could also activate mechanoreceptors 
(Figure 1.5). 
 
 
Figure 1.5: TRPV1 activation 
Capsaicin is a potent activator of TRPV1 (Caterina et al., 1997), along with low pH (Jordt et al., 2000), the 
endocanniboid eicosanoid derivative anandamide (Smart et al., 2000), arachidonic acid derivatives 
(Zygmunt et al., 1999; Kagaya et al., 2002) and temperatures exceeding 43oC (Caterina et al., 1997).  
TRPV1 activation also occurs downstream of activation of GPCRs by PGE2 and Bradykinin (Grace et al., 
2012). Once activated, TRPV1 can cause several cellular effects which initiates following activation of both 
human and guinea pig vagal nerves (Maher et al., 2009; Grace et al., 2012; Birrell et al., 2014). TRPV1 
agonists have been shown to cause cough in both animal and humans (Fox et al., 1993; Lalloo et al., 1995; 
Caterina et al., 1997; Nasra and Belvisi, 2009; Riccio, et al., 1996) and bronchoconstriction as the result of 
parasympathetic activation and release of ACh (Raemdonck et al., 2012) or through release of 
neuropeptides (Lalloo et al., 1995; Lundberg et al., 1985; Belvisi, 2002).  
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TRPV1 in disease  
TRPV1 has also been shown to play an important role in airway disease, where expression levels 
of the channel are altered. Animal models of disease have indicated that exposure to cigarette 
smoke; allergen and virus can lead to hypersensitivity of TRPV1 agonist inhalation (Karlsson et 
al., 1991; Lewis et al., 2007; Maher and Belvisi, 2010; Grace and Belvisi, 2011b; Lieu et al., 2012).  
Following both cigarette smoke (CS) and allergen exposure, nodose ganglia from the guinea pig 
have been shown to become more responsive to the TRPV1 agonist capsaicin, therefore 
proposing that there is a phenotypic switch in receptor expression in disease (Wortley et al., 2011; 
Lieu et al., 2012). Furthermore, in a CS exposure model, guinea pig and human vagal tissue show 
enhanced responses to TRPV1 agonists (Wortley et al., 2011). In addition, six TRPV1 SNPs 
associated with a higher risk of chronic cough have also been identified from two independent 
studies from 8 European countries (Smit et al., 2012). It has also been established that there is 
an increased tussive response to capsaicin in a number of animal disease models (Karlsson et 
al., 1991; Carr et al., 2002; Myers et al., 2002; Lewis et al., 2007; Maher and Belvisi, 2010; Wortley 
et al., 2011). In addition, patients with airway diseases such as COPD and idiopathic cough show 
an increased cough response to inhaled capsaicin (Choudry and Fuller, 1992; Groneberg, 2004; 
Nieto et al., 2003; Prudon et al., 2005; Ternesten-Hasséus et al., 2006; Sumner et al., 2013). 
Taken together with the fact that there is an increased amount of endogenous TRPV1 agonists 
present in the diseased airways (e.g. low pH, arachidonic acid derivatives, an increased 
temperature), further implicates TRPV1 in the cough response.  
TRPV1 antagonists as potential antitussives  
A role for TRPV1 in patients with chronic cough has been outlined as these patients exhibit an 
increased tussive response to capsaicin compared to healthy controls (Choudry and Fuller, 1992; 
Nieto et al., 2003; Groneberg et al., 2004; Prudon et al., 2005; Ternesten-Hasséus et al., 2006; 
Sumner et al., 2013), and increased expression of TRPV1 has been demonstrated to occur in 
vagal nerves in patients with idiopathic cough (Groneberg et al., 2004). Furthermore, TRP 
channels are chemically tractable targets and therefore there is an opportunity to develop effective 
therapies (Veldhuis et al., 2015). Taken together this would suggest that TRPV1 is an attractive 
target for the treatment of chronic cough. However, traditionally, TRPV1 antagonists are known 
to cause hyperthermia and impaired perception of noxious heat which is a problem for potential 
antitussive compounds (Gavva et al., 2007, 2008; Eid, 2011; Krarup et al., 2011). Two recent 
clinic studies have utitlised TRPV1 inhibitors which seem to have circumvented the issue of 
1. Introduction 
 
42 
 
hyperthermia. The TRPV1 antagonist SB 705948 (Gunthorpe and Chizh, 2009) is rapidly 
absorbed with a long elimination life of 50-60 hours (Chizh and Sang, 2009).  However, using 
both capsaicin cough challenge and 24 hour ambulatory cough monitoring, SB 705498 caused a 
very small shift in the capsaicin induced cough response curve, and did not affect spontaneous 
cough (Khalid et al., 2014).  However despite this lack of efficacy of the drug, it does not rule out 
a role for TRPV1 in disease related chronic cough given the lack of proof of target engagement 
in this study.  A double blind, randomized, placebo controlled phase II clinical trial is currently 
being undertaken in patients with COPD with a novel highly potent TRPV1 antagonist XEN-
DO501. The primary end point is objective cough measurement in patients with COPD, alongside 
a capsaicin challenge to ensure target engagement.  This compound has previously undertaken 
Phase I studies which have shown it to be both well tolerated and safe, and has shown no issues 
with hyperthermia (Round et al., 2011), Preclinical studies have shown that XEN-D0501 also 
inhibits capsaicin induced cough in naïve guinea pigs, and guinea pigs exposed to cigarette 
smoke (Wortley et al., 2014).  
Transient Receptor Potential Ankyrin 1: TRPA1 
The ion channel TRPA1 is a Ca2+ permeable, non-selective cation channel with 14 ankyrin repeats 
in its amino terminus (Voets et al., 2005). It was initially isolated from cultured fibroblasts 
(Jaquemar et al., 1999) and is the only known mammalian member of the Ankyrin TRP family. 
Similarly to TRPV1, TRPA1 has also been implicated in the tussive response, where it is activated 
by a wide range of environmental irritants including cigarette smoke components such as acrolein 
and crotonaldehyde (Bautista et al., 2006; Andrè and Campi, 2008a; Andrè et al., 2009; Birrell et 
al., 2009; Lin et al., 2010; Volpi et al., 2011).  It is therefore thought to be the major mediator of 
peripheral irritant sensation as it is bound to and activated by a wide range of pungent natural 
compounds known to cause pain and inflammation (Macpherson et al., 2005; Bautista et al., 2013; 
Bandell et al., 2004).  
Expression 
Similarly to TRPV1, the majority of TRPA1 expression is found in neuronal tissue, including spinal 
DRGs, nasal trigeminals and vagal airway neurons (Bandell et al., 2004; Bautista, 2005; 
Nassenstein et al., 2008; Jang et al., 2012; Story et al., 2003). Protein expression is not yet 
established, however, functional expression of TRPA1 has been determined in ganglia cells, 
where agonists of the TRPA1 channel induce Ca2+ flux in jugular, but not nodose, ganglia (Grace 
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et al., 2012), and TRPA1 agonists also induce depolarisation of both animal and human vagal 
nerves in vitro (Birrell et al., 2009; Grace et al., 2012).  
Activation 
Covalent modification of N-terminal cysteines or lysines by electrophilic compounds is the major 
mode of activation of the TRPA1 channel (Bandell et al., 2004; Hinman et al., 2006; Banner et al., 
2011).  TRPA1 was initially characterised as a thermal receptor activated by noxious cold (Story 
et al., 2003), however it has since been shown that it can be activated by a diverse range of 
environmental and natural irritants such as mustard oil (Capasso et al., 2012; Jordt et al., 2004), 
cinnamaldehyde (Bandell et al., 2004), and allicin (garlic) (Bautista et al., 2006),  tear gas, exhaust 
fumes, components of cigarette smoke (e.g. acrolein), formalin and αβ-unsaturated aldehydes 
(Bandell et al., 2004; Bautista et al., 2006; McNamara et al., 2007; Andrè et al., 2008; Macpherson 
et al., 2005; Bautista et al., 2013; Dicpinigaitis et al., 2014). Furthermore, TRPA1 is the target for 
many by-products of oxidative stress including Reactive Oxygen Species (ROS) and other 
electrophilic compounds including nitric oxide, hydrogen peroxide and hypochlorite (Bautista, 
2005; Bessac and Jordt, 2008; Andersson et al., 2008; Sawada et al., 2008; Takahashi and Mori, 
2011).  TRPA1 is also indirectly activated by GPCR agonists such as PGE2 and bradykinin (Grace 
et al., 2012).  
Activation of the channel leads to a wide range of effects in both animal and human tissue 
including activation of vagal bronchopulmonary C fibres (Bessac and Jordt, 2008; Nassenstein et 
al., 2008; Taylor-Clark et al., 2008), sensory nerve depolarisation (Birrell et al., 2009, Grace et 
al., 2012), cough (Andrè et al., 2009; Birrell et al., 2009; Grace et al., 2012) and also 
bronchoconstriction, secondary to release of neuropeptides (Andre et al., 2008) (Figure 1.6). 
Unlike TRPV1 ligands, the TRPA1 ligand acrolein was only capable of activating C fibres, and 
had no effect on Aδ fibres in guinea pig airway single fibre firing (Adcock et al., 2014). 
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Figure 1.6: TRPA1 activation 
TRPA1 is activated by a number of exogenous and endogenous ligands including low temperatures (below 
17oC) (Story et al., 2003), cigarette smoke and components including acrolein (Andre et al., 2009; Bautista 
et al., 2006), oxidative stress (Bessac and Jordt, 2008), environmental irritants such as wood smoke 
(Shapiro et al., 2013) and ozone (Taylor Clark et al., 2010). It can also be indirectly activated by agonists 
of GPCRs such as PGE2 and bradykinin (Grace et al., 2012).  Downstream effects include sensory nerve 
firing in animals and man (Andre et al., 2009, Birrell et al., 2009), cough in both animals and man (Birrell et 
al., 2009, Andre et al., 2009, Grace et al., 2012) and bronchoconstriction via the release of neuropeptides 
(Andre et al., 2008).   
 
TRPA1 in disease 
Despite the fact that many components of cigarette smoke are known to activate TRPA1 (Bautista 
et al. 2006; Andrè et al., 2008; Andrè et al. 2009; Lin et al. 2010; Volpi et al. 2011) it is not yet 
known if expression levels of the channel are altered in disease. Furthermore, Smit et al have 
stated that there are no TRPA1 SNPs associating smoking or occupational exposure with cough 
(Smit et al., 2012).  Unlike TRPV1 agonists, the tussive response to TRPA1 agonists has not yet 
been shown to be altered in disease states.  
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However,  chronic cough in disease states is associated with inflammation and the release of 
endogenous direct and indirect TRPA1 ligands such as ROS and PGE2 (Grace et al., 2011, Grace 
et al., 2012), suggesting that TRPA1 may play a yet undiscovered role. 
TRPA1 antagonists as antitussives 
As a sensor of oxidative stress, alongside its role as a sensor of exogenous and endogenous 
respiratory irritants and the fact that agonists are capable of causing a cough response in animals 
and man makes TRPA1 a prospective therapeutic target for the treatment of chronic cough. 
Utilisation of a TRPA1 antagonist may also circumvent the temperature regulation safety concerns 
that are involved with TRPV1 antagonists.  
There are several TRPA1 antagonists currently in pre-clinical development for the treatment of 
airway disease such as asthma, which could show potential therapeutic capability for the 
treatment of cough. Janssen has a TRPA1 antagonist currently in the preclinical stages, which 
has been suggested to have antitussive activity (Preti et al., 2012). However, Glenmark 
pharmaceuticals are the only company to have a compound currently undergoing clinical studies 
in both healthy and asthmatic volunteers in an allergen challenge model (Preti et al., 2012). GRC 
17536 has already been shown to inhibit citric acid induced cough in the guinea pig 
(Mukhopadhyay et al., 2014) and has recently been taken forward into a Phase II clinical trial to 
treat patients with chronic cough.  
Transient Receptor Potential Vanilloid 4 (TRPV4) 
TRPV4 was initially characterised as a sensor of osmotic stress, as mice devoid of the TRPV4 
receptors show abnormalities with systemic osmotic stimuli (Strotmann et al., 2000; Liedtke and 
Friedman, 2003; Suzuki et al., 2003). The channel is a Ca2+ permeable polymodal receptor with 
6 ankyrin repeats within the cytosolic N terminus (Nilius and Szallasi, 2014) activated by moderate 
temperatures.   
Expression 
TRPV4 is widely expressed in the airways, including in smooth muscle, alveolar wall, lung tissue, 
macrophages, epithelial cells and lung vessels (Jia et al., 2004; Alvarez et al., 2006; Dietrich et 
al., 2006; Yang, 2006; Baxter et al., 2014). There are also high levels of expression in the epithelial 
linings of trachea, bronchi and lower airways (Alvarez et al., 2006; Fernández-Fernández et al., 
2008; Willette et al., 2008). TRPV4 has also been shown to be expressed in neurons of both the 
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central and peripheral nervous system including in DRG neurons (Grant et al., 2007) and mRNA 
levels of TRPV4 have been found in pulmonary sensory neurons (Ni et al., 2006).   
Activation 
TRPV4 is activated by moderate temperatures (>24oC) and is therefore constitutively active at 
normal body temperature. The channel has been well characterised as both a mechanosensor 
and osmosensor (Nilius et al., 2001), but there are also a number of exogenous and endogenous 
ligands which activate the channel. The small molecule activator GSK1016790a (Everaerts et al., 
2010; Thorneloe et al., 2012) and synthetic phorbol esters such as 4α-phorbol 12,13-didecanoate  
(4αPDD) (Watanabe et al., 2002) have been shown to activate the TRPV4 channel in both in vivo 
and in vitro systems. TRPV4 has also been well characterised as a receptor for hypotonic solution 
(Liedtke, et al., 2000; Strotmann et al., 2000; Jia et al., 2004), and other endogenous ligands 
including arachidonic acid derivatives such as 5’6’ epoxyeicosatrienoic acid (EET) (Watanabe et 
al., 2003; Vriens et al., 2005). Similarly to both TRPV1 and TRPA1, TRPV4 activation has been 
linked to activation of a GPCR. Stimulation of PAR2 has been shown to sensitise TRPV4 
expressed on DRG neurons and amplify responses to painful stimuli alongside causing 
neurogenic inflammation (Alessandri-Haber et al., 2006; Grant et al., 2007).  PAR2 activation has 
also been shown to stimulate TRPV4 channels directly, through receptor operated gating of 
TRPV4 (Poole et al., 2013; Grace et al., 2014) (Figure 1.7).  
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Figure 1.7: TRPV4 activation 
TRPV4 is known to be activated by hypoosmolarity (Liedtke et al., 2000; Strotmann et al., 2000; Suzuki et 
al., 2003), small molecule activators such as GSK1016790a (Thorneloe et al., 2008), arachidonic acid 
derivatives such as 5’6’epoxyeicosatrienoic acid (Watanabe et al., 2003) and temperatures above 24oC 
(Nilius and Szallasi, 2014). TRPV4 can also be indirectly activated by agonists of PAR2 (Poole et al., 2013). 
Downstream effects in airway sensory nerves are yet to be elucidated.  
 
Role of TRPV4 in airway sensory nerves and cough 
Despite the abundance of literature outlining the role of the TRPV1 and TRPA1 in sensory nerves 
and the cough reflex, relatively little is known about the role of TRPV4. The channel has already 
been shown to play a role in the airways, as agonists have been shown to cause contraction of 
airway smooth muscle via the release of cysteinyl leukotrienes (McAlexander et al., 2014), and 7 
SNPs of the channel are associated with COPD pathogenesis (Zhu et al., 2009).  As TRPV4 was 
originally characterised as a mechanosensor, this channel may therefore play a role in the more 
mechanically sensitive afferent airway fibres, rather than the chemosensitive C fibres which are 
activated by agonists of the TRPV1 and TRPA1 channels. Since antagonists of other ion channels 
expressed on airway sensory nerves such as TRPV1, TRPA1 and P2X3, have been shown to 
have promising therapeutic potential in the treatment of chronic cough, further understanding of 
the role of TRPV4 in airway sensory nerves and cough, may help to uncover a novel therapeutic 
target.  
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1.6: Thesis plan 
Hypothesis: Activation of TRPV4 causes activation of vagal sensory nerves and cough via the 
release of ATP and activation of P2X3. 
In order to address this hypothesis, the aims of this thesis are; 
 To pharmacologically assess the role of TRPV4 in airway sensory nerves and the cough 
reflex using selective agonists and antagonists of the channel and receptor deficient mice 
in a number of in vivo and in vitro systems. (Chapter 3). 
 To investigate the possible role for endogenous mediators of TRPV4 in the activation of 
airway sensory nerves both in vivo and in vitro (Chapter 4) 
 To investigate the potential mechanisms involved in TRPV4 induced activation of airway 
sensory nerves, and identify possible signalling pathways following TRPV4 activation 
involved in sensory nerve activation and cough (Chapter 5). 
 
These aims will be achieved by;  
 
 Using imaging of intracellular calcium flux in airway specific ganglia neurons to assess the 
effect of TRPV4 ligands in  airway sensory nerves 
 Using an in vitro isolated vagal nerve preparation which will allow direct investigation of 
the mechanism of activation of the airway afferents using relevant pharmacological tools 
 Using in vivo electrophysiology to investigate single airway afferent firing using specific 
tool compounds 
 Using an in vivo naïve guinea pig model to investigate the pro-tussive capabilities of 
TRPV4 ligands. 
 Furthermore key experiments will be repeated using donor human vagus nerve tissue to 
enable translation of the findings in animal tissue.  
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2.1 Introduction 
This chapter outlines the general methodology used for the techniques employed throughout my 
thesis.  More detailed methods including experimental protocols and statistical analysis is 
included in the methods section within each chapter.  A summary of all drugs, reagents and 
vehicles used is included in the Appendix.  
2.2 Human and animal tissue  
Male Dunkin Hartley guinea pigs and wild type (WT) male C57Bl/6j mice were purchased from 
Harlan (Bicester, UK) and housed in temperature controlled rooms (21oC) with food and water 
freely available for at least 7 days before commencing experiments. All work was approved by 
Imperial College London Ethics Review Committee, performed in accordance with the UK Home 
Office guidelines for animal welfare based on the Animals (Scientific Procedures) Act of 1986 and 
under Project Licence number 70/7212.  
Donor human tissue unsuitable for transplant was obtained from the International Institute for the 
Advancement of Medicine (IIAM, NJ, USA).  Ethics approval for human tissue use was obtained 
from the Royal Brompton & Harefield Trust  
2.3 KO mouse breeding and genotyping 
2.3.1: Genetically modified mouse breeding 
Homozygous breeding pairs of mice genetically modified to disrupt the TRPV1 (Trpv1-/-) and 
TRPA1 (Trpa1-/-) genes were purchased from Jackson Laboratories (USA) (Caterina, 2000; Kwan 
et al., 2006). Homozygous breeding pairs of genetically modified mice lacking the TRPV4 gene 
(Trpv4-/-, RBRC No.01939) were obtained from Riken Bioresource Centre (Tsukuba, Japan) 
(Mizuno et al., 2003; Suzuki et al., 2003). Mice devoid of the Pannexin 1 gene (Px1-/) were a kind 
gift from Dr. Vishva Dixit, (Genentech, US) (Bargiotas et al., 2011).  
 
All mice were bred on a C57Bl/6 background, were viable and fertile and breeding colonies 
maintained at Imperial College London.  Colonies of wild-type (WT) C57Bl/6 mice were bred 
alongside the genetically modified mice to be used as controls.  Regular genotyping was 
undertaken to ensure the continuation of gene disruption in each generation. 
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2.3.1: Genotyping and PCR 
DNA extraction was performed on tail tips taken from genetically modified mice using a DNA 
extraction kit (‘Extracta DNA prep for PCR’, Quanta Biosciences, Gaithesberg USA). Tail tips 
(approximately 0.2cm) from each knockout mouse were removed and placed into 75µl of 
extraction buffer and heated at 95oC for 30 minutes.  Once cooled to room temperature, 75µl of 
stabilisation buffer was added. The concentration of DNA could then be analysed using 
spectrophotometry at wavelengths of A260/A280 using GeneQuant RNA/DNA quantifier 
(Amersham Pharmacia, UK). The concentration of DNA was then adjusted to 10ng/ml using 
nuclease free water. 
Once the DNA was extracted, a PCR was then undertaken to amplify the DNA sequence of 
interest between two primers. A reaction mixture totalling 25µl was made containing 50ng of 
extracted DNA (5µl), reaction buffer (5µl), 0.2mM dNTPs (1µl), 2mM MgCl2 (2 µl), 1.25U Taq 
polymerase (0.2 µl), 10pmol forward and reverse primers of the gene target (1 µl) and the 
remainder of the reaction volume made up using nuclease free water. (PCR reagents were 
obtained from Promega, UK and primers from Invitrogen, UK). Samples were then heated to 94oC, 
following which 40 cycles of denaturing, annealing and extension were carried out, the exact 
temperature and duration of which was dependent upon the sequence of the primers used and 
the length of the expected DNA sequence (See Table 2.1 for exact details of primers used). At 
the end of the 40 cycles, the samples were kept at 72oC for 10 minutes to ensure that all gene 
sequences were at full length, and then the reaction stopped by cooling the samples to 4oC for 5 
minutes.  The resulting PCR products were run on a 2% agarose gel (80 V for 1 hour) in TBE 
buffer containing 0.05 μl/ml Safeview (NBS Biologicals Ltd, Huntingdon, UK) alongside a relevant 
DNA ladder. The gel was then visualised under UV light and photographed 
In the TRPV4, TRPV1 and Pannexin knockout mouse, an additional neomycin (Neo) primer was 
used. This was used to identify the knockout mice which had a neomycin cassette inserted into 
the target gene to produce the desired knockout genotype. The neomycin cassette gives 
resistance to neomycin allowing positive identification of knockout cells. Primer sequences were 
designed so that the WT amplicon would span the disrupted site of the desired gene which 
allowed for easier identification between wild type and knockout mice based on amplicon size. 
 
 
2. Methodology 
 
52 
 
Table 2.1: Details of primer sequence for genotyping 
TRPA1 WT Forward: 5’-TCA TCT GGG CAA CAA TGT CAC CTG CT-3’  
TRPA1 WT Reverse: 5’-TCC TGC AAG GGT GAT TGC GTT GTC TA-3’  
TRPA1 KO Forward: 5’-GAG CAT TAC TTA CTA GCA TCC TGC CGT GCC-3’  
TRPA1 KO Reverse 5’-CCT CGA ATC GTG GAT CCA CTA GTT CTA GAT-3’  
TRPV4 Forward: 5’-TGT TCG GGG TGG TTT GGC CAG GAT AT-3’  
TRPV4 Reverse: 5’-GGT GAA CCA AAG GAC ACT TGC ATAG-3’ 
TRPV4 Neo: 5’-TGG ATT CGA CGC AGG TTC TC-3’ 
TRPV1 Forward: 5’-CCT GCT CAA CAT GCT CAT TG-3’ 
TRPV1 Reverse: 5’-TCC TCA TGC ACT TCA GGA AA-3’ 
TRPV1 Neo:  5’-CAC GAG ACT AGT GAG ACG TG-3’ 
Pannexin1 Forward: 5’-TGA CCA CAG ACA GCA CTT AAG-3’ 
Pannexin1 Reverse: 5’-CGT CTG AGA GCT CCC TGG CG-3’ 
Pannexin1 Neo: 5’-TCC GTT CAG TAC ATC CAC CTA CC-3’ 
 
2.4 Measurement of mRNA levels to assess gene expression 
In order to determine if target genes were present in airway sensory nerves, real time PCR was 
undertaken in isolated whole ganglia from guinea pigs. The jugular and nodose ganglia provide 
the nerve fibres that make up the vagus nerve, which detects potential tussive stimuli within the 
lungs. Gene expression in the ganglia would suggest that (at least at the mRNA level) these genes 
are also present on the vagus nerve. 
2.4.1: RNA extraction 
The RNA extraction method was carried out according to the method previously described by 
McCluskie et al (McCluskie et al., 2004).  Guinea pig whole nodose and jugular ganglia were 
dissected from the animal, cleared of connective tissue and transferred to two separate 
autoclaved 2ml eppendorf tubes. The eppendorfs were autoclaved to ensure that no active 
ribonucleases were present which could cause the catalytic degradation of RNA. TriReagent (1ml, 
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Sigma), was then added to each eppendorf and mixed, following which the samples were 
centrifuged (15,000g for 15min at 4oC) to remove any insoluble material such as cell membranes. 
The supernatant (which contains RNA, DNA and protein) was then transferred into a new 
eppendorf and left to stand at room temperature (RT) for 5 minutes to allow for complete 
disassociation of the nucleoprotein complex. 0.2ml of chloroform was subsequently added and 
the eppendorf vigorously shaken before being left to stand for 15 minutes at RT. The samples 
were then centrifuged (15,000g for 15min at 4oC) which generated three phases of sample; 
organic (protein), interphase (DNA) and aqueous phase (RNA). The RNA phase was aspirated, 
placed into a 1.5ml eppendorf, mixed with 1:10 isopropanol (Sigma) and left to stand at RT for 5 
minutes following which the sample was centrifuged (12,000 x g, 10min, 4oC). The rest of the 
isopropanol (to give a final volume of 0.5ml) was then added and mixed, the sample stood at RT 
for 5 minutes and subsequently centrifuged (12,000 x g, 10min, 4oC). The centrifugation step left 
an RNA precipitate on the side of the tube, and from this point on the samples were kept on ice. 
The supernatant was removed and sample washed with 1ml of 70% ethanol, vortexed and 
centrifuged (12,000 x g for 5 minutes, 4oC). The supernatant was removed and the sample air 
dried for 5 minutes, following which the RNA pellets were dissolved in 50µl nuclease free water.  
In order to determine the purity and concentration of the RNA, a small sample was taken and 
diluted 1:10 in nuclease free water. The sample was then analysed using A260/A280 
spectrophotometry on a Birtek Powerwave XS microplate spectrophotometer (BioTek) and 
adjusted to 0.05mg/ml in nuclease free water.  
2.4.2: cDNA synthesis 
Using Taqman reverse transcription reagents (Applied Biosystems, UK), RNA samples (0.5µg in 
10ml) were reverse transcribed.  A master mix was made up consisting of 1x Taqman RT buffer 
(5µl), MgCl2 (5.5mM, 11µL), deoxyNTP mix (500uM/NTP; 10µL), random hexamers (2.5µM; 
2.5uL), RNAse inhibitors (0.5U/µL; 1µL) and Multiscribe reverse transcriptase (1.25U/µL: 1.25µL) 
to give a final reaction volume of 50µL (All reagents from Applied Biosystems). The samples were 
then incubated for 10 minutes at 25oC, 30 minutes at 48oC and 2 minutes at 95oC in a thermal 
cycler (model 480; Perkin Elmer, Boston, USA). Samples were frozen at -80oC until required. 
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2.4.3: Taqman real-time PCR 
The cDNA produced was then used for RTPCR amplification using an ABI PRISM 7000 Taqman 
machine (Applied Biosystems). A reaction mix totalling 25µL was prepared containing 2x Taqman 
universal master mix containing Taq DNA polymerase (12.5µL), sample cDNA (10ng), Assay On 
Demand (AOD) reagent containing specific primers and probes (1.5µL) and 18s internal control 
(1.5µL) (All regents from Applied Biosystems). The amplification protocol consisted of 1 cycle at 
50oC for 2 minutes, 1 cycle at 95oC for 10 minutes, 40 cycles at 95oC for 15 seconds and finally 
the sample is kept for 1 minute at 60oC.  
The Taqman RTPCR probes contain a fluorescent reporter dye at the 5’ end and a quencher at 
the 3’ end (e.g. FAM and TAMRA respectively). When the quencher is close to the reporter probe, 
fluorescence emission by the reporter dye is reduced, but as the Taq polymerase increases the 
primer, the 5’ nuclease activity of the probe cleaves the probe annealed to the template strand 
releasing the fluorophore and separates the reporter from the quencher leading to an increase in 
fluorescence. Each new copy of cDNA transcribed causes an increase in fluorescence, and the 
fluorescence detected is directly proportional to the fluorophore released and amplicon produced. 
The housekeeping gene 18s is used as a control, as this gene is present in all eukaryotic cells. 
This uses a different quencher dye (VIC) which can allow multiplex reactions where signals from 
target genes and control can be detected from the same reaction. The control signal can be 
compared to the target cDNA probe to give relative expression of the gene of interest.  
2.4.4: Analysis 
Samples were analysed using Sequence Detection Systems software (v 1.2.1, Applied 
Biosystems, UK) and the amount of target gene normalised to amount of 18s in the same cycle.  
A threshold value was set manually on the amplification plot on the geometric (linear) phase of 
amplification following guidelines supplied by Applied Biosystems. The Threshold Cycle (Ct) is 
the cycle number where fluorescence passes the threshold, and Ct values are inversely 
proportional to the initial copy number so a lower Ct value means a higher concentration of target 
in the sample. The gene expression data is expressed as arbitrary values using Ct values from 
reporter dyes of target normalised to the control 18s emission (ΔCt). To take into account 
exponential amplification reactions the data was transformed and presented as 2- ΔCt. This allows 
the mRNA in different samples to be compared relative to expression of the endogenous control.  
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2.5 Isolated jugular and nodose ganglia recordings 
Once the gene of interest was found to be expressed at the mRNA level in the whole ganglia, a 
functional effect was then investigated using isolated jugular and nodose ganglia recordings. The 
effects of agonists on intracellular free Ca2+ ([Ca2+]i) from the ganglia were investigated.as 
described in (Dubuis et al., 2013). This technique allows the examination of airway terminating 
neurons using a retrograde lipophilic dye. 
2.5.1: Labelling of airways neurons by retrograde tracking 
12-14 days prior to the experiment, Male Dunkin Hartley guinea pigs were dosed with 1 ml/kg of 
0.25 mg/ml DiIC18 (3) (1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate (DiI) 
(Invitrogen) intranasally (i.n), which ensured specific staining of airway innervating neurons by 
retrograde transport (Undem, 2002b). The DiI was dissolved in ethanol and diluted on the day of 
the experiment to give 2% V/V ethanol in 0.9% saline.  
2.5.2: Ganglia dissection and dissociation 
Guinea pigs were sacrificed by injection of pentobarbitone (200mg/i.p) and both nodose and 
jugular ganglia were carefully removed and placed in ice cold sterile Hanks Balanced Salt Solution 
(HBSS: containing 5.33M KCl, 0.441mM KH2PO4, 138mM NaCl, 0.3mM Na2HPO4-7H, 5.6mM 
glucose, 5mM HEPES and pH 7.4). The tissue was then cleared of connective tissue under the 
microscope and in sterile conditions and the nodose and jugular ganglia were enzymatically 
digested as described previously (Grace et al., 2012; Dubuis et al., 2013). Briefly, ganglia were 
digested in 2 steps: They were first incubated with activated papain (20 active units/ml, Sigma, 
UK) in Papain Activation Solution (PAS: HBSS supplemented with 400mg/L L-Cysteine, 1ml/L 
EDTA 0.5M stock solution and 1.5ml/L CaCl2 1M stock solution) for 30 minutes at 37oC. The 
ganglia were then incubated for 40 minutes with Type IV collagenase (Worthington, USA, 2mg/ml) 
and Dispase II (Roche, UK, 2.4mg/ml) at 37oC in sterile HBSS. Once digested, the ganglia were 
washed by centrifugation, supernatant removal and the pellet resuspended in sterile HBSS. The 
cells were dissociated by trituration with a heat-smoothed glass Pasteur pipette coated with L15 
medium. In order to separate the cells from unwanted cell types and remaining undigested tissue, 
the suspension was centrifuged through L15 medium containing 20% Percoll v/v and the neuron 
pellet was resuspended in L15 alone.  After centrifugation the cells were resuspended in complete 
F12 medium (containing 1% FBS, 1% Penicillin and 100,000u/ml streptomycin) and adhered to 
Poly-D-Lysine and laminin (22.5µg/ml) coated fluorodishes. The cells were left to adhere for 2 
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hours following which the plates were flooded with 2ml of with complete F12 medium and kept at 
37oC (5%CO2/95%O2) for 16 hours prior to use. Fluorodishes containing cells were imaged within 
24 hours.  
2.5.3: Staining and imaging 
The dishes containing the neurons were loaded using a ratiometric calcium sensitive dye (Fura2-
AM, 3µM Invitrogen) for 40 minutes in the dark at 25oC, following which the dye was aspirated 
and replaced with ECS to allow for a de-esterification step for 30 minutes at 25oC. Fura2-AM has 
a different excitation and emission spectrum according to the binding state. If bound to calcium, 
Fura2 has a maximum excitation wavelength of λ=340nm and emission wavelength of λ=520nm, 
whereas unbound has an excitation of λ=380nm and emission at λ=514nm. Following de-
esterification, the cells were washed with ECS (containing in mM: KCl, 5.4; NaCl, 136; MgCl2, 1; 
CaCl2, 1.8;  NaH2PO4, 0.33; glucose, 10; HEPES 10 at pH 7.4 and 37oC) and the fluorodish 
mounted on a Widefield inverted microscope (Zeiss Axovert 200, Carl Zeiss Microscopy, UK). 
The microscope stage was surrounded by an incubation chamber maintained at 37oC and 5% 
CO2, and contained a custom made perfusion system which allowed the delivery of compounds 
dissolved in ECS and a rapid changeover (3 seconds) between different compounds of interest 
while keeping the fluorodish at a constant volume of 600µL. All solutions were maintained at 37oC 
and 5% CO2 throughout the whole experimental protocol. A Hammamatsu EM-CCD C9100-02 
camera connected to simple PCI software was used to visualise the cells. 
Neurons were identified using bright field illumination at x20 magnification. Airway specific cells 
could then be identified by imaging the cells at excitation and emission fluorescence wavelengths 
of λ=520 nm and λ=570 nm, which identifies the DiI labelled cells. Intracellular Ca2+ ([Ca2+]i) 
responses were then investigated as previously described (Grace et al., 2012, Dubuis et al., 
2013). Neuron responsiveness and viability was assessed by application of K50: a potassium 
chloride solution (containing in mM: 50mM KCl, 91.4mM NaCl, 1mM MgCl2, 2.5mM CaCl2, 0.3M 
NaH2PO4, 10mM glucose 1mM HEPES at pH 7.4) for 15 seconds at the start and end of recording, 
which also was used to normalise neuron responses. Following the K50 response, the fluorodish 
was washed with ECS until the calcium signal returned to baseline. Agonist responses could then 
be carried out by perfusing the compound of choice onto the fluorodish for 10 minutes and 
following with a wash step with ECS. Throughout the experiment one image was taken of Fura2 
emission following excitation at 340 nm and 380 nm in close succession every 10 seconds 
producing two parallel sets of images taken throughout the experimental protocol and used to 
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produce the ratio of intensities. Only neurons producing a fast response to K50 which was easily 
washed, and that had a diameter of over 20µM were analysed. 
2.5.4: Analysis 
Each cell was individually analysed using Image J software (64-bit, version 1.43u, NIH, USA) and 
the ratio of the signal emitted at 520nm when excited at 340nm divided by the signal emitted at 
520nm when excited at 380nm was calculated. This ratio accounts for any degradation of the dye 
by photo-bleaching and also inter-experimental differences in loading of Fura2-AM. The sequence 
of ratios was then uploaded into Origin software (Version 8.6, OriginLabs Corp, USA) to produce 
a graph of emission over time. The calcium signal induced by each agonist was calculated using 
total area under the curve, (A.U.C.) which reflects the change in intracellular calcium from resting 
level over time. This was then normalised to a percentage of the calcium signal (A.U.C.) induced 
by K50 application, so that differences between individual cell responses can be accounted for.  
2.6 Isolated vagal nerve recordings 
The isolated vagus preparation provides a high-throughput, pharmacological amenable 
technique, which allows the use of tissue from guinea pig and knock-out mice alongside donor 
human tissue. In addition, this in vitro model provided a preparation free from the complications 
of bronchoconstriction and mucus production that can occur in vivo, and may account for, or 
influence, the results seen. 
2.6.1: Tissue Dissection: Animals 
Male Dunkin Hartley guinea pigs (250-350g), WT (C57Bl/6j) or genetically modified mice  
(Trpv1-/-, Trpa1-/-, Trpv4-/- and Px1-/-) (18-20g) were euthanized via overdose of pentobarbitone i.p. 
(200mg/kg). The neck was opened by cervical incision to expose the trachea and thorax and 
tissue cleared until the vagal nerves were revealed.  Following removal of the ribcage, segments 
of both vagus nerves caudal to the nodose ganglia were removed and placed into modified Krebs 
solution containing (in mM: NaCl 118; KCl 5.9; MgSO4 1.2; CaCl2 2.5; NaH2PO4 1.2;NaHCO3 25.5 
and glucose 5.6; pH 7.4) and bubbled with 95% O2 / 5% CO2. The nerve was cleared of any 
further connective tissue and (in the case of the guinea pig) carefully desheathed and cut into 
sections 10-15mm long prior to experimentation. Care was taken not to stretch or crush the nerve 
trunks and that they remained in oxygenated Krebs solution throughout the experiment.   
 
2. Methodology 
 
58 
 
2.6.2: Tissue Dissection: Human 
Whole human lungs unsuitable for transplant were purchased from IIAM, and received on ice 
within 36 hours of cross clamp. Upon arrival the lungs were placed immediately into Krebs solution 
and bubbled with 95% O2 / 5% CO2. Sections of the vagus nerve were identified running alongside 
the trachea and dissected free from surrounding and connective tissue. The perineural and 
epineural sheath is much harder to remove in human tissue, so care was taken to remove as 
much as possible under a dissecting microscope. Similarly to the guinea pig and mouse tissue, 
the nerves were then cut into sections 10-15mm long and kept in oxygenated Krebs throughout 
the experiment.  
2.6.3: Vagal nerve recordings 
Once dissected, the nerves were loaded into a grease-gap recording chamber (Figure 2.1) as 
previously described by (Birrell et al., 2002; Maher et al., 2009; Grace et al., 2012). Each piece of 
nerve was pulled through a custom made Perspex chamber and each end of the nerve electrically 
and chemically isolated using petroleum jelly injected through a side arm.  A glass rod was 
carefully filled to avoid any air bubbles with modified Krebs solution and placed into an Ag/AgCl 
pellet half-cell electrode (Mere 2 flexible electrodes, WPI, UK) and rested on one end of the nerve.  
A similar electrode was prepared and placed on the opposite end of the nerve. These were 
connected to a DAM50 differential amplifier unit (WPI, UK) which amplified the DC potential signal 
(x10 gain, high filter 1KHz, 5Hz sample rate) and fed back to a chart recorder (Lectromed 2, 
Lectromed, UK (now Digitimer, UK)). The chart recorder recorded depolarisation in mV and was 
calibrated so that 1mm was equal to 0.01mV. One end of the nerve (recording electrode) was 
constantly perfused with Krebs solution at a rate of approximately 2ml/minute, and the other end 
(reference electrode) was kept in a chamber containing Krebs solution (Figure 2.1).  Krebs 
solution and agonists or antagonists dissolved in Krebs were kept in syringes above the 
chambers, oxygenated and maintained at 37oC using heated water jackets. 
This technique measures the compound depolarisation caused by a difference in ionic potential 
of all nerve fibres within the nerve rather than single action potentials or specific nerve firing. 
When a drug which activates the nerve is perfused onto the end of the nerve fibre, this causes 
Na+ ions from the Krebs solution to move into the nerve cell, leaving excess Cl- ions which interact 
with the AgCl pellet in the electrode to electrically stimulate the circuit. There would be no change 
in Cl- ions in the reference electrode, causing a potential difference between the two ends of the 
nerve which is amplified and recorded as depolarisation on the chart recorder.  When the 
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stimulation is washed off with Krebs, K+ ions leave the nerve cell which causes the Cl- ions to 
disassociate from the AgCl pellet. The potential difference between the two ends of the nerve is 
lost and this is recorded as repolarisation.  
 
Figure 2.1: Isolated vagus set up 
The nerve is drawn into a grease gap recording chamber where each end of the nerve is electrically and 
chemically isolated using Vaseline. One end of the nerve is constantly perfused with either Krebs solution 
or compound of interest at a rate of 2ml/min and connected to a recording AgCl electrode. All solutions are 
bubbled with 95%O2/5%CO2 and kept at 37oC by a water jacket connected to a water bath. The other end 
of the nerve is kept in Krebs for the duration of the experiment and connected to a reference AgCl electrode.  
When a stimulus is added to the recording end of the nerve, this causes a potential difference between the 
two ends of the nerve which is detected by the electrodes and amplified via a DAM50 differential amplifier 
and can be recorded as depolarisation on a chart recorder.   
 
2.6.4: Agonists and antagonists experimental protocol 
In order to determine if a compound caused activation of the nerve, non-cumulative concentration 
responses to potential tussive stimuli were carried out. This involved stimulating the nerve with 
single concentrations of an agonist for 2 minutes, following which the nerve was washed with 
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Krebs until it returned to baseline, and this repeated with the full range of concentrations.   A 
similar stimulation was also carried out with vehicle to ensure that it had no effect. Depolarisation 
was recorded in mV. Following characterisation, a sub maximal concentration of agonist was 
taken forward for antagonist experiments. A concentration response with a maximum of 5 
stimulations could be carried out on each piece of nerve from any one animal or patient.  
A classical pharmacological approach was used to investigate inhibition of agonist responses by 
antagonists. The nerve would be exposed to agonist for 2 minutes and then washed with Krebs 
until the response returned to baseline. This was repeated to provide two control agonist 
responses. The nerve would then be incubated with an antagonist for 10 minutes, and then re-
stimulated with agonist in the presence of antagonist for 2 minutes 20 seconds (the extra 20 
seconds is to allow for the changeover of stimuli)  to assess if the antagonist was able to affect 
the magnitude of the depolarisation induced by the agonist. Following a brief washout period the 
nerve was exposed to agonist for 2 minutes to provide a recovery response to ensure nerve 
viability and that the antagonist was washed off (Figure 2.2). The inhibitory activity of the 
antagonist on the agonist responses was assessed by comparing the magnitude of depolarisation 
of the nerve following antagonist incubation to the mean magnitude of the two control agonist 
responses, to give a % inhibition. Only one concentration of antagonist was tested on each piece 
of nerve from any one animal or patient.   
 
Figure 2.2: Example trace from an antagonist protocol 
Once the nerve is loaded into the grease-gap recording chamber and a stable baseline obtained, two 
reproducible agonist responses are carried out following which the nerve is incubated with either antagonist 
or vehicle for a set period of time (normally 10 minutes). The nerve is then stimulated with agonist in the 
presence of antagonist, and response compared to the mean of the original two agonist responses.  After 
a short washout period, the nerve is re-stimulated with agonist to ensure washout of antagonist and also 
viability of nerve tissue. 
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Although high throughput and amenable to pharmacology, there are several limitations to 
consider with this technique. Responses are a summation of all events within the nerve trunk 
following treatment with an agonist and are not single action potentials as depolarisation induced 
by an agonist may not be of sufficient magnitude to generate an action potential. As drugs are 
applied to the nerve trunk, this may not be indicative of what happens in vivo at the nerve terminals 
as receptors may be present in a different confirmation, and also not all fibres within the trunk 
specifically innervate the airways. Nevertheless, depolarisation of the isolated vagus has been 
shown to be predictive of a cough response in vivo (Maher et al., 2009), and results from both 
guinea pigs and human vagus have been shown to be comparable (Nasra and Belvisi, 2009). In 
addition, the key advantage of this technique is the use of human tissue to provide translational 
data.  All results were repeated (where possible) using airway single fibres and in vivo cough.  
2.7 In vivo single fibre experiments 
An in vivo anaesthetised guinea pig single fibre preparation was used to investigate the effect of 
specific agonists on action potential firing of single afferent airway terminating fibres. This 
experimental technique involves anaesthetising a guinea pig and cutting both vagal nerves at the 
central end, using fibres from the left vagal nerve for recordings. Therefore any responses were 
effects on the nerve fibre itself and not as a result of a reflex arc.  This had the advantage of 
measuring the effect of compounds on the nerve termini with an end point of nerve firing, and so 
was more physiologically relevant than both the isolated vagus and ganglia.  In addition the effect 
of compounds on tracheal pressure as a measure of bronchoconstriction could be monitored in 
the absence of a reflex arc.  
2.7.1: Surgery 
Male Dunkin-Hartley guinea pigs (400-750g) were anaesthetised with urethane (1.5g kg-1) i.p. 
with additional urethane supplied if required, and paralysed with vecuronium bromide (0.10mg/kg 
i.v. initially) and every 20 minutes thereafter (0.05mg/kg). Levels of anaesthesia were constantly 
monitored throughout. The guinea pigs were then prepared as described in (Adcock et al., 2003), 
and summarised in Figure 2.3. Briefly, the trachea was cannulated and both blood gas and pH 
maintained at physiological levels using a ventilator (Ugo Basile small animal ventilator). The 
guinea pig was artificially ventilated at a tidal volume of 10ml/kg and 50-60 breaths per minute.  A 
nebuliser (Aerogen nebuliser, Buxco) was used for the delivery of aerosolised compound of 
interest or vehicle. The nebulizer assembly was connected to the ventilator and arranged so that 
inspired air was passed through the medication chamber before entering the lungs of 
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anaesthetized animals via the tracheal cannula.  Both the right jugular artery and carotid were 
cannulated for the administration of drugs and to measure blood pressure respectively. Both blood 
pressure and heart rate were monitored throughout the experiment using a transducer (Gould 
P2X3L, MEMSCAP SP 844), and body temperature monitored using a rectal thermometer and 
maintained at 37ºC using a heated blanket (Harvard Apparatus, UK). In addition to action potential 
firing, this technique also allows the measurement of tracheal pressure using an air pressure 
transducer (SenSymb647, MEMSCAP SP 844) attached to a side arm of the tracheal cannula.  
Both cervical vagal nerves were then cut at the central end and dissected free from the carotid 
artery, sympathetic and aortic nerves.  Only the left vagal nerve was used for recording, and this 
was cleared of all surrounding tissue and fascia, and the skin and muscle surrounding the incision 
tied to a metal ring to form a well and filled with light mineral oil. Recording of action potentials 
was undertaken using Bipolar Teflon coated platinum electrodes which were exposed at the tips.  
The reference electrode was placed on the nerve fascia.  Using a binocular microscope, thin 
filaments of nerve were teased free from the whole vagus until a single active unit of no more than 
2-3 fibres was obtained and placed on the recording electrode.  These electrodes were connected 
to a pre amplifier headstage (Digitimer NL100k) and the signal from action potentials amplified 
(x1000-5000, Digitimer NL104), filtered (at a range of LF30Hz-HF8.5KHz, Digitimer NL125) and 
passed through a Humbug noise reducer (AutoMate Scientific) before recording. All signals 
(including blood pressure, heart rate and tracheal pressure) were recorded using Spike 2 data 
acquisition software via a CED Micro 1401 interface. This software allowed pulse training counting 
over selected time period. The input signal was also monitored using a digital storage oscilloscope 
(Tektronix DPO 2012) and fed through an audio amplifier to a loudspeaker.  Guinea pigs were 
euthanized by an overdose of pentobarbitone (i.p.) at the end of the experiment. 
2.7.2: Nerve fibre identification 
Each nerve fibre could be identified as originating from the family of SARs, RARs or 
chemosensitive C fibres using a set of criteria (Adcock et al., 2003). These would include the 
pattern of spontaneous activity of the fibre, its response to hyper-inflation or deflation, Adaptation 
Induces (AIs), the response to capsaicin and citric acid, and conduction velocity.  In brief if a fibre 
had little or no spontaneous activity, no response to hyperinflation or deflation, and responded to 
a capsaicin aerosol, it was assumed that the fibre was a C fibre. If the nerve fibre had a set pattern 
of spontaneous activity and responded to hyperinflation and deflation, and to citric acid, it was 
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assumed to be an Aδ fibre (RAR). Assumptions would be verified at the end of the experiment 
where conduction velocities would be measured.  
Conduction velocities were measured using bipolar silver electrodes, which would stimulate the 
vagus nerve close to the thorax with a supra threshold of 0.5ms/1Hz (Grass stimulator). The 
action potential and stimulus would be recorded as a single sweep on Spike software and the 
time interval between them along with the distance between the simulating electrode and 
recording electrode taken to calculate the conduction velocity.  
2.7.3: Agonist experimental protocol 
The following basic experimental protocol was carried out to investigate the effects of agonists on 
both C fibres and Aδ fibres. Exact timings and agonists used are included in the relevant chapter. 
Once a lung afferent fibre had been identified, a baseline recording was taken for 2 minutes.  
Vehicle of the compound of interest was administered into the lungs for a 1 minute period during 
which any changes in fibre activity, intratracheal pressure and blood pressure were continuously 
recorded until they returned to baseline levels. After an interval of 10-20 minute, capsaicin 
(100μM) was administered for 20 seconds and changes in fibre activity, intratracheal pressure 
and blood pressure were continuously recorded until they returned to baseline levels. 10-20 
minutes following this, citric acid (0.3M) was administered for 1 minute during which changes in 
fibre activity, intratracheal pressure and blood pressure were continuously recorded until they 
returned to baseline levels. The compound of interest was then administered for up to 1 minute 
(by aerosol) and changes in fibre activity, intratracheal pressure and blood pressure were 
continuously recorded until they returned to baseline levels. If experimentation was carried out on 
a C fibre, a further capsaicin aerosol was given, and if an Aδ fibre used then a further citric acid 
aerosol was used following exposure to the agonist to ensure that the fibre was still responsive.  
Data was expressed as mean ± SEM and analysed using paired students t-test comparing 
responses as absolute values after stimulus to baseline values immediately before the response.  
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Figure 2.3: In vivo single fibre recording set up and example trace 
Guinea pigs were anaesthetised and ventilated and both vagal nerves cut. The left vagal nerve teased to a 
single fibre and attached to a platinum electrode as shown in (A). Compounds of interest could then be 
aerosolised and administered directly to the lungs using a nebuliser. Changes in trachea pressure and fibre 
firing could then be measured and recorded, and an example trace is shown in (B). The top panel represents 
an increase in tracheal pressure following administration of a test compound, and the bottom trace is an 
example of an increase in fibre firing following compound administration.  
 
2.8 In vivo guinea pig cough recordings 
This technique was used to assess the tussive capability of a compound of interest in a conscious, 
naïve guinea pig.  Unlike rats and mice, guinea pigs have a cough response similar to humans 
(Maher et al., 2009) and therefore if a compound causes cough in the guinea pig, it can be 
assumed that it could also be a tussive stimulus in humans. 
Conscious, unrestrained guinea pigs (250-300g) were placed in individual transparent Perspex 
plethysmography chambers (Buxco, Wilmington NC, USA) (Figure 2.4).  The chambers were 
attached to a central Aerogen nebuliser (Buxco, US), which allowed simultaneous aerosolisation 
of a tussive stimuli and visualisation of the responses of 2 guinea pigs at one time.  Both chambers 
were equipped with a microphone connected to an amplifier and a speaker. Cough was detected 
as preciously described (Birrell et al., 2009; Maher et al., 2009). Briefly, a potential tussive 
stimulus would be aerosolised for 5 minutes, and coughs manually counted by two trained 
observers which were blinded to treatment for 10 minutes. The mean of the counts by the two 
observers was used. Coughs were recognised by the characteristic stance and posture of the 
animal, the sound produced and also the change in flow recording (Figure 2.4). For antagonist 
studies, guinea pigs would be dosed with antagonist (i.p.) at a set time period prior to aerosol 
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stimulation with agonist. Guinea pigs would be monitored for any adverse health effects during 
this time period. At the end of the experiment, guinea pigs would be euthanised with an overdose 
of pentobarbitone (200mg/kg i.p.). 
 
 
 
Figure 2.4: Cough chamber set up 
Animals were placed into individual plethysmography chambers equipped with microphones (as shown in 
A), and a potential tussive stimulus was nebulised directly into each chamber.  The number of coughs to a 
given stimulus were then counted by two trained observers blinded to treatment.
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3.1: Rationale 
A number of members of the family of TRP ion channels have been shown to modulate a variety 
of functions in the airways including inflammation, airway smooth muscle tone and activation of 
airway afferents (Bessac and Jordt, 2008; Nassini et al., 2010). Two members of this family; 
TRPV1 and TRPA1 are well documented to play a role in airway sensory nerve activation and 
cough (Andrè et al., 2009; Birrell et al., 2009; Grace et al., 2012; Lieu et al., 2012), however, the 
role of other TRP channels such as TRPV4 in the lung, and particularly in modulation of airway 
sensory nerve activity, is relatively unexplored. 
TRPV4 is a calcium permeable polymodal receptor expressed in human airway smooth muscle 
cells, macrophages, pulmonary arterial smooth muscle and epithelial cells (Jia et al., 2004; 
Alvarez et al., 2006; Dietrich et al., 2006; Yang, 2006; Fernández-Fernández et al., 2008, Baxter 
et al., 2014; Hamanaka et al., 2010).  TRPV4 expression has also been found in DRG neurons 
(Grant et al., 2007) and also at the mRNA level in pulmonary sensory neurons (Ni et al., 2006).  
However a role in airway sensory nerves is yet to be established. Many endogenous activators of 
TRPV4, including arachidonic acid derivatives (Watanabe et al., 2003) and an altered airway 
osmolarity (Liedtke et al., 2000; Strotmann et al., 2000; Jia et al., 2004) are released or altered in 
the airways of patients with asthma and COPD (Naruyima et al., 1999, Joris et al., 1993, Rolin et 
al., 2005), where the cough response and therefore airway sensory nerve responses are altered. 
Therefore it could be hypothesised that TRPV4 could play a role in airway sensory nerve 
activation and cough.  
3.1.1: Chapter Hypothesis:  
Activation of TRPV4 on airway sensory nerves by selective agonists leads to nerve activation and 
cough 
3.1.2: Aims: 
 To evaluate the effect of two synthetic TRPV4 agonists, the phorbol derivative 4-alpha-
phorbol-12,13-didecanoate (4αPDD, (Watanabe et al., 2002), and GSK1016790a 
(GSK101) (Thorneloe et al., 2008), in airway sensory nerves in vitro. The tools will be 
assessed using calcium imaging of guinea pig airway specific ganglia and vagal nerve 
depolarisation in isolated murine, guinea pig and donor human tissue. 
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 The more potent of the two ligands, GSK101 will then be taken forward in vivo, initially 
to test whether it is able to propagate an all or nothing action potential in guinea pig 
isolated single fibres.  
 Finally GSK101 will then be investigated in the whole animal where its ability to cause 
cough in the conscious guinea pig will be evaluated. 
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3.2: Methods 
3.2.1: RT-PCR 
Quantitative real time PCR assays for the TRPV4 receptor were purchased from Applied 
Biosystems and validated using cDNA from tissue/organs from the guinea pig that expressed the 
target channel at high levels. 
Whole nodose and jugular ganglia were harvested from male Dunkin Hartley guinea pigs. 
Expression levels of TRPV4 was determined using the validated assays, with real time RT-PCR 
performed as described previously (Wong, Belvisi, and Birrell, 2009) and in Section 2.4. 
3.2.2: Ganglia imaging 
Male Dunkin Hartley guinea pigs were intranasally dosed with the retrograde tracer dye DiI to 
identify airway specific neurons, 14 days prior to dissection and enzymatic digestion of the nodose 
and jugular ganglia as described previously in Section 2.5.  Neurons were loaded into fluorodishes 
coated with laminin and allowed to adhere for 12 hours at 37oC 5%CO2/95% O2. 
Following incubation, cells were loaded with the calcium specific dye Fura-2-AM for 40 minutes 
at 25oC in the dark, which was followed by a de-esterification step for 30 minutes at 25oC in the 
dark. Following a wash step with ECS, each fluorodish containing neurons was then placed in a 
full incubation chamber and mounted on a Widefield inverted microscope as described in Section 
2.5. Neurons were then identified using bright field illumination at x20 magnification, and airway 
specific cells could then be identified by imaging the cells at excitation and emission fluorescence 
wavelengths of approximately λ=520-550nM and λ=570, which identifies the DiI labelled cells. 
Intracellular Ca2+ ([Ca2+]i)  responses were then investigated as previously described (Grace et 
al., 2012; Dubuis et al., 2013). 
3.2.2.1: Agonist Concentration Response Curves 
In order to determine if activation of TRPV4 was able to cause a change in [Ca2+]i signal in the 
nodose and jugular ganglia, the following experimental protocol was undertaken. Throughout the 
experiment, neurons were constantly superfused with ECS using an in house pressurised 
perfusion system that allows complete change of solution (600μL) in 3s. The neurons were 
exposed to a 50mM potassium solution (K50) for 10s to ensure neuron viability, and allowed to 
return to baseline. One concentration of the selective TRPV4 agonist (GSK101; 10-300nM) was 
then added to the dish for 10 minutes, and changes in [Ca2+]i recorded. 
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3.2.2.1: Analysis 
Only responding cells (cells with a response ≥ 10% of the K50 response) and cells with a diameter 
of over 20μm were analysed as these were more likely to be sensory neurons (Hunter et al., 
2000). Intracellular calcium signal induced by each agonist was calculated using total area under 
the curve, (A.U.C.) which is the total change in intracellular calcium from resting level over time. 
This was then normalised to a percentage of the total change induced by K50 application, so that 
differences between individual cell responses can be accounted for. The data is presented as 
mean ± S.E.M., N indicates number of animals, and n indicates number of cells. 
 
3.2.3: Isolated vagal nerve recordings 
Vagal tissue was dissected from male Dunkin-Hartley guinea pigs, WT C57/Bl6 mice and  
Trpv4-/- mice and placed in a grease-gap recording chamber as previously described in Section 
2.6. Key experiments were repeated using human donor tissue to provide translational data.  
 
3.2.3.1: Agonist concentration response curves 
In order to determine if activation of TRPV4 was able to depolarise the vagal nerve, the following 
experimental protocol was undertaken. Non-cumulative concentrations of the TRPV4 agonists 
(GSK101; 0.03-1μM and 4αPDD; 0.3-10μM) were applied to the vagal nerve trunk followed by a 
wash period where the nerve was washed with Krebs solution until it returned to baseline. In 
addition, vehicle (0.1% DMSO v/v) was tested on the nerve to ensure that it had no effect. 
Responses were recorded as mV depolarisation. Concentration ranges of each agonist were 
determined from published pEC50 values. GSK101 has previously been determined to have a 
pEC50 value ranging from 8.0 in rat to 8.7 in human tissue (Thorneloe 2011), and 4αPDD is 
known to be less potent, with a published pEC50 value of 6.9 in mouse (Xu, Satoh, and Iijima 
2003).   Responses were carried out in guinea pig and WT mouse tissue, and a submaximal 
concentration of each agonist used to determine activation of human tissue.  
3.2.3.2: Antagonist concentration response curves 
Depolarisation by each agonist was then tested against specific TRPV4 antagonists. There are 
several known TRPV4 antagonists, of which two have been used in this thesis, the selective 
TRPV4 inhibitor HC067047, which has been shown to block TRPV4 activation in a bladder model 
in mice and rats (Everaerts et al., 2010) and GSK2193874, an orally active antagonist shown to 
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block TRPV4 activity in a model of heart failure induced pulmonary oedema (Thorneloe et al., 
2012). Both are thought to be highly selective for the TRPV4 ion channel. 
A submaximal concentration of both GSK101 (300nM) and 4αPDD (1μM) were taken forward for 
inhibitor studies. Concentration-responses for the TRPV4 selective inhibitors HC067047 (0.1-
10μM), GSK2193874 (0.1-10μM) (or vehicle (0.1% dimethyl sulfoxide (DMSO) v/v in Krebs) were 
established against both GSK101 and 4αPDD on guinea pig and wild type mouse vagus. A 
classical pharmacological approach was used; two reproducible responses to each agonist was 
established, following which each nerve was incubated with a single concentration of one of the 
antagonists for ten minutes.  Following incubation, the nerve would be restimulated with agonist 
in the presence of antagonist to determine inhibition. The nerve would then be washed with Krebs 
until returned to baseline, and a final response to the agonist carried out to ensure nerve viability. 
From this, the concentration of antagonists exhibiting maximal inhibition of its receptor (10µM) 
was chosen for inhibition of activation of human tissue and for further experiments.  
3.2.3.3: Determining specificity of tools 
The selectivity of the available pharmacological tools was then established. Firstly the two TRPV4 
agonists were tested on Trpv4-/- vagal tissue. Knockout of the Trpv4 gene was confirmed using 
standard genotyping techniques as described in Section 2.3. Responses to both GSK101 and 
4αPDD were established in both Trpv4-/- tissue, and in age matched wild type controls. In order 
to ensure responses to other TRP agonists were not altered in the Trpv4-/- tissue, responses to 
capsaicin (1μM; TRPV1 agonist) and acrolein (300μM; TRPA1 agonist) were also established in 
knockout and wild type vagus.  
To determine agonist specificity, GSK101 and 4αPDD induced depolarisation was tested against 
TRPA1-selective (10 µM; HC-030031) and TRPV1-selective (100 µM JNJ17203212) antagonists 
on both guinea pig and mouse vagus. Furthermore, to ensure that the antagonist was not 
exhibiting off target effects on TRPV1 and TRPA1 receptors, HC067047 (10 µM) and 
GSK2193874 (10μM) were tested against acrolein (300 µM) and capsaicin (1 µM) induced vagal 
nerve depolarisation. Vehicle for all antagonists was 0.1% DMSO v/v in Krebs. Concentrations 
for the TRPA1 and TRPV1 antagonists had been previously established (Grace et al., 2012). 
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3.2.3.4: Analysis  
Individual nerve depolarisations were measured in mV, and the chart recorder calibrated so that 
1mm was equal to 0.01mV. Antagonist inhibitions were calculated by comparing the magnitude 
of depolarisation of the nerve following antagonist incubation to the mean magnitude of the two 
control agonist responses, to give a % inhibition. Statistical analysis for agonist concentration 
responses was carried out using a Kruskal Wallis test with a Dunns post-test comparing 
responses to vehicle. For antagonist studies; a two tailed t-test for matched pairs was used 
comparing the magnitude of depolarisation by the agonist with and without the presence of 
antagonist in the same piece of nerve. The data is presented as mean ± S.E.M., with statistical 
significance set at P < 0.05. 
 
3.2.4: Genotyping of Trpv4-/- Mice 
Homozygous breeding pairs of mice genetically modified to disrupt the TRPV4 gene (Trpv4-/: 
RBRC No.01939) were obtained from the Riken Bioresource centre (Tsukuba, Japan) (Mizuno et 
al., 2003; Suzuki et al., 2003) and breeding colonies maintained on a C57Bl/6 background at 
Imperial College London. Regular genotyping was carried out to ensure continued deletion of the 
TRPV4 allele. This involved amplification of the DNA sequence of interest using PCR as 
previously described in Section 2.3.1. 
DNA samples extracted from the tail tips of WT (C57Bl/6) and Trpv4-/- mice were amplified by 
PCR using primers (Invitrogen) and visualised on an agarose gel by electrophoresis. Samples 
were heated to 94oC, following which 40 cycles of denaturing, annealing and extension were 
carried out, the exact duration and temperatures of which are outlined in Table 3.1. The resulting 
PCR products were run on 2% agarose gel (80V for 1 hour) in TBE buffer containing 0.05 μl/ml 
Safeview (NBS Biologicals Ltd, Huntingdon, UK) alongside a 50-2000bp ladder (Hyperladder 
50bp, Bioline Reagents, UK). The expected wild type product was 740bp and knock out 1490bp.  
Table 3.1: PCR Protocol for Trpv4-/- mice 
 PCR Conditions  
TRPV4 Denaturing 
95oC 
30 sec 
Annealing 
60oC 
30 sec 
Extension 
72oC 
1min20sec 
Product Size (Base Pairs) 
WT: 740 
KO: 1490 
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3.2.5: In vivo single fibre recordings 
Male Dunkin Hartley guinea pigs (~350-400g) were anaesthetised with urethane (1.5g/kg i.p.) and 
paralysed with vecuronium bromide (0.1mg/kg i.v.) and ventilated. Heart rate, blood pressure and 
body temperature were constantly monitored for the duration of the experiment.  Guinea pigs 
were then prepared as described in Section 2.7.1 and as previously described (Adcock et al., 
2003). Briefly, both vagal nerves were cut at the cervical end but only the left vagal nerve used 
for recording.  This was dissected down to a single fibre and attached to a platinum electrode 
where single action potentials could be recorded using Spike 2 data acquisition software via a 
CED Micro 1401 interface. The nerve fibre was identified as originating from the family of SARs, 
RARs or chemosensitive C fibres using a set of criteria (Adcock et al., 2003) and as described in 
Section 2.7.3. This included the pattern of spontaneous activity, response to hyperinflation and 
hyperdeflation, Adaptation Indices, response to capsaicin and citric acid and finally conduction 
velocity which was determined at the end of the experiment.  
3.2.5.1: Agonist responses 
The following experimental protocol was undertaken to determine the effect of GSK101 on airway 
terminating vagal fibres. Following surgery, the animals were left to stabilise for 30 minutes, 
following which a control baseline recording was taken for 2 minutes. Vehicle (0.1% DMSO in 
0.9% saline) was then aerosolised into the airways for up to 1 minute, and changes in fibre activity, 
intra-tracheal pressure and blood pressure were constantly monitored until they returned to 
baseline or a steady state achieved. 20 minutes later, citric acid (0.3M) was administered via 
aerosol into the airways and responses monitored.  A further 20 minutes following return to 
baseline, GSK101 (10μg/kg; a concentration 10 fold higher than that tested in vitro) was 
aerosolised into the airway and changes in fibre activity, intra-tracheal pressure and blood 
pressure closely monitored. If a C fibre was under investigation, aerosolised capsaicin (100μM) 
would be administered to the airways at least 30 minutes following the response to the TRPV4 
agonist. 
3.2.5.2: Antagonist responses 
For antagonist studies only Aδ fibres were investigated, and a lower concentration of GSK101 
(100ng/ml) was used to allow for responses to return to baseline. Two reproducible responses to 
GSK101 (100ng/ml) were carried out 20 minutes apart, following which either the TRPV4 
antagonist GSK2193874 (300mg/kg) or vehicle (6% Cavitron 2Hydroxypropyl-β-cyclodextrin in 
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saline) was administered i.p. One hour later, GSK101 (100ng/ml) was aerosolised into the airways 
and changes in fibre activity, intra-tracheal pressure and blood pressure closely monitored. 
3.2.5.3: Analysis 
The data is expressed as mean ± S.E.M. and agonist studies analysed using paired students t-
test comparing responses as absolute values after stimulus to baseline values immediately before 
the response. For antagonist responses in the same fibres a paired t-test was used comparing 
agonist responses following antagonist to control responses. For responses in different fibres, an 
unpaired t-test was used comparing responses in antagonist fibres to vehicle fibres.  
3.2.6: Cough 
Conscious, unrestrained guinea pigs were placed in individual transparent Perspex 
plethysmography chambers (Buxco, Wilmington NC, USA), as described in Section 2.8. Cough 
was detected as previously described (Maher et al., 2009; Birrell et al., 2009.). An initial 
concentration response to GSK101 (1-30μg/ml), or vehicle (1% ethanol, 1% TWEEN in saline v/v) 
was carried out in each guinea pig. GSK101 was aerosolised for 5 minutes, and coughs counted 
for 10 minutes using two trained cough observers blinded to treatment. Coughs were recognised 
by the stance of the animal, the characteristic cough sound and changes in airflow.  Once a 
submaximal concentration of GSK101 had been determined, the cough response elicited by 
GSK101 was tested against the specific antagonists HC067047 (100mg/kg) or GSK2193874 
(300mg/kg). Guinea pigs were injected i.p. with a single antagonist or vehicle (1% DMSO in 0.9% 
saline v/v for HC067047, or 6% Cavitron/2-Hydroxypropyl-β-cyclodextrin in saline v/v for 
GSK2193874), 1 hour prior to exposure to GSK101 (3g/ml). GSK101 was aerosolised for 5 
minutes, and the number of coughs counted for 10 minutes. 
3.2.6.1: Analysis 
In order to test inhibition of cough by the TRPV4 antagonists, a Mann Whitney U test was used, 
which compared responses from the antagonist group to vehicle control. The data is presented 
as median ± interquartile range, with statistical significance set at P < 0.05. 
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3.3: Results 
3.3.1: TRPV4 expression in nodose and jugular ganglia 
The nodose and jugular ganglia are known to hold the cell bodies for airway terminating vagal 
fibres.  Prior to analysis of the ganglia, it was first confirmed that TRPV4 was expressed in guinea 
pig tissue, as guinea pigs are the only rodent known to have a cough reflex similar to that of man. 
RTPCR was carried out as described in Section 2.4.3 in a variety of tissues, and RNA from the 
tissue with the most abundant expression, in this case the kidney, was serially diluted and used 
for validation (Figure 3.1A). A further PCR experiment was carried out with the diluted tissues 
and graph was plotted of log cDNA vs Ct. The assay was found to be valid as the lines 
corresponding to TRPV4 and the internal control (18s) were parallel straight lines with difference 
in slopes < 0.1 and R2 value > 0.98, therefore showing both assays to be equally efficient (Figure 
3.1B). Following validation, quantitative RTPCR of whole nodose and jugular ganglia was carried 
out to investigate levels of TRPV4 mRNA. TRPV4 was determined to be expressed at the mRNA 
level in both ganglia, in accordance to previously published data (Ni et al. 2006) (Figure 3.1C). 
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Figure 3.1: mRNA expression of TRPV4 in whole ganglia 
(A): RTPCR was carried out on a variety of tissues from the guinea pig, where the kidney was found to 
have the most abundant expression. (B) The assay was found to be valid as the lines corresponding to 
TRPV4 and the internal control (18s) were parallel straight lines with difference in slopes <0.1 and R2 value 
> 0.98, therefore showing both assays to be equally efficient. (C) TRPV4 is expressed at the mRNA level 
in both nodose and jugular ganglia, with a higher level being present in the nodose. The data is expressed 
as mean±S.E.M., n=4, and is normalised to the 18s control. 
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3.3.2: Effect of TRPV4 on [Ca2+]i in nodose and jugular ganglia 
Once TRPV4 was known to be expressed at the mRNA level in whole ganglia, a functional effect 
was investigated using [Ca2+]i signal in guinea pig isolated nodose and jugular ganglia neurons, 
where a change in [Ca2+]i response is indicative of activation. Following a full concentration 
response to the TRPV4 agonist, GSK101 was shown to cause a concentration-dependent 
increase in [Ca2+]i signal in airway specific nodose, but had less effect in the jugular ganglia 
neurons (Figure 3.2 D-E). Maximum [Ca2+]i  signals in responsive cells from the nodose ganglia 
were 132%±50% of the K50 A.U.C. at 300nM of GSK101 (Figure 3.2 A-C). There were a total of 
36 airway nodose cells examined, of which 75% responded to GSK101, and 34 jugular airway 
cells of which only 12% were responsive to GSK101 stimulation (Figure 3.2D). Non-airway 
neurons indicated a similar pattern wherefrom a total of 58 non-airway nodose neuronal cells, 
52% were responsive, and of the 46 non-airway jugular neurons, 20% responded to GSK101 
stimulation.  
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Figure 3.2: Effect of TRPV4 on [Ca2+]i in nodose and jugular ganglia 
A-C indicate example images and traces from [Ca2+]i induced by GSK101 in nodose cells. A: Bright field 
and DiI stained cell indicating that the neuron is airway specific. B: An example trace of [Ca2+]i induced by 
GSK101 in a nodose cell, shown as changes in light intensity over time. The grey bar indicates 
administration of agonist and incubation time. C: Real time images of calcium release induced by 100nM 
GSK101. The numbers above each panel indicate number of seconds, with 0seconds indicating GSK101 
administration. Increase in red indicates increase in [Ca2+]i with an colour indicator to the right. D: GSK101 
caused a concentration-dependent increase in [Ca2+]i as shown by % K50 AUC, with a peak response at 
300nM. E: However, there was no effect of GSK101 on jugular neurons. 
The data is presented as mean ± S.E.M. of N=4-6, n=4-11. * indicates statistical significance (p < 0.05), 
Kruskall Wallis test with Dunns post-test comparing responses to vehicle. 
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3.3.3: Effect of TRPV4 agonists on depolarisation of isolated vagal nerves 
3.3.3.1: Effect of selective TRPV4 agonists 
The in vitro isolated vagal nerve technique provides an airway relevant model free from problems 
such as bronchoconstriction or mucus production that can occur in vivo, where a functional role 
for TRPV4 in sensory nerves can be demonstrated. A further advantage is that translational data 
can be obtained using donor human tissue. The ability of two synthetic ligands GSK101 and 
4αPDD to cause depolarisation of both guinea pig, murine and human isolated vagal nerves was 
investigated.  
The TRPV4 specific ligands GSK101 and 4αPDD caused a concentration dependent 
depolarisation of both guinea pig (Figure 3.3 A,B) and mouse (Figure 3.3 C,D) vagal tissue. 
GSK101 (1µM) caused a maximum depolarisation of 0.21mV±0.024mV, and 4αPDD (3µM) 
caused a maximum depolarisation of 0.21±0.038mV in guinea pig tissue, which were both around 
50-70% of the depolarisation induced by capsaicin (1µM). In mouse tissue, GSK101 (1µM) 
caused a maximum depolarisation of 0.25mV±0.039mV, and 4αPDD (3µM) 0.20mV±0.028mV, 
which was again around 50-70% of the control capsaicin response.  
Sub maximal concentrations of GSK101 (300nM) and 4αPDD (1µM), chosen from the 
concentration responses in guinea pig and murine tissue, were also able to activate isolated 
human vagus nerve (Figure 3.3 E). GSK101 was able to cause a depolarisation of 
0.10mV±0.039mV and 4αPDD 0.087mV ±0.01mV in the human vagus. 
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Figure 3.3: Effect of TRPV4 agonists on activation of isolated vagal nerves 
GSK101 and 4αPDD caused concentration-dependent depolarisation of guinea pig (A,B) and murine (C, 
D) tissue. Submaximal concentrations of both GSK101 (300nM) and 4αPDD (1µM) were also able to cause 
depolarisation of human vagal tissue. The data is shown as mean ± S.E.M.  of n=4-6 for guinea pig and 
mouse tissue, and n=3 for human and human tissue was obtained from 3 male donors aged 47-57 with no 
known respiratory disease. * indicates statistical significance at p<0.05 using Kruskal Wallis test and Dunns 
post-test comparing responses to vehicle.  
3. Investigating a role for TRPV4 in airway sensory nerves 
 
81 
 
 
3.3.3.2: Effect of selective TRPV4 antagonists 
The ability of two structurally distinct TRPV4 antagonists, HC067047 and GSK2193874 to inhibit 
TRPV4 dependent depolarisation was then investigated. A concentration response (0.1-10µM) to 
each antagonist against GSK101 (300nM) was initially carried out (Figure 3.4). HC067047 
(10µM) was able to inhibit GSK101 induced depolarisation in both guinea pig and mouse tissue 
(Figure 3.4 A,D). In guinea pigs, depolarisation was inhibited 86% ± 9% in the presence of the 
maximally effective concentration of HC067047 (10µM) and in mice, depolarisation was inhibited 
93% ± 4% by the same concentration of antagonist. HC067047 (10µM) also inhibited 4αPDD 
(1µM) induced depolarisation to 95% ± 4% in guinea pig and 86% ± 8% in mouse tissue (Figure 
3.4 B,E). 
The alternate TRPV4 antagonist GSK2193874, showed a similar profile against GSK101 in the 
guinea pig. At the maximal effective concentration (10µM), it was able to inhibit GSK101 (300nM) 
induced depolarisation 93% ± 7% (Figure 3.4 C). 
The maximal effective concentrations of HC067047 (10µM) and GSK2193874 (10µM) were 
investigated against GSK101 (300nM) and 4αPDD (1µM) induced depolarisation in human donor 
tissue. Both antagonists were also able to inhibit TRPV4 induced depolarisation to around 80-
100%, similar to what was seen in rodent tissue (Figure 3.5 A, B).  
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Figure 3.4: Effect of selective TRPV4 antagonists on TRPV4 induced depolarisation 
The TRPV4 specific antagonist HC067047 inhibited GSK101 (300nM) induced depolarisation in a 
concentration dependent manner in (A) guinea pig and (D) mouse tissue, with a maximal effect at 10µM. 
This maximal concentration was able to inhibit depolarisation induced by 4αPDD to around 90% in both 
guinea pig (B) and mouse (E) tissue.  (C): An alternate TRPV4 antagonist GSK2193874, also caused a 
concentration dependent inhibition of depolarisation induced by GSK101 (300nM) with similar potency to 
HC067047 in the guinea pig.  
Vehicle (Veh; 0.1% DMSO) had no effect on nerve activation induced by either agonist in any species 
tested. The data is presented as mean ± S.E.M. of n=4-6 observations. * indicates statistical significance 
(p < 0.05), paired t-test comparing responses in the same piece of nerve with and without antagonist. 
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Figure 3.5: Effect of selective TRPV4 antagonists on TRPV4 induced depolarisation in human 
tissue 
(A) Both antagonists were also able to inhibit depolarisation in human tissue, with an example trace 
indicated in (B).  
Vehicle (Veh; 0.1% DMSO) had no effect on nerve activation induced by either agonist in any species 
tested. The data is presented as mean ± S.E.M. n=2-3 observations, and human tissue was obtained from 
2 female and 1 male donor aged 38-70 with no known respiratory disease. * indicates statistical significance 
(p < 0.05), paired t-test comparing responses in the same piece of nerve with and without antagonist. 
 
3.3.3.3: Determining specificity of tools 
The next step was to investigate the specificity of the tools for the TRPV4 ion channel. In order to 
do this, the TRPV4 specific ligands were initially tested in vagal tissue from Trpv4-/- mice (Figure 
3.7). The ligands were tested alongside agonists for the TRPV1 (capsaicin) and TRPA1 (acrolein) 
ion channels, as these are both known activators of vagal sensory nerves (Grace et al., 2012). 
Channel knockout was determined using standard genotyping techniques, and an example gel is 
shown in Figure 3.6 where WT bands are at 740bp and Trpv4-/- at 1490bp. 
In the knockout mice, responses to the TRPV4 ligands GSK101 and 4αPDD were virtually 
abolished (Figure 3.7 p<0.05). Responses to the TRPV1 ligand capsaicin (1µM) and the TRPA1 
ligand acrolein (300µM) remained unchanged in both wild type and knockout tissue. In addition 
there was no change in any of the responses to the endogenous prostanoid agonists PGE2 and 
PGD2, which are also known to activate vagus tissue (Maher et al., 2009).  
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Figure 3.6: Trpv4-/- gel 
RTPCR was used to confirm knockout of the TRPV4 gene using DNA extracted from tail tips from mice 
used in Figure 3.7. Wild type mice produced a band at 740bp and KOs at 1490bp. A 50-2000bp ladder 
was used (L), and a water control (C). Wild type and knockout primers were run in the same reaction. 
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Figure 3.7: TRP ligands in Trpv4-/- mice 
Responses to the selective TRPV4 ligands GSK101 (300nM) and 4αPDD (1μM) were abolished in  
Trpv4-/- mice. Responses to the TRPV1 ligand Capsaicin (1μM), the TRPA1 ligand Acrolein (300μM) and 
the endogenous prostanoids PGE2 (10μM) and PGD2 (10μM) were unaltered. The data is presented as 
mean ± S.E.M.. of n=4-6. * indicates statistical significance (p < 0.05), unpaired t-test comparing responses 
in Trpv4-/- tissue with wild-type control. 
  
As the responses were found to be abolished in the knockout tissue, the ligands were then 
pharmacologically evaluated against TRPV1 and TRPA1 selective antagonists to ensure that the 
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agonists were not having an off target effect on the TRPV1 and TRPA1 ion channels. 
Depolarisation by GSK101 (300nM) and 4αPDD (1µM) were tested against the TRPA1 selective 
antagonist HC030031 (10µM, (Grace et al., 2012)) and the TRPV1 selective antagonist 
JNJ17230212 (100µM; (Grace et al., 2012)), using HC067047 (10µM) as a positive control in both 
guinea pig and mouse tissue (Figure 3.8). Depolarisation was inhibited by the specific TRPV4 
antagonist HC067047, but the TRPA1 antagonist (HC030031; 10µM) or TRPV1 antagonist 
(JNJ17230212; 100µM) had no effect on GSK101 (300nM) or 4αPDD (1µM) induced 
depolarisation in either guinea pig (A,B) or mouse (C,D) tissue (Figure 3.8). 
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Figure 3.8: Effect of TRPA1 and TRPV1 antagonists on depolarisation induced by TRPV4 agonists. 
The TRPV4 ligands GSK101 and 4αPDD were tested against the selective TRPA1 and TRPV1 antagonists 
HC030031 (10μM) and JNJ17203212 (100μM) in both guinea pig (A,B) and mice (C,D). In both species, 
both GSK101 and 4αPDD were inhibited by the TRPV4 antagonist HC067047 (10μM), but neither the 
TRPA1 antagonist nor the TRPV1 antagonist had any effect on depolarisation induced by either agonist. 
Data are presented as mean ± S.E.M. of n=4-6 observations. * indicates statistical significance (p < 0.05), 
paired t-test comparing responses in the same piece of nerve with and without antagonist. 
The specificity of the TRPV4 antagonists was also evaluated against depolarisation induced by 
capsaicin (1µM; TRPV1) and acrolein (300µM; TRPA1) in guinea pig and mouse tissue (Figure 
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3.9). Neither antagonist had any effect on capsaicin nor acrolein induced depolarisation, indicating 
that the antagonists had no effect on either TRPV1 or TRPA1 in guinea pig (A-B) or mouse tissue 
(C-D) and were therefore suitable tools to take forward in vivo.  
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Figure 3.9: Effect of TRPV4 antagonists on TRPV1 and TRPA1 induced depolarisation 
Neither HC67047 (10μM) (A) nor GSK2193874 (10μM) (B) had any effect on TRPV1 (Capsaicin) or TRPA1 
(Acrolein) induced depolarisation in the guinea pig. A similar result was seen in mouse tissue (C,D). The 
data is presented as mean ± S.E.M of n=3-6 observations 
 
3.3.3: Effect of TRPV4 agonists on firing of single vagal fibres in vivo 
Although TRPV4 ligands have been shown to cause induction of Ca2+ and depolarisation of the 
vagus, this may not be indicative of inducing an action potential. This was investigated using the 
in vivo single fibre recording technique which allows the investigation of action potential firing from 
a single airway terminating afferent fibre.  In addition, this technique provides a method to probe 
which airway specific fibre is responsible for TRPV4 mediated activation of the vagus nerve. 
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The effect of aerosolised GSK101 (10μg/ml, 1 minute) was investigated on both C-fibres and Aδ-
fibres.  These fibres were distinguished according to capsaicin and citric acid sensitivity, response 
to hyperinflation and deflation and spontaneous activity, and ultimately through determination of 
conduction velocity (CV) (Adcock et al., 2003).  The 3 C-fibres under investigation had CVs of 
0.52-0.92imp/s, and the 3 faster conducting Aδ-fibres had CVs of 2.3-7.14imp/s. Two of the 3 Aδ-
fibres were capsaicin sensitive. 
GSK101 (10μg/ml) caused a significant increase in firing in all 3 Aδ-fibres under investigation, but 
had no effect on C-fibres (Figure 3.10 A). The frequency of impulses was increased from 
2.0±0.6imp/s to 12.4±3.9imp/s following application of GSK101 in the Aδ-fibres (Figure 3.10 B), 
whereas there was no increase in the C-fibres investigated following GSK101, however both 
capsaicin and citric acid both caused a significant increase in firing frequency (Figure 3.10 C). 
Firing induced by GSK101 was much slower in onset to that caused by capsaicin or citric acid, 
but it was longer lasting, continuing for over 30 minutes. GSK101 also caused a marked 
bronchoconstriction in all animals investigated, which was also slow in onset and occurred after 
Aδ-fibre activation (Figure 3.10 D). 
In order to test specificity of fibre firing induced by the TRPV4 agonist, the TRPV4 antagonist 
GSK2193874 (300mg/kg) was tested against GSK101 (100ng/ml) induced firing in Aδ fibres. A 
lower concentration of GSK101 was used as the initial concentration did not allow repeated 
measurements. Following i.p administration of GSK2193874, firing frequency induced by GSK101 
(100ng/ml) was significantly reduced. Firing was reduced from 20.33±2.848imp/s to 
5.67±0.33imp/s (Figure 3.10 E).  
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Figure 3.10: Effect of aerosolised GSK101 on single fibre firing in vivo 
(A): Aerosolised GSK101 (10μg/ml, 1 minute) caused firing in Aδ fibres, but not C fibres, and also caused 
a marked bronchoconstriction as indicated by the example trace. The top panel of each trace indicated 
increase in tracheal pressure (increase in cmH20) following application of the agonist, and the lower panel 
indicates action potential firing. (B): Both citric acid (0.3M) and GSK101 caused a significant increase in 
firing frequency in Aδ fibres, but only capsaicin (100μM) and citric acid caused an increase in C fibres (C). 
(D): GSK101 (10μg/ml) agonist caused a large sustained bronchoconstriction in all animals. (D: Aδ fibres 
investigated and C fibres not shown). (E): The TRPV4 antagonist GSK2193874 (300mg/kg in 6% 
Cavitron/2-Hydroxypropyl-β-cyclodextrin in saline v/v) significantly inhibited firing induced by GSK101 
(100ng/ml) in Aδ fibres. The data is presented as mean ± S.E.M. of n=3 observations. Veh = vehicle. * 
indicates statistical significance (p < 0.05), paired t test comparing responses before and after aerosol 
administration of agonist or antagonist. 
3. Investigating a role for TRPV4 in airway sensory nerves 
 
89 
 
3.3.4: Effect of the TRPV4 agonist GSK1016790a on the naïve guinea pig cough response 
GSK101 has been shown to activate the vagal ganglia and depolarise vagal nerves, and cause 
firing of Aδ-fibres, which are all indicative of a cough response in vivo.  However, the ability of a 
TRPV4 agonist to cause reflex cough in a conscious whole animal system is yet to be determined. 
Therefore a guinea pig conscious cough model was next used to investigate the tussive capability 
of the more potent of the two TRPV4 ligands; GSK101.  
Aerosolised GSK101 (1-30µg/ml) caused a dose dependent increase in number of coughs in 
naïve, conscious guinea pigs (Figure 3.11 A).  The type of coughs caused by the agonists 
included single explosive coughs similar to those seen with acrolein and capsaicin (Grace et al., 
2012) but also caused trains of smaller coughs, similar to those seen with PGE2 (Maher et al., 
2009). Aerosolised vehicle (1% ETOH and 1% TWEEN in saline) had no effect on cough.  
A submaximal concentration of the GSK101 agonist (3µg/ml) was then taken forward to test 
against the TRPV4 specific antagonist HC067047 (100mg/kg i.p.). The antagonist caused a 
significant inhibition in the number of coughs caused by GSK101 compared to vehicle control 
(Figure 3.11B). The alternate antagonist GSK2193874 (300 mg/kg i.p.) reduced the number of 
coughs caused by the highest concentration of GSK101 (30µg/ml) (Figure 3.11 C). As these were 
two separate experiments with different cohorts of guinea pigs, a higher concentration of GSK101 
was required for the second experiment to induce a similar tussive response. Vehicle for either 
antagonist had no effect on the cough response.  
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Figure 3.11: GSK101 induced cough 
(A): GSK101 (aerosolised for 5 minutes) caused a dose dependent increase in number of coughs in 
conscious, naïve guinea pigs. (B) The selective TRPV4 antagonist HC067047 (100mg/kg in 1% DMSO in 
0.9% saline v/v i.p administered 1 hour before GSK101 exposure) significantly inhibited the number of 
coughs induced by GSK101 (3μg/ml). (C) An alternate TRPV4 antagonist GSK2193874 (300mg/kg i.p.) 
also inhibited the number of coughs induced by GSK101 (30μg/ml, 5 minutes), but did not reach 
significance. Vehicle (0.1% DMSO and 1% TWEEN in saline) had no effect on the cough response. The 
data is presented as median ± interquartile range of (A) n=4, (B) n=12 and (C) n=8 observations. * indicates 
statistical significance (p < 0.05), Mann Whitney U test comparing responses from the antagonist group to 
vehicle control. 
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3.4: Discussion 
The aim of this chapter was to investigate a role for the TRPV4 ion channel in activation of airway 
sensory nerves and cough. There is currently an abundance of literature that outline the role of 
two TRP channels TRPV1 and TRPA1 in airway sensory nerve activation and cough (for example; 
(Andrè et al., 2009; Birrell et al., 2009; Grace et al., 2012), however the role of TRPV4 remains 
relatively unexplored.  TRPV4 is a calcium permeable ion channel which has been shown to be 
expressed at the mRNA level in pulmonary sensory neurons in rats (Ni et al., 2006). A role for 
TRPV4 in the airways has been eluded to as TRPV4 ligands are known to cause contraction of 
airway smooth muscle (Jia et al., 2004; McAlexander et al., 2014) and polymorphisms of the 
channel are present in COPD (Zhu et al., 2009). TRPV4 is activated by a number of endogenous 
ligands present in the diseased airway such as arachidonic acid derivatives (Watanabe et al., 
2003) and an altered airway osmolarity (Liedtke et al., 2000; Strotmann et al., 2000; Jia et al., 
2004), where airway sensory nerve responses are thought to be altered, and therefore it may be 
assumed that TRPV4 could play a role in airway sensory nerve activation and cough. This was 
evaluated by determining a functional role for TRPV4 in airway ganglia and in depolarisation of 
vagal nerves, in addition in vivo studies were carried out to investigate the effect of TRPV4 on 
airway single fibre firing and guinea pig conscious cough. 
Before determining a functional role for TRPV4, it was established that the TRPV4 ion channel 
was expressed at the mRNA level in nodose and jugular ganglia, which contain the cell bodies of 
the afferent fibres which project to the lung. As TRPV4 was expressed in both ganglia, a functional 
role was determined using calcium imaging of airway specific fibres.  It was shown that GSK101, 
a potent and selective activator of the TRPV4 ion channel (Thorneloe et al., 2008), caused an 
increase in [Ca2+]i signal in airway specific nodose ganglia in a concentration dependent manner. 
Interestingly, in all cases there appeared to be a short delay prior to activation. However GSK101 
did not appear to affect the jugular ganglia tested. In general, it is thought that the more 
chemosensitive C-fibres originate from the jugular ganglia, whereas the more mechanosensitive 
Aδ-fibres originate from the nodose (Ricco et al., 1996; Undem et al., 2004; Canning et al., 2006b), 
therefore suggesting a potential novel role for TRPV4 in activation of mechanosensitive Aδ-fibres.  
The effects of TRPV4 ligands were then pharmacologically evaluated in the in vitro model of vagal 
nerve depolarisation. Both guinea pig and mouse tissue were used as guinea pigs have a cough 
reflex similar to that of man, and mice, as although they do not cough per se, the afferent arm of 
the reflex has been shown to act similarly (Maher and Belvisi, 2010), and also allows the use of 
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transgenic animals. The selective TRPV4 ligands GSK101 and 4αPDD were shown to cause 
concentration dependent increases in depolarisation in both guinea pig, and mouse tissue. The 
submaximal concentration of GSK101 taken forward for antagonist studies was 300nM, and 
4αPDD; 1μM in the guinea pig tissue, which relate to the published pEC50 values from mouse of 
7.7 for GSK101 and 6.7 for 4αPDD (Watanabe et al., 2002; Thorneloe et al., 2008). The selective 
TRPV4 antagonists HC067047 and GSK2193874 were both shown to inhibit submaximal 
responses of each of these agonists indicating that the depolarisation seen was through activation 
of the TRPV4 ion channel. Both antagonists elicited maximal inhibition at 10μM, which would 
indicate that the antagonists are less potent than the published IC50s (HC067047 of 7.8 and 
GSK219 of 8.3 in mouse tissue) would suggest (Everaerts et al., 2010; Thorneloe et al., 2012). 
This could signify that these antagonists are less potent in guinea pig tissue, or differences in the 
in vitro preparation used.  
A major advantage of the vagus technique meant that key experiments with both agonists and 
antagonists could be repeated in donor human tissue. TRPV4 ligands were shown to activate 
human vagal nerves, and this activation was inhibited by the selective antagonists to a similar 
degree as seen in rodent tissue. This indicates that the results obtained with guinea pig and 
mouse tissue are likely to translate to the clinic. 
Selectivity of the ligands was determined initially in TRPV4 knockout mice, where the responses 
to both GSK101 and 4αPDD were abolished in the knockout tissue; however responses to the 
TRPV1 and TRPA1 agonists capsaicin and acrolein, and the endogenous prostanoid agonists 
PGE2 and PGD2 remained unchanged. This highlights a further difference between TRPV4 and 
the further characterised TRP channels; depolarisation induced by PGE2 has been shown to be 
due to indirect agonism of both the TRPV1 and TRPA1 ion channels (Grace et al., 2012), whereas 
it was clear that PGE2 induced responses were unchanged in the TRPV4 knockouts.  
Furthermore, both GSK101 and 4αPDD induced depolarisation was tested against the TRPV1 
selective antagonist JNJ17203212 and the TRPA1 antagonist HC030031 where it remained 
unaffected. Neither HC067047, nor GSK2193874, showed any inhibitory effect on capsaicin or 
acrolein induced depolarisation in the guinea pig or mouse. This therefore indicates that the 
TRPV4 ligands used were selective for their receptor.  
By using in vitro studies to pharmacologically evaluate the TRPV4 ligands, this provided a reliable 
alternative to in vivo experiments which can have complex pharmacokinetic issues and require a 
large number of animals and compounds, and are therefore also expensive. However, the vagus 
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nerve can also innervate visceral organs other than the airways (Standring, 2005), and also the 
expression of receptors and signal transduction pathways on the nerve trunk may not be the same 
as on the nerve endings (Patel et al., 2003). Therefore to circumvent this, the more potent of the 
two ligands, GSK101, was taken forward into in vivo studies where its ability to propagate an 
action potential, and also cause cough in the conscious guinea pig was evaluated.  
According to current understanding there are several known airway sensory afferents as 
described in the introduction (Section 1.3.1). Of these, three fibre types are more mechanically 
sensitive; RARs (classical RARs, irritant receptors and Aδ fibres (Adcock et al., 2003, 2014)), 
SARs and the cough receptor. Chemosensitive afferent fibres include the Aδ nociceptors and C 
fibres.  GSK101 was shown to cause sustained firing (lasting for over 30 minutes) of the Aδ fibre 
subset of RARs (CVs ranging from 2.3-7.14m/s) in the anaesthetised guinea pig, and of the 3 
fibres investigated, two were capsaicin sensitive. The ligand did not induce firing of any of the C 
fibres investigated. In addition this firing was significantly inhibited following i.p. administration of 
the TRPV4 antagonist GSK2193874 (300mg/kg). The Aδ fibres under investigation had a 
spontaneous discharge with a clear rhythmical respiratory pattern and adapted rapidly to 
hyperinflation and deflation. These fibres were a subset of the fast conducting, myelinated RAR 
fibres which conduct action potentials in the Aδ range  (CV >3m/s (Canning et al., 2006b)), are 
thought to be housed in the nodose ganglia and respond to mechanical stimuli along with citric 
acid (Ricco et al., 1996; Adcock et al., 2003; Canning et al., 2006b). In addition it has recently 
been shown that there is a subset of RAR Aδ fibres which respond to capsaicin regardless of 
conduction velocity (Adcock et al., 2014).  In contrast, a large number of chemical stimuli which 
have been shown to cause cough in animals and in man  along withTRPV1 and TRPA1 ligands, 
have been shown to more commonly activate the chemosensitive C fibres (Coleridge and 
Coleridge, 1984; Lalloo et al., 1995; Canning, 2004; Birrell et al., 2009).  These fibres are 
unmyelinated and slower conducting (CV <2m/s), are relatively insensitive to mechanical stimuli 
and are thought to be mostly derived from the jugular ganglia (Undem 2004, Canning 2006). As 
the fibres are unresponsive to mechanical stimuli, the chemical stimuli activate the nerves directly 
(Undem 2004; Chuaychoo et al. 2005).  
RARs are traditionally thought to be extremely sensitive to mechanical stimuli, but are not typically 
activated by a direct chemical stimulus (with the exception of citric acid) and therefore activation 
of a typically mechanosensitive fibre by a TRPV4 ligand is a highly interesting and novel 
observation. RARs can be indirectly activated following bronchoconstriction and mucus 
production induced by activation of C fibres (Widdicombe, 2003; Canning et al., 2006a); however 
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in all cases with TRPV4, bronchoconstriction began after fibre firing, so activation is unlikely to be 
through this mechanism.  Alongside the Ca2+ data from the nodose ganglia, these results confirm 
a novel role for TRPV4 in activation of mechanosensitive Aδ fibres. This novel observation, along 
with the mechanism of activation requires further investigation.  
It was interesting to note that TRPV4 was expressed at the mRNA level in both the nodose and 
the jugular ganglia, but a functional response was only seen in the nodose and in Aδ fibres; 
GSK101 did not seem to have an effect on the calcium signal from the jugular ganglia or on C 
fibre firing.  This would suggest that TRPV4 is present on C fibres, but activation does not lead to 
action potential firing. However, mRNA expression does not indicate protein levels and active 
channel activity, so in order to further examine this, protein levels should be measured from both 
ganglia. Unfortunately the lack of reliable antibodies for TRP channels has meant that protein 
level could not be assessed at this time. One caveat to mention is that expression was measured 
in whole ganglia, which houses a variety of cell types including dendritic cells, glia and 
macrophages. Therefore TRPV4 may not be expressed on nerves themselves and instead on 
surrounding cells which could then induce signalling pathways which lead to activation of sensory 
nerves.  
In addition to prolonged fibre firing, GSK101 caused a marked, sustained bronchoconstriction in 
all animals investigated. The sustained firing could have been a secondary result of this 
bronchoconstriction seen with GSK101, as it occurred on mechanosensitive Aδ fibres. However, 
it has been shown in vitro that GSK101 is capable of causing compound depolarisation of the 
vagus nerve and alter [Ca2+]i signal in the vagal ganglia, in systems free from bronchoconstriction. 
In addition, firing began prior to bronchoconstriction in all fibre types investigated, and in all cases, 
bronchoconstriction was slow in onset and lasted for over 30 minutes. Furthermore, both vagal 
nerves were cut at the central end and so this response seems unlikely to be through a reflex 
event. Previous work in vitro has indicated that GSK101 is able to cause contraction of isolated 
guinea pig and human airway smooth muscle (Jia et al., 2004; McAlexander et al., 2014), through 
release of cysteinyl leukotrienes, which was blocked by TRPV4 antagonists. These results would 
suggest that TRPV4 is able to cause bronchoconstriction independent from Aδ fibre firing.  
Although the single fibre technique allows the investigation of airway fibre firing, as both vagal 
nerves were cut and the guinea pig anaesthetised, it was yet to be seen if TRPV4 was able to 
cause a full reflex event in a conscious animal. In order to investigate this, a guinea pig cough 
model was utilised which allowed the aerosolisation of compounds to the conscious guinea pig 
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where cough responses could be monitored by two blinded trained cough observers, and also 
effects on bronchoconstriction could be monitored.  The key advantage of this technique is that 
studies have shown that tussive responses induced in guinea pigs closely resemble that seen in 
man (Laude et al., 1994; Birrell et al., 2009), and therefore results could translate to the clinic. 
GSK101 was demonstrated to cause a concentration dependent increase in the cough response 
in the conscious guinea pig.  The cough response was inhibited by two antagonists of TRPV4; 
HC067047 and GSK2193874. These results indicate that GSK101 is capable of causing full reflex 
events in a conscious animal through the TRPV4 channel. 
In summary, TRPV4 ligands have been shown to directly activate airway sensory nerves in vitro, 
through causing an increase in [Ca2+]i signal in airway cells from the nodose ganglia, and also 
causing concentration dependant depolarisation in both guinea pig and human vagal nerves. In 
vivo, GSK101 was shown to cause a significant, sustained firing of mechanosensitive Aδ fibres, 
and also caused reflex cough in the conscious guinea pig.  This body of data outlines a role for 
the TRPV4 ion channel in activation of sensory nerves and the cough reflex, through activation of 
nodose derived Aδ mechanoreceptors, a different mechanism to what is seen with other TRP 
channels. Therefore, it can be concluded that the chapter hypothesis ‘Activation of TRPV4 on 
airway sensory nerves by selective agonists leads to nerve activation and cough’ can be 
accepted. This is an exciting and novel observation which requires further investigation.  
Throughout this chapter the role of TRPV4 has been determined using exogenous, synthetic 
ligands which, although are selective for the TRPV4 ion channel, do not occur in vivo. TRPV4 
was originally characterised as a sensor of osmotic stress, (Strotmann et al., 2000; Liedtke and 
Friedman, 2003; Suzuki et al., 2003) as Trpv4-/- mice show abnormalities with systemic osmotic 
and external somatosensory stimuli (Liedtke et al., 2000) and also as a mechanosensor, as a 
sensor of osmotic stress it is sensitive to cell swelling (Liedtke et al., 2000). Airway osmolarity is 
known to be altered in disease (Joris et al., 1993; Jia et al., 2004), where airway sensory nerve 
responses are known to be enhanced. Therefore in the following chapter, I will outline a role for 
the activation of sensory nerves by TRPV4 using changes in osmolarity; an endogenous, disease 
relevant stimuli. 
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4.1: Rationale 
Alterations in airway osmolarity can occur in disease; in asthmatics the osmolarity airway 
surface fluid in the lungs is decreased (Joris et al., 1993), and asthmatics also experience 
exercise induced bronchoconstriction following dehydration of the airway surface liquid after 
exercise which leads to an increase in airway osmolarity (Weiler et al., 2010; Anderson and 
Kippelen, 2012; Hallstrand, 2012). Furthermore, solutions of both increased and decreased 
osmolarity have been reported to cause activation of airway sensory nerves and reflex events 
such as cough in both animals and humans (Eschenbacher et al., 1984; Fuller and Collier, 
1984; Lalloo et al., 1995). However, the mechanism by which this occurs in airway sensory 
nerves is yet to be determined. The ion channel TRPV4 was originally characterised as a 
sensor of osmotic stress, and mice lacking the TRPV4 ion channel have shown abnormalities 
in osmotic regulation (Liedtke, et al., 2000; Mizuno et al., 2003; Suzuki et al., 2003). In addition, 
TRPV4 has been well documented to act as an osmosensor and mechanosensor in both 
nerves and the brain (Alessandri-Haber et al., 2003; Mizuno et al., 2003; Suzuki et al., 2003). 
As demonstrated in the previous chapter, activation of TRPV4 is capable of causing firing of 
airway sensory nerves and cough in a conscious animal, and therefore it could be 
hypothesised that TRPV4 acts as an osmosensor in airway sensory nerves.  
4.1.1: Chapter Hypothesis: 
TRPV4 channels present on airway sensory nerves are activated by changes in osmolarity 
4.1.2: Aims; 
 This will initially be achieved by pharmacological characterisation of solutions of both 
increased (prepared using increasing concentrations of sucrose) and decreased 
(prepared by salt reduction and compensation with sucrose) osmolarity.  These 
solutions will be evaluated using the in vitro isolated vagus system with guinea pig, 
murine and human tissue  
 To determine the role of TRPV4 and also TRPV1 and TRPA1 in the activation of 
sensory nerves by changes in osmolarity, using selective antagonists of the TRPV1 
(JNJ17203212; 100µM), TRPA1 (HC030031; 10µM) and TRPV4 (HC067047; 10µM 
and GSK2193874; 10µM) channels alongside Trpv1-/-, Trpa1-/- and Trpv4-/- knockout 
mice.  
 Finally the solutions will then be taken forward to be tested in vivo to determine whether 
they are able to propagate an action potential in guinea pig single fibres, and if so 
which fibre type is responsible.  
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4.2: Methods 
4.2.1: Preparation of solutions 
Hyperosmotic solutions were prepared fresh on the day of the experiment using a modified 
Krebs Heinslett solution with increasing concentrations of sucrose. Modified Krebs solution 
was prepared as described previously in Chapter 2, and to increase the osmolarity of the 
solution, increasing concentrations of sucrose were added. A solution of 305mOsm (10 mOsm 
above normal osmolarity of ~295mOsm (Denton et al., 1996; Bourque and Oliet, 1997)) was 
prepared by adding 10mM of sucrose (+10mOsm), a solution of 325mOsm; 30mM 
(+30mOsm), a solution of 395mOsm; 100mM (+100mOsm), a solution of 495mOsm; 200mM 
(+200mOsm) and a solution of 595mOsm; 300mM (+300mOsm). The control solution for these 
experiments was modified Krebs solution.  
The hypoosmotic solutions were also made fresh on the day of the experiment using a 
modified Krebs-Heinslett solution with salt reduction, followed by gradual compensation with 
sucrose. A solution of 195mOsm (100mOsm below normal osmolarity) contained (in mM; 7 
KCl, 63 NaCl, 1.2 MgCl2, 1.2 NaH2PO4, 5.6 D-Glucose, 25.5 NaHCO3, 2.5 CaCl2). Solutions 
of increasing osmolarity were then made by addition of sucrose. For solutions of 215mOsm (-
80), 235mOsm (-60), 255mOsm (-40), 275mOsm (-20) and 295mOsm (0), sucrose was added 
to the modified Krebs solution (in mM: -80mOsm: 20, -60mOsm: 40, -40mOsm: 60, -20mOsm: 
80, 0mOsm: 100). As the chloride content of these solutions is significantly reduced and 
therefore could have a functional effect, the 0mOsm solution was used both before and after 
application of the hypoosmotic solution.  
Osmolarity of all solutions used was confirmed using a cryo-osmometer (Osmomat030, 
Gonotec, Germany).  
 
4.2.2: Isolated vagal nerve recordings 
Vagal tissue was dissected from male Dunkin-Hartley guinea pigs, WT C57/Bl6 mice, and 
knockout (Trpv4-/--, Trpa1-/- and Trpv1-/-) mice, and placed in a grease-gap recording chamber 
as previously described in Section 2.6. Human donor tissue was also obtained for translational 
data, where key experiments were repeated. 
4.2.2.1: Concentration response curves 
Concentration response curves were carried out in WT C57/Bl6 mice, male Dunkin Hartley 
guinea pigs and donor human vagal tissue. In order to determine if osmotic solutions were 
able to depolarise the vagal nerve, the following experimental protocol was undertaken. Non-
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cumulative concentrations of either hypoosmotic (0mOsm to -100mOsm below normal 
osmolarity of 295mOsm), or hyperosmotic solutions (0mOsm to +1000mOsm above normal 
osmolarity of 295mOsm) were applied to the vagal nerve trunk followed by a wash period 
where the nerve was washed with Krebs solution until it returned to baseline. Responses were 
recorded as mV depolarisation. A submaximal concentration of each of the osmotic stimuli 
was then taken forward to be tested against TRP antagonists and in knockout mice. 
4.2.2.2: Pharmacological assessment of hyper and hypo-osmolarity induced 
depolarisation: Knockout Mouse 
In order to determine the role of TRP channels in depolarisation caused by increases or 
decreases of osmolarity, initially mice devoid of the Trpv4, Trpv1 or Trpa1 gene were used in 
the in vitro isolated vagus nerve system. Although mice do not have a functional cough 
response, the afferent arm of the reflex has been reported to act similarly and the use of 
knockouts allows the investigation of the importance of a particular receptor in a response 
without pharmacological intervention. Knockout of the Trpv1 or Trpa1 gene was confirmed 
using standard genotyping techniques as described in Section 2.3. Responses to both hyper- 
and hypoosmotic solutions were established in Trpv4-/-, Trpv1-/- and Trpa1-/- tissue, and in age 
matched wild type controls. As a control measure, responses to capsaicin (1μM; TRPV1 
agonist) acrolein (300μM; TRPA1 agonist) and GSK101 (300nM; TRPV4 agonist) were also 
established in each of the knockouts and wild type tissue.  
 
4.2.2.3: Pharmacological assessment of hyper and hypo-osmolarity induced 
depolarisation: Guinea pig and human 
Depolarisation induced by either hyperosmotic or hypoosmotic solutions was then tested 
against specific antagonists for the TRPV1, TRPA1 and TRPV4 channels in guinea pig tissue 
and translational results obtained in donor human vagus. Selective antagonists for TRPV1 
(JNJ17203212; 100µM), TRPA1 (HC030031; 10µM) and TRPV4 (HC067047; 10µM and 
GSK2193874: 10μM) were pharmacologically evaluated against depolarisation induced by a 
submaximal concentration of hyper- or hypoosmotic solution.  
A classical pharmacological approach was used; two reproducible responses to each osmotic 
solution was established, following which each nerve was incubated with a single 
concentration of one of the antagonists for ten minutes.  Following incubation, the nerve was 
restimulated with agonist in the presence of antagonist to determine inhibition. The nerve was 
then washed with Krebs until returned to baseline, and a final response to the agonist carried 
out to ensure nerve viability. 
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4.2.2.4: Analysis  
Individual nerve depolarisations were measured in mV, and the chart recorder calibrated so 
that 1mm was equal to 0.01mV. Antagonist inhibitions were calculated by comparing the 
magnitude of depolarisation of the nerve following antagonist incubation to the mean 
magnitude of the two control agonist responses, to give a % inhibition. Statistical analysis for 
inhibition studies was carried out in guinea pig and WT mouse tissue using a two tailed t-test 
for matched pairs comparing the magnitude of depolarisation by the agonist with and without 
the presence of antagonist in the same piece of nerve. For mouse knockout work, an unpaired 
t-test was used to compare responses between WT and KO mice. For concentration 
responses, the data was analysed using a Kruskall Wallis test and Dunns post-test comparing 
responses to vehicle. The data is presented as mean ± S.E.M., with statistical significance set 
at P < 0.05. 
 
4.2.3: Genotyping of knockout mice 
The genotyping details for TRPV4 have been outlined previously in Chapter 3.  Homozygous 
breeding pairs of mice genetically modified to disrupt the TRPV1 (Trpv1-/-) and TRPA1    
(Trpa1-/-) genes were purchased from Jackson Laboratories (USA) (Caterina, 2000; Kwan et 
al., 2006). Breeding colonies were maintained on a C57Bl/6 background at Imperial College 
London and regular genotyping was carried out to ensure continued deletion of the TRPV1 
and TRPA1 allele. This involved amplification of the DNA sequence of interest using PCR as 
previously described in Section 2.3.1. 
DNA samples extracted from the tail tips of WT (C57Bl/6), Trpv1-/-and Trpa1-/- mice were 
amplified by PCR using primers (Invitrogen) and visualised on an agarose gel by 
electrophoresis. Samples were heated to 94oC, following which 40 cycles of denaturing, 
annealing and extension were carried out, the exact duration and temperatures of which are 
outlined in Table 4.1. The resulting PCR products were run on 2% agarose gel (80V for 1 
hour) in TBE buffer containing 0.05 μl/ml Safeview (NBS Biologicals Ltd, Huntingdon, UK) and 
a DNA ladder (Hyperladder, Bioline Reagents, UK). For TRPV1, the expected wild type 
product was 984bp and knock out 600bp and for TRPA1, wild type product expected was 
317bp and knockout 184bp. 
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Table 4.1: PCR Protocol for Trpv1-/- and Trpa1-/- mice 
 PCR Conditions  
TRPV1 Denaturing 
95oC 
30 sec 
Annealing 
64oC 
1 min 
Extension 
72oC 
1 min  
Product Size (Base 
Pairs) 
WT: 984bp 
KO: 600bp 
TRPA1 Denaturing 
95oC 
30 sec 
Annealing 
68oC 
30 sec 
Extension 
72oC 
1 min 
Product Size (Base 
Pairs) 
WT: 317bp 
KO 184bp 
 
4.2.3: In vivo single fibres 
Male Dunkin Hartley guinea pigs (~350-400g) were anaesthetised with urethane (1.5g/kg i.p.) 
and paralysed with vecuronium bromide (0.1mg/kg i.v.) and artificially ventilated. Heart rate, 
blood pressure and body temperature were constantly monitored for the duration of the 
experiment.  Guinea pigs were then prepared as described in Section 2.7.1 and as previously 
described (Adcock et al., 2003). Briefly, both vagal nerves were cut at the cervical end but 
only the left vagal nerve used for recording.  This was dissected down to a single fibre and 
attached to a platinum electrode where single action potentials could be recorded using Spike 
2 data acquisition software via a CED Micro 1401 interface. The nerve fibre was identified as 
originating from the family of SARs, RARs or chemosensitive C fibres using a set of criteria 
(Adcock et al., 2003) and as described in Section 2.7.3. This included the pattern of 
spontaneous activity, response to hyperinflation and hyperdeflation, Adaptation Indices, 
response to capsaicin and citric acid and finally conduction velocity which was determined at 
the end of the experiment.  
4.2.3.2: Agonist responses 
The following experimental protocol was undertaken to determine the effect of hypoosmolarity 
on airway terminating vagal fibres. Following surgery, the animals were left to stabilise for 30 
minutes, following which a control baseline recording was taken for 2 minutes. Depending on 
fibre type, responsiveness to capsaicin (C fibre: 100μM) or citric acid (Aδ fibre: 300mM) was 
determined and changes in fibre activity, intra-tracheal pressure and blood pressure were 
constantly monitored until they returned to baseline or a steady state achieved. Following this, 
a 0mOsm solution was administered for 1 minute by aerosol and variables were continuously 
recorded. Following an interval of 20 min, increasing concentrations of hypoosmotic solution 
of (0mOsm to -100mOsm) were administered by aerosol for 1 minute, 20 minutes apart and 
the changes in fibre activity, intratracheal pressure and blood pressure were continuously 
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recorded. Nerve viability at the end of the experiment was assessed using capsaicin or citric 
acid.  
4.2.3.3: Analysis 
The data is expressed as mean ± S.E.M. and analysed using paired students t-test comparing 
responses as absolute values after stimulus to baseline values immediately before the 
response.  
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4.3: Results 
4.3.1: Effect of osmotic solutions on depolarisation of isolated vagal nerves 
Initially, the ability of a hyperosmotic solution (made using modified Krebs solution and 
increasing concentrations of sucrose) and a hypo-osmotic solution (prepared using a modified 
Krebs solution with salt reduction and gradual compensation with sucrose) to depolarise 
isolated vagus nerves from both guinea pig and wild type mice was investigated. In addition, 
translational data was obtained with human tissue where available. 
Both hyperosmotic and hypoosmotic solutions caused a concentration dependent 
depolarisation of guinea pig (Figure 4.1 A,B), mouse (Figure 4.1 C,D) and human tissue 
(Figure 4.1 E,F). In mice, maximum depolarisation induced by a +1000mOsm hyperosmotic 
solution was 0.44mV±0.03mV, in guinea pigs maximum depolarisation was 
0.573mV±0.104mV and in human tissue depolarisation maximum depolarisation was 
0.260mV±0.08mV. In all cases, depolarisation induced by a +1000mOsm solution exceeded 
that of the control capsaicin response (1μM). For hypoosmotic solutions, the maximum 
depolarisation elicited by -100mOsm in mice was 0.29mV±0.06mV, in guinea pigs was 
0.22mV±0.05mV and in human tissue was 0.11mV±0.01mV.  Once again, depolarisation 
induced by this level of hypoosmolarity exceeded that of the control capsaicin response (1μM). 
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Figure 4.1: Concentration response curves to osmotic stimuli 
Hyperosmotic and hypoosmotic solutions caused a concentration dependent increase in depolarisation 
in mouse (A,B), guinea pig (C,D) and human (E,F) tissue. Capsaicin was used in all cases as a positive 
control. Data is shown as mean ± S.E.M of n=4-6 for rodent and n=2 for human tissue. Human tissue 
was from 1 male and 1 female donor aged 38-68 with no known respiratory diseases. 
* indicates statistical significance at p<0.05 using Kruskal Wallis test and Dunns post test comparing 
responses to vehicle. Due to limited N numbers, statistical analysis was not carried out on data in human 
tissue.  
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4.3.2: Pharmacological assessment of hyper and hypo-osmolarity induced 
depolarisation: Knockout Mouse 
In order to determine whether any TRP channels, in particular TRPV4, are involved in the 
depolarisation induced by osmotic changes, each solution was initially profiled in knockout 
mice. Although mice do not have a functional cough response it has been shown that the 
afferent arm of the reflex acts similarly and compounds which cause depolarisation in guinea 
pig and human tissue also cause depolarisation in mouse tissue. Mice are a useful model as 
the genetic template can be modified and knockouts can be utilised which allows the 
investigation of the importance of a particular receptor without pharmacological intervention.  
Pairs of mice genetically modified to remove the Trpv1, Trpa1 or Trpv4 gene were obtained 
and bred in house, and male homozygous knockout mice used for experiments. Regular 
genotyping was undertaken to ensure that the gene of interest was knocked out. An example 
gel for the Trpa1-/- mice and Trpv1-/- mice is shown below (Figure 4.2 A,B), and an example 
Trpv4-/- knockout gel was shown previously in Chapter 3. All mice were bred on a C57Bl/6 
background, and therefore male C57Bl/6 mice were used as wild type controls. 
 
Figure 4.2 Example knockout gels 
A: Trpa1-/- knockout gel. RTPCR was used to confirm knockout of the TRPA1 gene using DNA extracted 
from tail tips from mice used in Figure 4.3. Wild type mice produced a band at 317bp and KOs at 184bp. 
A 25-500bp ladder was used (L), and a water control (C). Wild type and knockout primers were run in 
the same reaction. 
B: Trpv1-/- knockout gel. RTPCR was used to confirm knockout of the TRPV1 gene using DNA extracted 
from tail tips from mice used in Figure 4.3. Wild type mice produced a band at 984bp and KOs at 600bp. 
A 50-1000bp ladder was used (L), and a water control (C). Wild type and knockout primers were run in 
the same reaction. 
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A submaximal concentration of hyperosmolar (+300mOsm) and hypoosmolar (-80mOsm) 
solutions were taken forward to test in the knockout mice, along with a submaximal 
concentration of TRPV1, TRPA1 and TRPV4 agonists: capsaicin, (1μM; TRPV1), acrolein 
(300μM; TRPA1) and GSK101 (300nM; TRPV4).  
 
In vagal tissue from Trpa1-/- mice, acrolein induced depolarisation was abolished, confirming 
knockout of the channel and indicating that the TRPA1 gene was not functional. Capsaicin 
and GSK101 induced depolarisation remained unchanged in knockout tissue indicating that 
loss of TRPA1 had no effect on TRPV1 or TRPV4 responses. +300mOsm induced 
depolarisation also remained unchanged from wild type to knockout, with depolarisation of 
0.232mV±0.029mV in the wild type and 0.2440mV±0.051mV in the knockout, indicating that 
the TRPA1 channel does not play a role in hyperosmolarity induced depolarisation in the 
mouse.  Knockout of the TRPA1 gene also had no effect on the -80mOsm induced 
depolarisation, where depolarisation of 0.225mV±0.06mV in the wild type mice was only 
slightly reduced to 0.1960±0.02551mV in the knockout tissue (Figure 4.3 A). 
 
In tissue from Trpv1-/- mice, capsaicin induced depolarisation was abolished indicating that the 
ion channel was non-functional. Both acrolein and GSK101 induced depolarisation remained 
unchanged in the knockout tissue, indicating that knockout of the TRPV1 ion channel had no 
effect on TRPA1 or TRPV4 responses.  +300mOsm induced depolarisation was only slightly 
reduced in the knockout tissue, with a depolarisation of 0.276mV±0.05mV in wild type tissue 
and 0.200±0.035mV in knockout tissue demonstrating that the TRPV1 channel plays a minor 
role in hyperosmotic induced depolarisation. However, responses to 
-80mOsm solution were significantly reduced to around 50% in the knockout tissue, with a 
depolarisation of 0.3320mV±0.0484mV in wild type tissue reduced to 0.15mV±0.021mV in 
knockout tissue, indicating that the TRPV1 channel plays a role in hypoosmotic induced nerve 
depolarisation in the mouse (Figure 4.3 B).  
 
In tissue from Trpv4-/- mice, GSK101 induced depolarisation was virtually abolished, indicating 
that the TRPV4 channel was not functional. Acrolein and capsaicin induced depolarisation 
remained unchanged; indicating that knockout of the TRPV4 gene does not affect other TRP 
channel responses. +300mOsm induced depolarisation was unchanged in   Trpv4-/- tissue, 
with depolarisation of 0.16mV±0025mV in the wild type tissue and 0.21±0.026mV in the 
knockout tissue, demonstrating that the TRPV4 ion channel does not play a role in 
hyperosmotic induced depolarisation in the mouse.  However, similarly to the Trpv1-/- tissue, -
80mOsm induced depolarisation was significantly reduced to around 50% (from 
0.3050±0.017mV in WT tissue to 0.1452±0.017mV in the knockout) indicating that the TRPV4 
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ion channel plays a major role in hypoosmotic induced depolarisation in the mouse (Figure 
4.3 C). 
 
This data indicates that the TRPV1 and TRPV4 ion channels are required for hypoosmotic 
induced depolarisation in the mouse, with the TRPA1 channel not playing a role.  However, 
although responses to hyperosmotic stimuli were reduced in Trpv1-/- mice, indicating that the 
TRPV1 ion channel may play a role, knockout of any of the TRP genes did not have any 
statistically significant effect on hyperosmotic induced depolarisation. 
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Figure 4.3: Effect of hyper and hypoosmotic solutions in knockout mice 
A: Trpa1-/- mice: Only responses to the TRPA1 agonist acrolein were significantly inhibited in the Trpa1-
/- mice. Responses to hyper (+300mOsm) and hypoosmotic (-80mOsm) solutions along with responses 
to TRPV1 (capsaicin) and TRPV4 (GSK101) ligands remained unchanged. B: Trpv1-/- mice; Responses 
to capsaicin and hypoosmotic solutions were significantly inhibited in the Trpv1-/- mice and responses 
to hyperosmotic solution were reduced. However responses to TRPA1 agonists and TRPV4 agonists 
remained unchanged. C: Trpv4-/- mice: Responses to GSK101 and hypoosmotic solutions were 
significantly reduced in the Trpv4-/- mice. Responses to hyperosmotic solutions along with TRPV1 and 
TRPA1 agonists remained unchanged. The data is presented as mean ± S.E.M.. of n=4-6. * indicates 
statistical significance (p < 0.05), unpaired t-test comparing responses in knockout- tissue with wild-type 
control. 
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4.3.3: Pharmacological assessment of hyper and hypo-osmolarity induced 
depolarisation: Guinea Pig and Human vagal tissue 
Although the knockout mice provided key data without pharmacological intervention, as 
mouse airway innervation differs to that of guinea pigs and humans and as such may possess 
a different confirmation of receptors and fibres. Therefore, osmotic stimuli were assessed 
against specific TRP antagonists in both guinea pig and donor human vagal nerve tissue, 
which are more physiologically relevant systems. The osmotic stimuli were pharmacologically 
assessed against specific antagonists for the TRPV1 (JNJ17203212: 100μM), TRPA1 
(HC030031: 10μM) and TRPV4 (HC067047: 10μM and GSK2193874: 10μM) ion channels 
(Figure 4.4).  A summary of the inhibition induced by each of the antagonists is shown in 
Table 4.2. 
For depolarisation induced by hyperosmotic solutions, in the guinea pig the TRPV1 antagonist 
significantly inhibited the response 80.9±9.4%, whereas TRPA1 and TRPV4 seemed to play 
a similar smaller role in inhibiting depolarisation induced by the osmotic stimulus, both 
inhibiting the response 30-50%. In contrast in human tissue, TRPA1 and TRPV4 both played 
a bigger role in inhibition of the response; both antagonists inhibited the response by around 
60%, whereas the TRPV1 antagonist played a much smaller role. This would indicate a 
species difference in the mechanism of hyperosmotic induced depolarisation (Figure 4.4 A, 
B). The results seen in the guinea pig tissue were similar to those seen in the knockout mouse, 
where only tissue from Trpv1-/- showed any reduction in depolarisation induced by 
hyperosmotic solution.  
For depolarisation induced by hypoosmotic solution, a similar profile was seen in both guinea 
pig and human tissue. In both cases, the TRPV4 antagonist HC067047 was shown to have 
the greatest inhibition of hypoosmotic induced depolarisation, with HC067047 inhibiting the 
response 86.33%±12.30%in guinea pigs and 76.95%±3.74% in human tissue. GSK2193874 
also inhibited the response similarly in guinea pig tissue. The TRPV1 antagonist also played 
a large role, inhibiting the response by around 50% in both species. TRPA1 was shown to 
have less of an effect (Figure 4.4 C,D). This is concurrent with the knockout mouse data, 
where depolarisation induced by -80mOsm was significantly inhibited in both Trpv1-/- and 
Trpv4-/- mice. 
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Figure 4.4: Effect of TRP antagonists on osmotic activation of vagal nerves 
A: Guinea pig: The TRPV1 antagonist JNJ17203212 (100μM) significantly inhibited depolarisation 
induced by hyperosmotic solution (+300mOsm), the TRPA1 (HC030031: 10μM) and TRPV4 
antagonists (HC067047: 10μM and GSK2193874: 10μM) all inhibited the response similarly to around 
30-40%.  B: Human: Both TRPA1 and TRPV4 antagonists inhibited the responses to around 50-60%, 
however the TRPV1 antagonist seemed to play a smaller role only inhibiting the response to around 
30%. C: Guinea pig: Both the TRPV1 antagonist and the TRPV4 antagonists significantly inhibited the 
depolarisation induced by hypoosmotic solution (-80mOsm), with the TRPA1 antagonist having no 
effect. D: A similar profile was seen in donor human tissue. n=4 for GP and n=3 for human. Human 
tissue was obtained from 2 female and 1 male donor aged 38-68 with no known respiratory disease.  * 
indicates statistical significance (p < 0.05), paired t-test comparing responses in the same piece of 
guinea pig nerve with and without antagonist. Due to limited numbers of human experiments, statistical 
analysis was not undertaken. 
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Table 4.2: Summary of the role of TRP channels in depolarisation induced by osmotic 
solutions. 
ANTAGONIST GUINEA PIG HUMAN 
Hyperosmolar Solutions (+300mOsm) 
JNJ17203212 (100μM: TRPV1) 80.9±9.4% 29.1±11.2% 
HC030031 (10μM: TRPA1) 37.3±5.4% 62±5.5% 
HC067047 (10μM: TRPV4) 27.1±18.8% 58.9±13.5 
GSK2193874 (10μM: TRPV4) 47±2.9% N/A 
Hypoosmolar Solution (-80mOsm) 
JNJ17203212 (100μM: TRPV1) 50.1±10.20% 61.29±9.39% 
HC030031 (10μM: TRPA1) 0% 19.9±4.3% 
HC067047 (10μM: TRPV4) 86.3±12.3% 76.9±3.7% 
GSK2193874 (10μM: TRPV4) 67.4±2.9% N/A 
N/A: Antagonist not tested. 
4.3.4: Characterisation of hypo osmotic solution on firing of single vagal fibres in vivo  
As depolarisation induced by hypoosmotic solution was found to be predominantly through 
activation of TRPV4, and because of limited time, only hypoosmotic solution was taken 
forward in vivo to test in the airway single fibre recording technique. This technique allows the 
investigation of action potential firing from a single airway terminating afferent fibre, in the 
absence of a full reflex arc as both vagal nerves are cut at the central end.  
A concentration response to aerosolised hypoosmotic solution (0mOsm to -100mOsm below 
normal osmolarity) was carried out on both C-fibres and Aδ-fibres. These fibres were 
distinguished according to their capsaicin and citric acid sensitivity, response to hyper-inflation 
and deflation, spontaneous activity and ultimately though determination of a conduction 
velocity (CV) at the end of the experiment.  The 3 C-fibres under investigation had CVs of 
0.47-0.85imp/s and a total of 4 Aδ fibres were investigated with CVs of 4.7-11.3imp/s. Two of 
the 4 Aδ-fibres investigated responded to capsaicin. 
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Citric acid activated all Aδ fibres under investigation, and in all cases a solution of 0mOsm 
below normal airway osmolarity was used as a control. Hypoosmotic solutions caused a 
concentration dependent increase in firing frequency in the Aδ fibres examined, but solutions 
with an osmolarity of -60mOsm, -80mOsm and -100mOsm below normal osmolarity  increased 
fibre firing significantly in the Aδ fibres investigated. -60mOsm increased firing frequency from 
1imp/s to 11.75±2.056 imp/s, -80mOsm increased firing frequency from 2.33±0.33 imp/s to 
10.33±1.764 imp/s and -100mOsm increased firing from 1.67±0.67 imp/s to 11.33±1.76imp/s 
(Figure 4.5A). All fibres responded to citric acid at the end of the experiment. 
Capsaicin activated all C fibres under investigation and a solution of 0mOsm was used as a 
control. In contrast to the Aδ fibres investigated, hypoosmotic solution did not cause a 
concentration dependent increase in firing in C fibres.  Instead, only a solution of -100mOsm 
increased firing frequency significantly from 0 to 19±4.933 imp/s (Figure 4.5B). All fibres 
responded to capsaicin at the end of the experiment. 
In all cases, hypoosmotic solution caused bronchoconstriction, which was significant at -80 
and -100 mOsm, as indicated by an increase in tracheal pressure (Figure 4.5C,D). 
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 Figure 4.5: Effect of osmolarity on firing of airway sensory nerves  
(A): Aδ-fibres: Aerosolised hypoosmotic solution (0mOsm to -100mOsm) caused a concentration 
dependent increase in firing frequency in Aδ-fibres, with -60mOsm to -100mOsm causing a significant 
increase. Citric acid also caused a significant increase in firing frequency. (B): C-fibres: Both capsaicin 
and citric acid caused a significant increase in firing frequency, but only hypoosmotic solution at -
100mOsm was able to activate the C-fibres examined. (C,D). C and D indicate that hypoosmotic 
solution caused a large sustained bronchoconstriction in all animals (C: Animals where Aδ-fibres were 
investigated and  D: animals where C-fibres were investigated). The data is presented as mean ± S.E.M. 
of n=3-4 observations. Veh = vehicle. * indicates statistical significance (p < 0.05), paired t test 
comparing responses before and after aerosol administration of agonist. 
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4.4: Discussion 
The aim of this chapter was to determine the mechanism of osmotic activation of airway 
sensory nerves, and to determine whether TRPV4 plays a role. Solutions of both increased 
and decreased osmolarity have been reported to cause activation of airway sensory nerves 
and reflex events such as cough in both animals and humans (Fox et al., 2005.; Eschenbacher 
et al., 1984; Fuller and Collier, 1984; Lalloo et al., 1995). Hypoosmotic solution is well 
documented to be an activator of the ion channel TRPV4 (Alessandri-Haber et al., 2003; Jia 
et al., 2004) and TRPV4 is activated by changes in osmolarity as little as -30mOsm (Liedtke 
et al., 2000; Strotmann et al., 2000). TRPV4 has also been shown to be the ion channel 
transducer which mediates nociceptive behaviour induced by small changes in osmolarity 
(Alessandri-Haber et al., 2005). However, the role of TRPV4 in osmotic activation of airway 
sensory nerves is yet to be determined.  Therefore in this chapter, the role of TRPV4 as an 
osmosensor in airway sensory nerve was explored by investigating activation of vagal nerves 
induced by both hyper and hypoosmotic stimulation, and using both specific TRPV4 
antagonists alongside tissue from TRPV4 knockout mice. The role of other TRP channels 
TRPV1 and TRPA1 was also investigated as these have been shown to play a role in airway 
sensory nerves, and along with TRPV4, TRPV1 has also been shown to contribute to 
osmosensitivity of neurons (Bonini et al., 1996; Alessandri-Haber et al., 2003).  
Osmotic stimulation is defined as a deviation from an osmotic set point, which in many animals 
is ~295mOsml-1 (Denton et al., 1996; Bourque and Oliet, 1997).  The osmolarity of the airways 
in determined by the airway surface fluid, which is a low viscosity thin layer covering the 
mucosal surface of the airway epithelia which line the conducting airways (Joris et al., 1993). 
In normal, healthy humans, the osmolarity of airway surface fluid is thought to be mildly 
hypoosmotic, with an osmolarity of 222mOsm, which is around 80% of the isotonic body fluids 
(Joris et al., 1993). In asthmatic patients, the osmolarity of airway surface fluids is thought to 
be further reduced (Joris et al., 1993). At a cellular level, hypoosmolarity is a mechanical 
stimulus, as it causes cells to swell which is a process dependent upon Ca2+ channels (Lang 
et al., 1998). The hypoosmotic solution distilled water is a potent activator of airway fibres in 
vivo (Fox et al., 1995) and ultra-nebulised distilled water is used as a cough challenge agent 
in the clinic (Eschenbacher et al., 1984; Dicpinigaitis, 2007). This is reported to cause both 
cough and bronchoconstriction in subjects (Cheney and Butler, 1968; Fontana et al., 1999, 
2002). Together with the fact that hypoosmolarity is a known activator of the TRPV4 ion 
channel (Jia et al., 2004), it was decided to investigate the role of TRPV4 in hypoosmotic 
induced depolarisation. 
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In this study, hypoosmotic solutions caused a concentration dependant increase in 
depolarisation in mouse, guinea pig and human tissue. Depolarisation in all species was found 
to be predominantly through the TRPV4 ion channel, as Trpv4-/- mice and treatment with the 
TRPV4 antagonists HC067047 (10μM) and GSK2193874 (10μM) significantly inhibited vagal 
nerve activation induced by hypoosmotic solutions. However, despite blocking the majority of 
the response (around 70-80%) in all species, the TRPV4 antagonist did not block the whole 
response.  The remainder of the activation instead looks to be through the TRPV1 ion channel, 
with TRPA1 antagonists having no effect different to that of vehicle. Both TRPV1 and TRPV4 
have been shown to contribute to osmosensitivity (Bonini et al., 1996; Alessandri-Haber et al., 
2003), where they have previously been shown to play complementary roles (Lechner et al., 
2011). Most importantly, translational results were obtained in human tissue, which would 
suggest that these results may translate to the clinic.  
In vivo, hypoosmotic solutions were shown to activate Aδ-fibres, the same fibre type as 
activated by the TRPV4 agonist GSK101, at osmolarity changes as small as -60mOsm. 
However, hypoosmotic solutions were only able to activate C-fibres at an osmolarity of  
-100mOsm, indicating Aδ-fibres are more sensitive to activation by smaller changes in 
osmolarity. This agrees with previous work which has shown that distilled water (a solution of 
around -300mOsm) activated all Aδ-fibres in the guinea pig and dog, and also all C-fibres in 
the guinea pig (Pisarri et al., 1992; Fox et al., 1995). In all cases, solutions from -60mOsm 
upwards caused bronchoconstriction as indicated by an increase in tracheal pressure.  This 
is in agreement in with data from the clinic which has shown that cough challenge with distilled 
water (fog) does cause bronchoconstriction as well as cough in the subjects (Cheney and 
Butler, 1968; Fontana et al., 1999, 2002).  
 
Responses of TRPV4 to hypotonic solutions, phorbol esters and heat have been shown to be 
transient with rapid decay and are dependent on calcium (Plant and Strotmann, 2007). 
However, TRPV4 induced activation by hypoosmotic stimuli has been shown to involve a 
different mechanism to activation caused by 4αPDD and heat. Hypoosmotic solutions induce 
cell swelling which induces activation of PLA2 and causes the release of polyunsaturated fatty 
acids including arachidonic acid from membrane phospholipids. It is thought that the 
arachidonic acid is then broken down by the enzyme cytochrome P450 epoxygenase which 
produces 5,6 epoxy-eicosatrienoic acid (5,6 EET) which then activates TRPV4 (Vriens et al., 
2004; Vriens et al., 2005). Evidence for this theory exists as four structurally unrelated 
inhibitors of PLA2 along with a cytochrome p450 epoxygenase inhibitor, have been shown to 
block swelling induced Ca2+ signals in TRPV4 expressing HEK cells, but had no effect on 
activation of TRPV4 by heat, 4αPDD or arachidonic acid derivatives (Vriens et al., 2005). In 
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addition, it has recently been shown that activation of TRPV4 by hypoosmotic stimulus 
involves PIP2 binding to a domain in the N terminus, and this interaction rearranges the 
cytosolic domains (Garcia-Elias et al., 2013).  
Although in normal, healthy humans the airway surface fluid is hypoosmotic, it can also 
become hyperosmotic, which is common during exercise where evaporation of water leads to 
dehydration of airway surface liquid and an increase in osmolarity (Anderson et al., 2010; 
Anderson and Kippelen, 2012). In asthmatics this has been known to lead to exercise induced 
bronchoconstriction (Weiler et al., 2010; Anderson and Kippelen, 2012; Hallstrand, 2012). 
Furthermore, hyperosmolar solutions are known to cause cough and bronchoconstriction in 
both humans (Eschenbacher et al., 1984) and guinea pigs (Lalloo et al., 1995) and the 
hypertonic solution mannitol (which is devoid of both sodium and chloride ions) is a commonly 
used tussive stimulus in the clinic (Morice et al., 2007). Therefore, it was decided to also 
investigate the role of TRPV4 in hyperosmotic induced activation of airway sensory nerves.  
Depolarisation induced by hyperosmotic solution was shown to be partly conducted through 
the TRPV1 ion channel, with Trpv1-/- mice showing a reduction in depolarisation induced by a 
hyperosmotic stimulus of +300mOsm, and in guinea pigs, depolarisation induced by 
+300mOsm was significantly reduced following application of the TRPV1 antagonist 
JNJ17203212 (100μM). This is concurrent with the current literature where TRPV1 has 
already been implicated in osmolarity sensing in neurons from the Organum Vasculosum 
Lamina Terminalis (OVLT), which is responsible for the monitoring of blood solute 
concentration, in the CNS (Ciura and Bourque, 2006; Ciura et al., 2011). Despite TRPV4 being 
the widely accepted TRP channel osmosensor, it was shown that hypertonicity induced 
excitation of these neurons was abolished in Trpv1-/- mice (Ciura and Bourque, 2006), whereas 
Trpv4-/- mice remained unaffected (Ciura et al., 2011), and TRPV4 has previously been shown 
not to be activated in vitro by hypertonicity (Alessandri-Haber et al., 2005). Furthermore, 
responses to both hyperosmolar stimulation and cell shrinkage were abolished in wild type 
mice following treatment with a TRPV1 antagonist (Ciura et al., 2011). Trpv1-/- mice have been 
shown to be chronically hyperosmolar and show an impaired water intake and ADH release 
in response to i.p. injections of hypertonic saline (Ciura and Bourque, 2006; Sharif Naeini et 
al., 2006). Taken together this would suggest that TRPV1 is responsible for hyperosmotic 
induced activation of airway sensory nerves in both the mouse and the guinea pig. However, 
this was not the case in the translational human tissue, where both TRPV4 and TRPA1 
antagonists were shown to inhibit hyperosmolarity induced depolarisation, with TRPV1 playing 
a lesser effect.  This highlights the importance of carrying out translational work in human 
tissue.  
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In order to expand upon the single fibre data and in order to ensure that the firing seen is 
through TRPV4, a TRPV4 antagonist should be taken in vivo to test against a submaximal 
concentration of hypoosmolarity on both C fibres and Aδ fibres. As ultra-nebulised distilled 
water is used as tussive stimuli in the clinic, hypoosmotic solutions could also be taken forward 
into the conscious guinea pig cough system, and the role of TRPV4 assessed using 
antagonists. Effect of hypoosmotic solutions can also be investigated on [Ca2+]i signal in 
isolated ganglia, to determine if hypoosmotic solutions activate the nodose ganglia similarly to 
the TRPV4 ligands.  Alongside hypoosmotic solution, an effect of hyperosmotic solutions on 
fibre firing and cough in conscious guinea pigs is something that can be investigated at a later 
time point. Previous studies have indicated that hypertonic stimuli activate C afferents (Fox et 
al., 1995; Pedersen et al., 1998) and have induced tachykinin release from isolated cultured 
DRG neurons which were phenotypically C fibres (White et al., 1995). Furthermore, both 
stimuli could also be taken forward in disease models. As the epithelium is damaged in 
respiratory disease (Laitinen et al., 1985; Elia et al., 1988), it could be hypothesised that airway 
sensory nerve terminals may be more exposed to the airway surface fluid which may lead to 
activation of the TRPV4 or TRPV1 channels, which may contribute to the enhanced reflex 
events seen in disease.   
In summary, the chapter hypothesis ‘TRPV4 channels present on airway sensory nerves are 
activated by changed in osmolarity’ can be partially accepted. This body of data has shown 
that activation of airway sensory nerves by hypoosmotic solutions are predominantly mediated 
through the TRPV4 ion channel in all species examined. This agrees with previous data which 
outlines hypoosmotic solutions as activators of the TRPV4 ion channel (Alessandri-Haber et 
al., 2003; Jia et al., 2004). TRPV4 antagonists inhibited the response to -80mOsm induced 
depolarisation, and depolarisation was also significantly inhibited in Trpv4-/- mice. Hypoosmotic 
stimuli were also found to activate both Aδ and C fibres, however Aδ fibres were much more 
sensitive to smaller changes in osmolarity, and these fibres were the same fibres as activated 
by the TRPV4 agonist GSK101. In contrast, activation of sensory nerves by hyperosmotic 
solutions is predominantly mediated through TRPV1 in murine and guinea pig tissue, with little 
effect of TRPV4. This is an important, novel finding as alterations of airway osmolarity occur 
in disease, and this data would suggest that the TRPV4 and TRPV1 channels may play a role 
in mediating the effects.  
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5.1: Rationale 
In the previous chapters it has been demonstrated that activation of TRPV4 by both synthetic 
agonists and by hypoosmolar solutions causes depolarisation of the vagus nerve, single 
airway fibre firing and reflex cough in the conscious guinea pig through activation of nodose 
derived Aδ fibres. Both calcium signal and firing of airway afferent fibres demonstrated a short 
delay prior to activation by the TRPV4 agonist GSK101 indicating the possible release of a 
secondary mediator.  In the bladder, activation of TRPV4 by 4αPDD, 5,6,EET and mechanical 
stretch has been shown to cause an increase of [Ca2+]i and ATP release (Birder et al., 2007; 
Mochizuki et al., 2009). In addition firing of bladder afferents by the TRPV4 agonist GSK101 
has been shown to be blocked by the P2X inhibitors PPADs and also the P2X3/P2X2/3 
antagonist TNP-ATP (Aizawa et al., 2012). Furthermore, it has recently been shown that 
TRPV4 plays a key role in cigarette smoke induced ATP release in human primary epithelial 
cells (Baxter et al., 2014). As the ion channel P2X3 is expressed in both human and guinea 
pig airway sensory nerves (Kwong et al., 2008; Undem and Nassenstein, 2009; Sato et al., 
2014), and activation of sensory nerves by ATP has been shown to be through P2X3 (Kwong 
et al., 2008), it can be hypothesised that perhaps activation of TRPV4 induces ATP release 
and subsequent activation of P2X3. Furthermore, It has previously been shown in human 
epithelial cells that ATP release following TRPV4 activation is mediated through the Pannexin 
1 ion channel (Seminario-Vidal et al., 2011; Baxter et al., 2014), and so the role of the 
Pannexin 1 ion channel will also be investigated. 
5.1.2: Chapter Hypothesis:  
Activation of TRPV4 on airway sensory nerves leads to the release of ATP and activation of 
P2X3. 
5.1.3: Aims 
 To confirm that P2X3 is expressed on vagal ganglia, and in addition that agonists are 
capable of activating airway sensory nerves. This will be carried out using αβ-
MethyleneATP (αβ-MeATP), a more stable agonist at P2X1 and P2X3 receptors and 
investigating its effects on calcium movement and vagal nerve depolarization. Two 
structurally distinct antagonists will be used; TNP-ATP and AF-353, to confirm the role 
of the P2X3 receptor.  
 Examine the effect of selective P2X3 antagonists against TRPV4 mediated activation 
of airway sensory nerves in vitro using calcium movement in guinea pig isolated airway 
ganglia and vagal nerve depolarization in isolated murine, guinea pig and human 
tissue. 
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 Examine the role of Pannexin 1 in TRPV4 mediated depolarization using vagus from 
Pannexin 1 knockout mice. 
 Examine the effect of a selective P2X3 antagonist AF-353 against TRPV4 mediated 
events in vivo using single airway nerve firing and reflex cough in the guinea pig.  
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5.2: Methods 
5.2.1: RT-PCR 
Quantitative real time PCR assays for the P2X3 receptor were purchased from Applied 
Biosystems and validated using cDNA from tissue/organs from the guinea pig that expressed 
the target channel at high levels. 
Whole nodose and jugular ganglia were harvested from male Dunkin Hartley guinea pigs. 
Expression levels of P2X3 were determined using the validated assays, with real time RT-
PCR performed as described previously (Wong et al., 2009) and in Section 2.4. 
 
5.2.2: Ganglia imaging 
Male Dunkin Hartley guinea pigs were intranasally dosed with the retrograde tracer dye DiI to 
identify airway specific neurons, 14 days prior to dissection and enzymatic digestion of the 
nodose and jugular ganglia as described previously in Section 2.5.  Neurons were loaded into 
fluorodishes coated with laminin and allowed to adhere for 12 hours at 37oC 5%CO2/95% O2. 
Following incubation, cells were loaded with the calcium specific dye Fura-2-AM for 40 minutes 
at 25oC in the dark, which was followed by a de-esterification step for 30 minutes at 25oC in 
the dark. Following a wash step with ECS, each fluorodish containing neurons was then placed 
in a full incubation chamber and mounted on a Widefield inverted microscope as described in 
Section 2.5. Neurons were then identified using bright field illumination at x20 magnification, 
and airway specific cells could then be identified by imaging the cells at excitation and 
emission fluorescence wavelengths of approximately λ=520-550nM and λ=570, which 
identifies the DiI labelled cells. Intracellular Ca2+ ([Ca2+]i)  responses were then investigated 
as previously described (Grace et al., 2012; Dubuis et al., 2013). 
5.2.2.1: Agonist Responses 
In order to determine if activation of P2X3 was able to cause a change in [Ca2+]i signal in the 
nodose and jugular ganglia, the following experimental protocol was undertaken. Throughout 
the experiment, neurons were constantly superfused with ECS using an in house pressurised 
perfusion system that allows complete change of solution (600μL) in 3s. The neurons were 
exposed to a 50mM potassium solution (K50) for 10s to ensure neuron viability, and allowed to 
return to baseline.  αβ-MethyleneATP (αβ-MeATP; 10μM), a more stable agonist at P2X1 and 
P2X3 containing receptors was then added to the dish for 10 minutes, and changes in [Ca2+]i 
recorded. The concentrations of agonist were chosen from previous publications (Weigand et 
al., 2012). 
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5.2.2.2: Antagonist responses 
In order to determine if the P2X3 receptor played a role in TRPV4 mediated [Ca2+]i signal, a 
pharmacological approach was used. Following identification of airway specific neurons, the 
P2X3 selective antagonist AF-353 (10μM (Weigand et al., 2012)) was incubated with the 
ganglia cells for 10 minutes prior to agonist stimulation with GSK101 (30nM). A vehicle control 
(0.1% DMSO) was also carried out in cells from the same animal. 
5.2.2.3: Analysis 
Only responding cells (cells with a response ≥ 10% of the K50 response) and cells with a 
diameter of over 20μM were analysed as these were more likely to be sensory neurons 
(Hunter et al., 2000). Intracellular calcium signal induced by each agonist was calculated using 
total area under the curve, (A.U.C.) which is the total change in intracellular calcium from 
resting level over time. This was then normalised to a percentage of the total change induced 
by K50 application, so that differences between individual cell responses can be accounted for. 
The data is presented as mean ± S.E.M., N indicates number of animals, and n indicates 
number of cells. Statistical analysis was carried out using an unpaired t test comparing cells 
pre incubated with vehicle prior to agonist treatment to cells preincubated with antagonist. 
 
5.2.3: Isolated vagal nerve recordings 
Vagal tissue was dissected from male Dunkin-Hartley guinea pigs, WT C57/Bl6 mice and    
Px1-/- mice and placed in a grease-gap recording chamber as previously described in Section 
2.6. Key experiments were repeated using human donor tissue to provide translational data.  
5.2.3.1: Agonist concentration response curves 
In order to determine if activation of P2X3 was able to depolarise the vagal nerve, the following 
experimental protocol was undertaken. Non-cumulative concentrations of the P2X3 agonist 
αβ-MeATP (10-300μM) were applied to the vagal nerve trunk for two minutes followed by a 
wash period where the nerve was washed with Krebs solution until it returned to baseline. In 
addition, vehicle (0.1% dH20 v/v) was tested on the nerve to ensure that it had no effect. 
Responses were recorded as mV depolarisation. Concentration ranges of each agonist were 
determined from published work (Weigand et al., 2012). Responses were carried out in guinea 
pig tissue, and a submaximal concentration used to determine activation of human tissue.  
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5.2.3.2: Antagonist responses 
To ensure specificity for the P2X3 ion channel, two structurally distinct P2X3 antagonists were 
utilised; TNP-ATP (10μM) and AF-353 (10μM) against a submaximal concentration of αβ-
MeATP; (100μM). AF-353 is thought to be more selective for the P2X3 ion channel, whereas 
TNP-ATP blocks both P2X3 and the heterometic P2X2/P2X3 channel. Concentrations of each 
antagonist were based on previous work (Weigand et al., 2012) and published potency values 
(Virginio et al., 1998; Gever et al., 2010). Once the antagonists were shown to inhibit P2X3 
induced responses, the antagonists were then tested against TRPV4 (GSK101; 300nM) 
induced depolarisation in order to determine if P2X3 is involved in the mechanism of TRPV4 
induced activation of airway sensory nerves. The antagonists were also profiled against 
capsaicin (1µM) and acrolein (300µM) induced depolarisation to determine selectivity.  
A classical pharmacological approach was used; two reproducible responses to each agonist 
was established, following which each nerve was incubated with a single concentration of one 
of the antagonists for ten minutes.  Following incubation, the nerve was restimulated with 
agonist in the presence of antagonist to determine inhibition. The nerve was then washed with 
Krebs until returned to baseline, and a final response to the agonist carried out to ensure nerve 
viability.  
5.2.3.3: Analysis 
Individual nerve depolarisations were measured in mV, and the chart recorder calibrated so 
that 1mm was equal to 0.01mV. Antagonist inhibitions were calculated by comparing the 
magnitude of depolarisation of the nerve following antagonist incubation to the mean 
magnitude of the two control agonist responses, to give a % inhibition. Statistical analysis was 
carried out using a two tailed t-test for matched pairs comparing the magnitude of 
depolarisation by the agonist with and without the presence of antagonist in the same piece 
of nerve. The data is presented as mean ± S.E.M., with statistical significance set at P < 0.05. 
 
5.2.4: Genotyping of Px1-/- Mice 
The role of Pannexin 1 was investigated using Pannexin 1 knockout mice.  Homozygous 
breeding pairs of mice genetically modified to disrupt the Pannexin 1 gene (Px1-/-) were a kind 
gift from Dr. Vishva Dixit, (Genentech, US) and breeding colonies maintained on a C57Bl/6 
background at Imperial College London. Regular genotyping was carried out to ensure 
continued deletion of the Pannexin 1 allele. This involved amplification of the DNA sequence 
of interest using PCR as previously described in Section 2.3.1. 
5: The role of ATP and P2X3 in TRPV4 mediated activation of airway sensory nerves 
123 
 
DNA samples extracted from the tail tips of WT (C57Bl/6) and Px1-/- mice were amplified by 
PCR using primers (Invitrogen) and visualised on an agarose gel by electrophoresis. Samples 
were heated to 94oC, following which 40 cycles of denaturing, annealing and extension were 
carried out, the exact duration and temperatures of which are outlined in Table 5.1. The 
resulting PCR products were run on 2% agarose gel (80V for 1 hour) in TBE buffer containing 
0.05 μl/ml Safeview (NBS Biologicals Ltd, Huntingdon, UK) alongside a 50-1000bp ladder 
(Hyperladder 50bp, Bioline Reagents, UK). The expected wild type product was 600bp and 
knock out 350bp.  
Table 5.1: PCR Protocol for Px1-/- mice 
 PCR Conditions  
Pannexin Denaturing 
94oC 
30 sec 
Annealing 
60oC 
1min 
Extension 
72oC 
1min 
Product Size (Base 
Pairs) 
WT: 600 
KO: 350 
 
5.2.5: In vivo single fibre recordingss 
Male Dunkin Hartley guinea pigs (~350-400g) were anaesthetised with urethane (1.5g/kg i.p.) 
and paralysed with vecuronium bromide (0.1mg/kg i.v.) and ventilated. Heart rate, blood 
pressure and body temperature were constantly monitored for the duration of the experiment.  
Guinea pigs were then prepared as described in Section 2.7.1 and as previously described 
(Adcock et al., 2003). Briefly, both vagal nerves were cut at the cervical end but only the left 
vagal nerve used for recording.  This was dissected down to a single fibre and attached to a 
platinum electrode where single action potentials could be recorded using Spike 2 data 
acquisition software via a CED Micro 1401 interface. The nerve fibre was identified as 
originating from the family of SARs, RARs or chemosensitive C fibres using a set of criteria 
(Adcock et al., 2003b) and as described in Section 2.7.3. This included the pattern of 
spontaneous activity, response to hyperinflation and hyperdeflation, Adaptation Indices, 
response to capsaicin and citric acid and finally conduction velocity which was determined at 
the end of the experiment. For this set of experiments, only Aδ fibres were investigated.  
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5.2.5.1: Agonist responses 
The following experimental protocol was undertaken to determine the effect of αβMe-ATP on 
the firing of airway terminating vagal Aδ-fibres. Following surgery, the animals were left to 
stabilise for 30 minutes, following which a control baseline recording was taken for 2 minutes. 
Vehicle (1% TWEEN80, 1% ETOH in saline v/v) was then aerosolised into the airways for up 
to 1 minute, and changes in fibre activity, intra-tracheal pressure and blood pressure were 
constantly monitored until they returned to baseline or a steady state achieved. 20 minutes 
later, citric acid (0.3M) was administered via aerosol into the airways and responses 
monitored.  A further 20 minutes following return to baseline, αβMe-ATP (300μM; The 
concentration of αβMe-ATP which was based on concentrations shown to cause firing of 
airway fibres (Weigand et al., 2012), was aerosolised into the airway for 1 minute and changes 
in fibre activity, intra-tracheal pressure and blood pressure closely monitored.  
5.2.5.2: Antagonist responses 
For antagonist experiments, only Aδ-fibres were investigated.  To investigate the antagonist 
activity of the P2X3 antagonist AF-353, two control responses to αβ-MeATP: 300μM were 
carried out twenty minutes apart following which the antagonist or vehicle was administered 
i.p (AF-353: 30mg/kg in 10% Polyethylene Glycol 400 in 0.9% saline v/v, vehicle: 10% 
Polyethylene Glycol 400 in 0.9% saline v/v). One hour later, αβ-MeATP was re-aerosolised 
into the airways and responses monitored, and twenty minutes later GSK1016790a 
(100ng/ml) was re-administered to the airways and responses monitored. A similar protocol 
was undertaken for the TRPV4 antagonist GSK2193874 where two control responses to the 
TRPV4 agonist GSK101 (100ng/ml) were carried out twenty minutes apart, following which 
antagonist or vehicle were administered i.p (GSK2193874: 300mg/kg in 6% 
Cavitron/2Hydroxypropyl-β-cyclodextrin in saline, Vehicle: 6% Cavitron/2Hydroxypropyl-β-
cyclodextrin in saline v/v). One hour later, GSK1016790a (100ng/ml) was administered and 
responses monitored. Twenty minutes later, αβMe-ATP (300μM) was aerosolised into the 
airways and responses monitored. Changes in fibre activity, intratracheal pressure and blood 
pressure were continuously recorded throughout the experiment. 
 
5.2.5.3: Analysis 
The data is expressed as mean ± S.E.M. and agonist studies analysed using a paired students 
t-test comparing responses as absolute values after stimulus to baseline values immediately 
before the response. For antagonist responses in the same fibres a paired t-test was used 
comparing agonist responses following antagonist to control responses. For responses in 
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different fibres, an unpaired t-test was used comparing responses in antagonist fibres to 
vehicle fibres.  
5.2.6: Cough 
Conscious, unrestrained guinea pigs were placed in individual transparent Perspex 
plethysmography chambers (Buxco, Wilmington NC, USA), as described in Section 2.8. 
Cough was detected as previously described (Maher, et al., 2009; Birrell et al., 2009.). The 
cough response induced by GSK101 (30µg/ml) was tested against the specific P2X3 
antagonist AF-353 (10mg/ml). Guinea pigs were injected i.p. with antagonist or vehicle (10% 
Polyethylene Glycol 400 in 0.9% saline), 1 hour prior to exposure to GSK101 (30g/ml). 
GSK101 was aerosolised for 5 minutes, and the number of coughs counted for 10 minutes. 
5.2.6.1: Analysis 
In order to test inhibition of cough by the P2X3 antagonist, a one tailed Mann Whitney U test 
was used, which compared responses from the antagonist group to vehicle control. The data 
is presented as mean±S.E.M., with statistical significance set at P < 0.05. 
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5.3: Results 
5.3.1: P2X3 expression in nodose and jugular ganglia 
Prior to functional characterisation, it was first confirmed that P2X3 was expressed in guinea 
pig ganglia, as these hold the cell bodies of the fibres which project to the lung. Guinea pig 
ganglia were utilised as they are the species of choice to measure sensory nerve driven 
responses in vivo and in vitro. Following validation of the assay using tissue with the most 
abundant expression, quantitative RT-PCR of whole nodose and jugular ganglia was carried 
out to investigate levels of P2X3 mRNA. Although P2X3 was determined to be expressed at 
the mRNA level in both ganglia, predominant expression was found in the nodose, the ganglia 
type previously shown to respond to the TRPV4 agonist GSK101  (Figure 5.1). 
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Figure 5.1: Expression of P2X3 in isolated guinea pig ganglia 
P2X3 is expressed at the mRNA level in both nodose and jugular ganglia, with a higher level being 
present in the nodose. The data is expressed as mean±S.E.M., n=8, and is normalised to the 18s 
control. 
5.3.2: Effect of the P2X3 agonist αβ-MeATP on depolarisation of isolated vagal nerves 
In order to determine a functional effect of the P2X3 agonist αβ-MeATP on airway sensory 
nerves, a concentration response curve to the agonist was carried out in guinea pig vagal 
tissue.  The P2X3 agonist αβ-MeATP (10-300μM) caused a concentration dependent increase 
in depolarization in the guinea pig vagal tissue (Figure 5.2A). αβ-MeATP (100μM) caused a 
maximal depolarization of 0.17±0.02mV in guinea pig tissue, which was around 60-70% of the 
depolarization induced by the TRPV1 agonist capsaicin (1μM). αβ-MeATP (100μM) also 
caused depolarization of isolated human tissue as indicated by the example trace (Figure 
5.2B).  
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Figure 5.2: Effect of αβ-MeATP on depolarisation of isolated vagal tissue 
A: αβ-MeATP caused a concentration dependent depolarization of guinea pig isolated vagus nerve. B: 
100μM αβ-MeATP also caused depolarization of isolated human tissue. The data is shown as mean ± 
S.E.M.  of n=4-6 for guinea pig vagal tissue.* indicates statistical significance at p<0.05 using Kruskal 
Wallis test and Dunns post test comparing responses to vehicle.  
 
In order to determine if the depolarisation induced by αβ-MeATP was through the P2X3 ion 
channel, the ability of two structural distinct P2X3, P2X2/3 antagonists, TNP-ATP (10μM) and 
AF-353 (10μM) to inhibit αβ-MeATP induced depolarization was investigated. In guinea pigs, 
depolarization was inhibited 70.52±4.9% by TNP-ATP and 82.7±1.6% by AF-353 (Figure 
5.3A). In human tissue responses were inhibited 90.9±9.1% by TNP-ATP and 88.9±11.11% 
by AF-353 (Figure 5.3B).  
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Figure 5.3: Effect of P2X3 antagonists on αβ-MeATP induced depolarisation 
A: The P2X2/3, P2X3 antagonist TNP-ATP (10μM) and the P2X3 antagonist AF-353 (10μM) 
significantly inhibited depolarisation induced by αβ-MeATP (100μM) in guinea pig vagal nerves. B:A 
similar effect was seen in donor human tissue where both antagonists inhibited the depolarization 
induced by αβ-MeATP. Vehicle (Veh; 0.1% DMSO) had no effect on nerve activation induced by either 
agonist in any species tested. The data is presented as mean ± S.E.M. of n=4-6 observations, n=2 for 
human. Human tissue was obtained from 2 male and donors aged 38-57 with no known respiratory 
disease. * indicates statistical significance (p < 0.05), paired t-test comparing responses in the same 
piece of nerve with and without antagonist. Due to limited n numbers statistical analysis was not carried 
out on human tissue.  
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5.3.3:  Effect of P2X3 agonists on [Ca2+]i signal in nodose and jugular ganglia 
A further functional effect of P2X3 in airway sensory nerves was investigated  using [Ca2+]i 
signal in guinea pig isolated nodose and jugular ganglia, where a change in [Ca2+]i signal is 
indicative of activation of the ion channel. αβ-MeATP (10μM), was shown to activate airway 
stained ganglia, with a predominant effect in the nodose ganglia (Figure 5.4A). This is a 
similar ganglia activation profile to that seen with TRPV4 agonists. Maximum Ca2+ signals 
were 56±21.8% of K50 A.U.C in nodose ganglia, and 13.2±1.9% in jugular ganglia. An example 
trace of change in [Ca2+]i signal in the nodose ganglia following administration of αβ-MeATP 
is shown in Figure 5.4 B.  
 
Figure 5.4: Effect of αβ-MeATP on [Ca2+]i 
A: αβ-MeATP (10μM) caused an increase in [Ca2+]i in both jugular and nodose ganglia as indicated by 
an increase in K50 A.U.C, however a larger response was found in the nodose ganglia. B: Indicates an 
example trace of calcium release over time. The trace shows calcium release over time, and 
corresponding images below. Increase in red indicates increase in [Ca2+]i. The data is presented as 
mean ± S.E.M. of N=2, n=2-4.  
 
5.3.4: Effect of the P2X3 agonist αβ-MeATP on single fibre firing  
Finally the effect of αβ-MeATP on action potential propagation in Aδ-fibres was investigated. 
αβ-MeATP (300μM) caused firing of all Aδ-fibres investigated, but appeared not to cause 
bronchoconstriction, as there was no increase in tracheal pressure (Figure 5.5).  
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Figure 5.5: Example trace of an Aδ fibre 
Example trace of action potential firing induced by αβ-MeATP (300μM) in an Aδ fibre. αβ-MeATP 
caused firing of the fibre (bottom panel), but had no effect on bronchoconstriction (top panel) 
5.3.5: Effect of P2X3 antagonists on TRPV4 induced activation of airway sensory 
nerves in vitro   
In order to determine if the P2X3 ion channel is involved in TRPV4 induced activation of airway 
sensory nerves, the 2 structurally distinct P2X3 antagonists TNP-ATP and AF-353 were 
investigated against both GSK101 (300nM) and -80mOsm induced depolarisation; which are 
exogenous and endogenous agonists of TRPV4 respectively.  
 
Both TNP-ATP (10μM) and AF-353 (10μM) significantly inhibited depolarisation induced by 
both GSK101 (300nM) and -80mOsm. TNP-ATP (10μM) reduced the GSK101 induced 
depolarisation 94.1±5.9% and -80mOsm by 73.1±10.3% in the guinea pig.  AF-353 (10μM) 
inhibited the GSK101 induced depolarisation 86.3±8% and -80mOsm 85.6±7.2% (Figure 
5.6A), indicating that P2X3 is involved in the mechanism of TRPV4 induced depolarisation in 
the guinea pig.  
 
A similar result was seen in donor human vagal tissue where depolarisation induced by 
GSK101 (300nM) was inhibited 100% by both antagonists. Depolarisation induced by -
80mOsm was inhibited 40±20% by TNP-ATP and 70±8.3% by AF-353 (Figure 5.6B).  
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Figure 5.6: Effect of P2X3 antagonists on TRPV4 induced depolarisation 
A: Guinea pig isolated vagus. Both TNP-ATP (10μM) and AF-353 (10μM) significantly inhibited 
depolarisation induced by the TRPV4 agonists GSK101 (300nM) and -80mOsm. B: Donor human 
isolated vagus. Both P2X3 antagonists also inhibited depolarisation induced by GSK101 (300nM) and 
-80mOsm in human vagal tissue.  Vehicle (Veh; 0.1% DMSO) had no effect on nerve activation induced 
by either agonist in any species tested. The data is presented as mean ± S.E.M. of n=4-6 observations 
in guinea pig and n=2 in human tissue. Human tissue was obtained from 2 male and 1 female donor 
aged 38-57 with no known respiratory disease * indicates statistical significance (p<0.05), paired t-test 
comparing responses in the same piece of nerve with and without antagonist. 
 
In order to ensure that this effect was unique to TRPV4 and the P2X3 antagonists were not 
just working as a global TRP inhibitors, AF-353 (10μM) was also tested against TRPV1 
(Capsaicin: 1μM) and TRPA1 (Acrolein: 300μM) induced depolarisation. AF-353 (10μM) had 
no effect on either capsaicin or acrolein induced depolarisation, indicating that the inhibitory 
effect of the P2X3 antagonist is unique to TRPV4 (Figure 5.7).  
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Figure 5.7: Effect of AF-353 on capsaicin and acrolein induced vagal nerve depolarisation 
AF-353 (10μM) had no effect on either TRPV1 (capsaicin, A) or TRPA1 (acrolein, B) induced 
depolarisation in the guinea pig. The data is presented as mean ± S.E.M. of n=4 observations in guinea 
pig 
 
In order to investigate if further functional effects induced by GSK101 (30nM) were also 
inhibited, AF-353 (10μM) was also tested in airway specific nodose neurons, where the P2X3 
antagonist significantly inhibited [Ca2+]i signal induced by GSK101 (30nM) (Figure 5.8).  
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Figure 5.8: Effect of AF-353 on GSK101 induced [Ca2+]i 
[Ca2+]i signal induced by GSK101 (30nM) was significantly inhibited following incubation with AF-353. 
N=4, n=5. * indicates statistical significance at p<0.05 using unpaired t-test comparing cells incubated 
with vehicle prior to GSK101 (30nM) to cells incubated with AF-353 prior to GSK101 (30nM).  
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5.3.6: Role of the Pannexin 1 ion channel 
The body of data so far has confirmed the hypothesis that activation of TRPV4 leads to ATP 
release and activation of P2X3. Two recent studies have also suggested that TRPV4 induced 
release of ATP in human epithelial cells, and this release is associated with the Pannexin-1 
channel (Seminario-Vidal et al., 2011; Baxter et al., 2014). To investigate if this signalling 
mechanism plays a role in TRPV4 mediated depolarisation, Px1-/- mice were utilised. Mice are 
a useful model as the genetic template can be modified and knockouts can be utilised which 
allows the investigation of the importance of the Pannexin 1 receptor without pharmacological 
intervention.  
Pairs of mice genetically modified to remove the Pannexin 1 gene were obtained and bred in 
house, and male homozygous knockout mice used for experiments. Regular genotyping was 
undertaken to ensure that the gene of interest was knocked out. An example gel for the   Px1-
/- mice is shown in Figure 5.9. All mice were bred on a C57Bl/6 background, and therefore 
male C57Bl/6 mice were used as wild type controls. 
In knockout mice, responses to the TRPV4 ligand GSK101 was virtually abolished (Figure 
5.10 p<0.05). However responses to the P2X3 agonist αβ-MeATP (100μM) alongside 
capsaicin (1μM) and acrolein (300μM) remained unchanged in both wild type and knockout 
tissue (Figure 5.10). 
 
Figure 5.9: Example gel from Px1-/- mice 
RTPCR was used to confirm knockout of the Pannexin1 gene using DNA extracted from tail tips from 
mice used in Figure 5.10. Wild type mice produced a band at 600bp and KOs at 350bp. A 20-1000 
ladder was used (L), and a water control (C). Wild type and knockout primers were run in the same 
reaction.  
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Figure 5.10: Effect of agonists in Px1-/- mice 
Responses to GSK101 (300nM) were abolished in Px1-/- mice. Responses to αβ-MeATP (100μM), 
capsaicin (1μM) and acrolein (300μM) remained unchanged. The data is presented as mean ± S.E.M.. 
of n=4-6. * indicates statistical significance (p < 0.05), unpaired t-test comparing responses in Px1-/- 
tissue with wild-type control. 
 
5.3.7: Effect of P2X3 antagonists on TRPV4 induced activation of airway sensory 
nerves in vivo 
As TRPV4 induced responses were inhibited in vitro following a P2X3 antagonist, it was next 
investigated if TRPV4 agonist responses were also inhibited in vivo. Initially the effect of the 
P2X3 and TRPV4 antagonists were investigated against both TRPV4 and P2X3 induced 
airway single fibre firing.  In these set of experiments, only Aδ-fibres were investigated. In all 
cases, citric acid activated the nerves under investigation and was used as an initial test for 
nerve fibre viability. To investigate the role of the P2X3 antagonist AF-353 on Aδ firing induced 
by αβMe-ATP and GSK101 6 Aδ-fibres were investigated with CVs ranging from 3.8-14.1 
imp/s. 
Two reproducible firing responses to αβ-MeATP were obtained 20 minutes apart, following 
which either vehicle (10% Polyethylene Glycol 400 in dH20) or AF-353 (30mg/kg) were 
administered.  Any changes in further responses to both αβ-MeATP and GSK101 were then 
observed. In the vehicle treated animals, neither αβ-MeATP nor GSK101 (100ng/ml) firing 
responses were inhibited (Figure 5.11A,C). However, following AF-353 (30mg/kg) 
administration, responses to both αβ-MeATP and GSK101 were significantly inhibited, as 
indicated in the example trace (Figure 5.11 B,D). Inhibition of the αβ-MeATP response was 
measured in the same fibre, whereas responses to GSK101 following antagonist were 
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compared to those following vehicle administration. GSK101 caused a slow onset prolonged 
bronchoconstriction in all fibres investigated, which was unchanged following either vehicle or 
AF-353 administration (Figure 5.11 E, F). 
In a separate set of experiments, the TRPV4 antagonist GSK2193874 (300mg/kg) was also 
investigated. Aδ-fibres (N=6) were investigated with CVs ranging from 3.2-14.3 m/s. Two 
reproducible responses to GSK101 (100ng/ml) were carried out following which either vehicle 
or GSK2193874 (300mg/kg) were administered. Following vehicle administration firing to 
GSK101 was unchanged. αβ-MeATP also caused firing of the fibres investigated. However, 
following administration of the GSK2193874 antagonist, firing induced by GSK101 (100ng/ml) 
was significantly inhibited.  However firing induced by αβ-MeATP remained unchanged from 
vehicle control indicating that antagonising TRPV4 does not inhibit P2X3 mediated responses 
(Figure 5.12 A,B,C). The TRPV4 antagonist also inhibited GSK101 induced 
bronchoconstriction (Figure 5.12 D,E). 
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Figure 5.11: Effect of the P2X3 antagonist AF-353 on P2X3 and TRPV4 induced airway Aδ fibre 
firing and bronchoconstriction 
A: Example trace from a vehicle treated animal. Two reproducible responses to αβ-MeATP (300μM) 
were carried out following which vehicle was administered i.p. The response to αβ-MeATP (300μM ) or 
GSK101 (100ng/ml) was unchanged. Graphical data in C. B: Example trace from an animal treated with 
AF-353 (30mg/kg). Two reproducible responses to αβ-MeATP caused firing of the Aδ-fibres 
investigated, AF-353 administration inhibited αβ-MeATP induced firing. GSK101 induced firing was also 
significantly inhibited compared to the vehicle control. Graphically represented in D.  
E. and F indicate that neither CA nor αβ-MeATP (300μM) have any effect on bronchoconstriction, and 
the bronchoconstriction induced by GSK101 remains unchanged following vehicle or AF-353 
administration. Data represents mean±S.E.M of n=3 for vehicle and n=3 for antagonist observations.  
* indicates statistical significance (p < 0.05), paired t test comparing responses before and after aerosol 
administration of agonist or antagonist. # indicates statistical significance (p<0.05) using unpaired t test 
comparing responses in antagonist treated fibres to vehicle treated fibres.  
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Figure 5.12: Effect of the TRPV4 antagonist GSK2193874 on TRPV4 and P2X3 induced airway 
Aδ fibre firing 
A: Example trace from an antagonist treated animal. Two reproducible responses to GSK101 
(100ng/ml) were carried out following which GSK2193874 (300mg/kg) was administered i.p. The 
response to GSK101 (100ng/ml) was inhibited, however αβ-MeATP (300μM) response was unchanged. 
This data is expressed graphically in C. B: Data from vehicle treated animals.  Responses to GSK101 
(100ng/ml) or αβ-MeATP (300μM) were unchanged following vehicle administration. D and E indicate 
that the TRPV4 antagonist significantly inhibited the bronchoconstriction induced by GSK101. Data 
represents mean±S.E.M of n=3 for vehicle and n=3 for antagonist observations. * indicates statistical 
significance (p < 0.05), paired t test comparing responses before and after aerosol administration of 
agonist or antagonist.# indicates statistical significance (p<0.05) using unpaired t test comparing 
responses in antagonist treated fibres to vehicle treated fibres.  
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Finally the ability of the P2X3 antagonist AF-353 to inhibit GSK101 induced reflex cough in 
the conscious guinea pig was investigated. Following i.p. administration of AF-353 (30mg/kg), 
GSK101 (30μg/ml) induced cough was inhibited to a similar level as seen with the TRPV4 
antagonist, indicating that inhibiting P2X3 also inhibits GSK101 induced reflex events (Figure 
5.13).   
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Figure 5.13: Effect of AF-353 on TRPV4 induced cough 
AF-353 inhibited cough induced by the TRPV4 agonist GSK101 (30μg/ml) compared to vehicle control. 
Data is displayed as median ± interquartile range of 8 observations * indicates statistical significance at 
p<0.05 using a one tailed Mann Whitney U test.  
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5.4: Discussion 
The aim of this chapter was to determine if P2X3 and ATP are involved in the mechanism of 
TRPV4 activation. In Chapters 3 and 4, TRPV4 agonists were shown to activate nodose 
derived Aδ-fibres in the guinea pig, and both calcium signalling and fibre firing induced by 
TRPV4 demonstrated a short delay prior to activation indicating the involvement of a 
secondary mediator. A possible candidate for this secondary mediator is ATP, as previous 
work in the bladder has suggested that TRPV4 can lead to ATP release and subsequent 
activation of P2X3 on bladder afferents (Mochizuki et al., 2009; Aizawa et al., 2012). 
Furthermore, a study in human epithelial cells has indicated that cigarette smoke induced ATP 
release is mediated through the TRPV4 ion channel (Baxter et al., 2014). P2X3 has been 
shown to be expressed in both guinea pig and human nodose ganglia (Kwong et al., 2008; 
Sato et al., 2014). P2X3 is an ionotropic purinergic receptor which is primarily expressed in 
sensory nerves (Burnstock and Verkhratsky, 2010) and αβMe-ATP, a more stable agonist at 
P2X1 and P2X3 containing receptors, is a potent agonist. From this, it can be hypothesised 
that activation of TRPV4 causes a calcium influx, which evokes ATP release, which in turn 
activates the P2X3 ion channels present on airway sensory nerves. This is of particular interest 
as recently a P2X3 antagonist AF-219, has been shown to significantly inhibit daytime 
objective cough frequency in patients with idiopathic chronic cough (Abdulqawi et al., 2014). 
Furthermore, ATP levels have been shown to be elevated in patients with asthma and COPD 
(Mohsenin and Blackburn, 2006; Polosa and Holgate, 2006; Idzko et al., 2007; Lommatzsch 
et al., 2010; Mortaz et al., 2010), where airway sensory nerve responses are thought to be 
enhanced. In addition, aerosolised ATP caused cough, dyspnea and tightness in asthmatics 
(Basoglu et al., 2005), smokers and patients with COPD (Basoglu et al., 2015).  
Extracellular ATP can activate two subsets of the cell surface purinergic P2 receptors, the 
ionotropic P2X receptors and the G protein-coupled P2Y receptors (Burnstock and Kennedy, 
1985). The ion channel P2X3 is a member of the ionotropic P2X family which are widely 
expressed in neuronal, epithelial, muscular and immune cells (Burnstock and Knight, 2004) 
and function as either homo or heterotrimers formed of protein subunits encoded by the 
genetically distinct P2X1-7 subtypes (North and Surprenant, 2000; Gever et al., 2006). The 
expression of P2X3 however, is primarily limited to sensory neurons (Chen et al., 1995; 
Burnstock, 2008) and is formed by homo/heterotrimeric assembly of P2X2 and P2X3 receptors 
(Burnstock and Verkhratsky, 2010). P2X3 is expressed in a large proportion of C- and Aδ-
fibres (Kwong et al., 2008; Undem and Nassenstein, 2009), which are known to be important 
for the detection of noxious stimuli in the lung. P2X3 has been shown to be involved in the 
activation of these fibres, which are critical to cough initiation and sensitisation (Undem and 
Nassenstein, 2009). In addition, extracellular ATP has been shown to cause firing of both 
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canine and rodent Aδ and C fibres (Pelleg and Hurt, 1996; Kwong et al., 2008), which was 
determined to be blocked by the P2X3/ P2X2/3 antagonist A-317491 (Kwong et al., 2008). 
Alongside causing direct activation of fibres, ATP has also been shown to enhance citric acid 
induced cough in guinea pigs which was inhibited with pretreatment with the P2X3/P2X2/3 
antagonist TNP-ATP.  ATP had no effect however on capsaicin induced cough (Brouns et al., 
2000).  
Before determining if P2X3 and ATP play a role in TRPV4 mediated activation of airway 
sensory nerves, it was firstly determined that the P2X3 agonist αβ-MeATP was able to activate 
airway sensory nerves. Expression of P2X3 was confirmed using RTPCR of the jugular and 
nodose ganglia, with a higher expression level found in the nodose, similar to the TRPV4 
expression profile. A concentration response to the P2X3 agonist αβ-MeATP was then carried 
out in the guinea pig isolated vagus ganglia, where αβ-MeATP caused a concentration 
dependent increase in depolarization of the guinea pig vagus nerve, and a submaximal 
concentration (100μM) also caused depolarization of donor human vagal nerves. This 
depolarization was shown to be specific to the P2X3 ion channel as two structurally distinct 
antagonists AF-353 (10μM) and TNP-ATP (10μM) significantly inhibited depolarization 
induced by the P2X3 agonist in both guinea pig and human tissue. When tested on airway 
specific ganglia, αβ-MeATP was also shown to cause an increase in [Ca2+]i, and although this 
was seen to a small degree in the jugular ganglia, the predominant effect was seen in the 
nodose. Finally, αβ-MeATP was shown to cause firing of airway terminating Aδ-fibres in vivo.  
Taken together, this indicates that the P2X3 agonist αβ-MeATP is capable of activating airway 
sensory nerves both in vitro and in vivo, and the activation profile is very similar to that seen 
by the TRPV4 agonist GSK101 as shown in Chapter 3.  
To determine the role of P2X3 in TRPV4 mediated responses, the P2X3 antagonists AF-353 
and TNP-ATP were then tested against TRPV4 mediated activation of airway sensory nerves.  
In isolated guinea pig vagal tissue, P2X3 antagonists significantly inhibited depolarisation 
induced by both the TRPV4 antagonist GSK101, along with hypoosmolar solution, to a similar 
extent as the selective TRPV4 antagonists shown in previous chapters.  This effect was 
mirrored in human tissue indicating that the results may translate to the clinic.  To determine 
if this inhibition was a global effect on TRP channels, the antagonists were also profiled against 
TRPV1 and TRPA1 mediated responses where they had no effect, indicating that the inhibition 
is likely to be specific to TRPV4. The effect of AF-353 was also investigated against [Ca2+]i in 
nodose ganglia, where the antagonist significantly inhibited the majority of calcium signal 
induced by the TRPV4 agonist GSK101 indicating that TRPV4 sensory nerve driven 
responses were indeed inhibited by P2X3 antagonists in vitro.  
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Several studies in airway epithelial cells have suggested that activation of TRPV4 can lead to 
ATP release via the Pannexin-1 pore. Pannexins are a family of plasma membrane proteins 
and Pannexin 1 primarily functions as an ATP release channel (Bao et al., 2004). Seminario–
Vidal et al indicated that hypotonicity induced ATP release was inhibited following antagonism 
of Pannexin 1 and also in Pannexin 1 (Px1-/-) knockout mice, and Baxter et al have shown that 
ATP release induced by a TRPV4 agonist was reduced following use of a Pannexin 1 
antagonist (Seminario-Vidal et al., 2011; Baxter et al., 2014). Furthermore, it was shown that 
ATP release through Pannexin 1 was downstream of RhoA activation and rho kinase 
dependent myosin light chain phosphorylation (Seminario-Vidal et al., 2011) indicating that 
TRPV4 activation may lead to RhoA activation. In this study, TRPV4 induced depolarisation 
of isolated vagal nerves was abolished in Px1-/- knockout mice, whereas responses to TRPV1 
(capsaicin), TRPA1 (acrolein) and P2X3 (αβ-MeATP) ligands remained unchanged.  This data 
indicates that Pannexin 1 has a critical involvement in ATP release induced following activation 
of the TRPV4 ion channel in the mouse vagus.  
The P2X3 antagonist AF-353 was then taken forward to test against TRPV4 mediated effects 
on single airway fibres in vivo.  TNP-ATP was not taken forward as the compound has low 
metabolic stability which is not ideal for in vivo studies (Jarvis et al., 2001; Honore et al., 2002; 
Ueno et al., 2003). Firstly, AF-353 was tested against both αβ-MeATP and GSK101 induced 
firing in guinea pig Aδ-fibres. Responses to αβ-MeATP were compared in the same animal 
after either antagonist or vehicle administration, whereas GSK101 induced responses were 
compared between antagonist treated and vehicle treated animals. Following antagonist 
administration, firing induced by αβ-MeATP (300μM) were significantly inhibited in the Aδ-
fibres investigated. Furthermore, firing responses to the TRPV4 agonist GSK101 (100ng/ml) 
were significantly inhibited in the antagonist treated animals when compared to those that 
were dosed with vehicle. In addition, αβ-MeATP had no effect on bronchoconstriction in any 
of the animals investigated, whereas GSK101 caused a slow onset, prolonged 
bronchoconstriction in all fibres investigated similar to that shown previously. This indicates 
that the P2X3 antagonist is also capable of inhibiting TRPV4 mediated Aδ-fibre firing in vivo. 
However, interestingly the antagonist had no effect on GSK101 induced tracheal pressure, 
which indicates that the underlying mechanism involved in TRPV4 mediated 
bronchoconstriction is likely to be independent of a direct effect on P2X3 on the airway smooth 
muscle. P2X3 is predominantly expressed on airway sensory nerves further indicating that 
P2X3 is unlikely to play a direct role in TRPV4 mediated bronchoconstriction. However, as 
both of the vagal nerves were cut, this does not rule out a role for P2X3 in reflex 
bronchoconstriction.  
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As a control measure, the TRPV4 antagonist GSK2193874 was also tested against GSK101 
and P2X3 induced fibre firing in guinea pig Aδ-fibres. In this case, responses to GSK101 were 
compared in the same animal after either antagonist or vehicle administration, whereas αβ-
MeATP induced responses were compared between antagonist treated and vehicle treated 
animals. GSK2193874 significantly inhibited TRPV4, but not αβ-MeATP mediated firing in the 
fibres, indicating that activation of P2X3 by ATP is downstream of activation of TRPV4. 
GSK2193874 also inhibited GSK101 induced bronchoconstriction in all fibres investigated.  
Finally the effect of AF-353 was assessed against GSK101 (30μg/ml) induced cough in the 
conscious guinea pig. Following i.p. administration of AF-353, GSK101 induced cough was 
significantly inhibited to a similar extent as with the TRPV4 antagonist GSK2193874 shown in 
Chapter 3. This indicates that AF-353 is capable of inhibiting TRPV4 mediated reflex events 
in the whole animal.  
In summary, this body of data would suggest that the chapter hypothesis ‘Activation of TRPV4 
on airway sensory nerves leads to the release of ATP and activation of P2X3’ can be accepted. 
Activation of airway sensory nerves both in vitro and in vivo was inhibited by two structurally 
distinct P2X3 antagonists, AF-353 and TNP-ATP, which had no effect on activation induced 
by other TRP agonists. The data would suggest that activation of TRPV4 on nodose derived 
Aδ-fibres induces a small, local increase in [Ca2+]i which in turn possibly could lead to RhoA 
activation and myosin light chain phosphorylation which then leads to the release of the 
neurotransmitter ATP through the Pannexin 1 ion channel.  This then activates the ionotropic 
P2X3 channel, which is also present on Aδ-fibres.  It is this activation of P2X3 that then leads 
to the subsequent activation of vagal reflex events such as cough. This has previously been 
suggested to occur in bladder afferents where hypotonicity or stretch cause ATP release and 
subsequent activation of P2X3, and GSK101 evoked currents are blocked by a P2X3 
antagonist (Birder et al., 2007; Mochizuki et al., 2009; Aizawa et al., 2012).  
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6.1: Summary of thesis 
A persistent cough is currently the most common reason for visiting a doctor in the UK 
(Schappert and Burt, 2006; Schappert and Rechtsteiner, 2011). Normally a defensive reflex 
which protects the lungs and airways from harmful particles, in certain inflammatory diseases 
such as asthma and COPD, the cough response can become augmented leading to excessive 
coughing. Chronic cough is a debilitating condition which can affect up to 40% of the 
population at any one time (Cullinan, 1992; Janson et al., 2001; Morice et al., 2001). Despite 
the prevalence there are currently no safe and effective therapies for treatment. Patients with 
asthma and COPD have shown increased cough sensitivity to inhaled tussive stimuli, 
suggesting that targeting the peripheral arm of the reflex could be effective (Key et al., 2010). 
Therefore treatments which target ion channel and receptors present on the peripheral arm of 
the cough reflex could provide novel therapeutics.  
Cough is a reflex carried out by airway sensory nerve fibres housed within the vagus nerve.  
Ion channels present on the vagus nerve have been shown to be activated by a wide range 
of stimuli which are found in the airways of patients with inflammatory airway diseases 
including an altered airway pH, ROS, changes in temperature, arachidonic acid derivatives 
and an altered airway osmolarity. Two member of the TRP family of ion channels; TRPV1 and 
TRPA1 have been well documented  in the activation of airway sensory nerves and the cough 
response (Birrell et al., 2009; Andrè et al., 2008; Grace et al., 2012; Lieu et al., 2012), however 
the role of other TRP channels, in particular TRPV4, remains relatively unexplored.  
TRPV4 is a calcium permeable ion channel which has been shown to be expressed in a 
number of cells within the airways including human airway smooth muscle cells, lung tissue, 
and a human bronchial epithelial cell line (Jia et al., 2004; Alvarez et al., 2006; Dietrich et al., 
2006; Yang, 2006; Fernández-Fernández et al., 2008). TRPV4 has also been shown to be 
expressed at the mRNA level in pulmonary sensory neurons (Ni et al., 2006). A role for TRPV4 
in the airways has been eluded to as TRPV4 has been shown to cause contraction of human 
airway smooth muscle (Jia et al., 2004; McAlexander et al., 2014), and 7 SNPs of the TRPV4 
gene are associated with developing COPD (Zhu et al., 2009).  The aim of this thesis was to 
determine a role for TRPV4 in airway sensory nerves and to investigate a possible mechanism 
of action. 
Initially, TRPV4 mRNA expression was confirmed in guinea pig ganglia, where interestingly it 
was found to be predominantly expressed in the nodose. As there is currently a lack of 
selective TRPV4 antibodies and therefore protein levels could not be measured, functional 
expression was determined using calcium imaging of airway specific guinea pig ganglia.  The 
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selective TRPV4 agonist GSK101 caused a concentration dependent increase in intracellular 
calcium signal in the nodose ganglia, which was noticeably slow in onset. The agonist had no 
effect on calcium signal from the jugular ganglia, which is activated by TRPV1 and TRPA1 
agonists, indicating an initial difference with the activation profile of TRPV4. In general it is 
thought that the jugular ganglia provide the more chemosensitive C fibres, and the nodose 
ganglia the more mechanosensitive Aδ fibres (Canning et al., 2006), suggesting that TRPV4 
may play a role in activation of Aδ fibres. 
The next step was to pharmacologically characterise two structurally different selective TRPV4 
agonists; GSK101 and 4αPDD, in the isolated vagal preparation. Guinea pig and murine tissue 
were utilised, as guinea pigs have a cough reflex similar to man and although mice do not 
cough, the afferent arm of the cough reflex acts in a similar manner (Maher and Belvisi, 2010). 
The use of mice also allows the use of transgenic animals which allows the investigation of 
the importance of a particular receptor, in this case TRPV4, without pharmacological 
intervention. Both GSK101 and 4αPDD were shown to cause a concentration dependent 
increase in depolarisation in both species, which was blocked by two structurally different 
TRPV4 antagonists GSK2193874 (10μM) and HC067047 (10μM), and abolished in Trpv4-/- 
mice. Specificity of the ligands for the TRPV4 receptor was determined as neither a TRPA1 
(HC030031: 10μM) nor a TRPV1 (JNJ17203212 100μM) antagonist had any effect on TRPV4 
responses, and the TRPV4 antagonists had no effect on TRPV1 (Capsaicin 1μM) or TRPA1 
(Acrolein 300μM) induced responses in the guinea pig or mouse.   
Importantly, key experiments were repeated in human tissue to ensure that the results seen 
were translatable to the clinic.  Donor human vagus was obtained, and both TRPV4 agonists 
were shown to cause depolarisation which was blocked by the TRPV4 antagonists, indicating 
that TRPV4 is also likely to play a role in human vagal nerve responses.  
As the vagus nerve houses a variety of fibre types, it was not able to distinguish the fibre type 
responsible for TRPV4 mediated activation of the vagus nerve in vitro.  Therefore the more 
potent of the 2 ligands; GSK101, was taken forward into the in vivo guinea pig isolated single 
fibre technique (Adcock, 2009) where its effect on fibre firing was investigated.  GSK101 was 
shown to produce a slow onset, significant and sustained firing of the mechanosensitive Aδ-
fibres, but had no effect on the chemosensitive C-fibres. This was shown to be selective to 
TRPV4 as the selective TRPV4 antagonist GSK2193874 (300mg/kg) inhibited the response. 
This is concurrent with the results from the guinea pig ganglia, which indicated that GSK101 
caused an increase in calcium signal in the nodose, but not the jugular ganglia.  This is of 
particular interest as both TRPV1 and TRPA1 ligands have previously been shown to mostly 
activate C-fibres (and Aδ nociceptors as TRPV1 is expressed), and not Aδ-fibres,  (Canning, 
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2006), suggesting that the TRPV4 channel plays a role in the cough reflex via a novel 
mechanism of action. GSK101 was then taken forward into a conscious  animal in a cough 
provocation study, where GSK101 was shown to cause cough in the conscious animal, which 
was blocked following i.p. administration of either HC067047 (100mg/kg) or GSK2193874 
(300mg/kg), indicating that TRPV4 agonists are capable of causing a tussive response in the 
conscious animal.   
This chapter had outlined a role for TRPV4 in both airway sensory nerves and cough through 
the activation of nodose derived Aδ mechanosensitive fibres, a different and novel mechanism 
to that seen by activation of TRPV1 and TRPA1 channels, which do not ordinarily activate 
these fibres in healthy airways. The activation of mechanosensitive fibres may be due to the 
reported role of TRPV4 in osmoregulation, where osmotic solutions can provide a mechanical 
stimulus through cell swelling or cell shrinkage. TRPV4 was initially characterised as a sensor 
of osmotic stress (Strotmann et al., 2000; Liedtke and Friedman, 2003; Suzuki et al., 2003). 
Therefore, for the next chapter, the role of TRPV4 in osmolarity induced activation of airway 
sensory nerves was investigated.  
Solutions of both hyper- and hypoosmolarity have been shown to cause activation of airway 
sensory nerves and reflexes such as cough in both animals and man (Fox et al., 2005.; 
Eschenbacher et al., 1984; Fuller and Collier, 1984; Lalloo et al., 1995), however the 
mechanisms behind activation have not been elucidated. Furthermore, airway disease 
patients including those with chronic cough and asthma have been shown to have a 
heightened tussive response to osmolar stimuli (Koskela et al., 2008), and airway osmolarity 
has been shown to be altered in disease (Joris et al., 1993). Hypoosmotic solutions have been 
shown to activate TRPV4 in many cell types including airway smooth muscle (Alessandri-
Haber et al., 2003; Jia et al., 2004), however the role of TRPV4 in osmotic activation of airway 
sensory nerves is unknown.   
Initially, solutions of increased (prepared using increasing concentrations of sucrose) and 
decreased (prepared by salt reduction and compensation with sucrose) osmolarity were 
prepared and characterised on isolated guinea pig, murine and donor human vagal nerves, 
where they were shown to cause concentration dependent depolarisation in all species. To 
determine the role of TRPV4, along with TRPA1 and TRPV1 in this activation, selective 
antagonists for each of the channels were used against depolarisation induced by both hyper 
and hypoosmolarity.  It was determined that the TRPV4 antagonist (HC067047: 10μM) 
inhibited the majority of depolarisation induced by hypoosmolar solution, with the remainder 
of the depolarisation inhibited by a TRPV1 antagonist (JNJ17203212: 100μM) in guinea pig 
and human tissue. Vagal nerve responses from knockout mice showed a similar profile, where 
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responses to hypoosmotic solution were significantly inhibited in both Trpv1-/- and Trpv4-/ - 
mice.  However, in contrast, TRPV4 was shown to play less of a role in hyperosmotic induced 
depolarisation; where, using knockout mice and selective antagonists in guinea pig and human 
tissue, the majority of activity was shown to be mediated through the TRPV1 ion channel.  
As activation of sensory nerves by hypoosmotic solution in vitro was shown to be mediated 
predominantly through the TRPV4 ion channel in all species investigated, we investigated the 
effect on single airway nerve fibre firing in the guinea pig in vivo. A concentration range of 
solutions (from 0 to -100mOsm) were shown to activate both Aδ- (similarly to the synthetic 
TRPV4 agonist GSK101), but only -100mOsm was able to significantly increase firing in C-
fibres, indicating that Aδ-fibres were more sensitive to smaller changes in osmolarity.  
This chapter suggested a likely role for TRPV4 in hypoosmotic induced activation of airway 
sensory nerves, however less of a role in hyperosmotic induced activation. This is in 
agreement with previous data which have shown that hypoosmotic solutions cause activation 
of the TRPV4 ion channel in vitro (Alessandri-Haber et al., 2003; Jia et al., 2004). 
The final aim of this thesis was to investigate a possible mechanism of TRPV4 activation of 
airway sensory nerves.  Both fibre firing and calcium release observed in Chapter 3 following 
administration of a TRPV4 agonist was slow in onset, potentially indicating the release of a 
secondary mediator. It was hypothesised that this secondary mediator could be ATP, as 
previous work in bladder sensory nerves has indicated that activation of TRPV4 can lead to 
ATP release and subsequent activation of P2X3 (Mochizuki et al., 2009; Aizawa et al., 2012). 
Furthermore, work in human epithelial cells has shown that cigarette smoke induced ATP 
release is inhibited following use of a TRPV4 antagonist (Baxter et al., 2014).  
P2X3 is an ionotropic purinoceptor predominantly expressed on sensory nerves (Chen et al., 
1995; Burnstock, 2008), and the stable derivative; αβMe-ATP, is a potent agonist. P2X3 can 
function as either a homotrimer consisting of three subunits of P2X3, or as a P2X2/3 
heterotrimer consisting of subunits of P2X2 along with P2X3 (Burnstock and Verkhratsky, 
2010). It was shown that P2X3 was present on predominantly the nodose ganglia in the guinea 
pig, similar to the TRPV4 channel, and the selective ligand αβMe-ATP caused a concentration 
dependent depolarisation in guinea pig vagus, which was blocked by two structurally different 
P2X3 antagonists AF-353 and TNP-ATP, induced calcium flux in airway specific nodose 
ganglia and induced firing of Aδ-fibres.  
In order to determine if P2X3 and ATP played a role in TRPV4 mediated activation of airway 
sensory nerves, the two structurally different P2X3 antagonists were tested against both 
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GSK101 and hypoosmolar induced depolarisation, where responses were inhibited in guinea 
pig and human vagus.  The antagonists however had no effect on responses induced by 
TRPV1 and TRPA1 agonists indicating that the responses were selective to TRPV4. AF-353 
was also shown to inhibit TRPV4 induced calcium flux in airway stained guinea pig nodose 
ganglia cells, indicating that this response also occurs in airway specific sensory nerves. 
A mechanism for ATP release was eluded to using Pannexin 1 knockout mice.  Previous 
publications in epithelial cells have indicated that activation of TRPV4 can lead to ATP release 
via signalling mechanisms which lead to the opening of the Pannexin 1 pore (Seminario-Vidal 
et al., 2011; Baxter et al., 2014). Using Px1-/- mice, it was demonstrated that GSK101 induced 
depolarisation was inhibited in tissue from these mice, whereas responses to capsaicin and 
acrolein remained unchanged.  
In vivo, AF-353 (10mg/kg) inhibited both GSK101 (100ng/ml) and αβMe-ATP (300μM) induced 
firing of single airway terminating Aδ-fibres in the guinea pig. However, use of the TRPV4 
antagonist GSK2193874 in the same preparation inhibited GSK101 but not αβMe-ATP 
induced firing indicating that activation of P2X3 by ATP is downstream of activation of TRPV4.  
Furthermore, despite inhibiting firing induced by TRPV4, AF-353 had no effect on GSK101 
induced bronchoconstriction, which was blocked by GSK2193874, indicating that GSK101 
induced bronchoconstriction is independent of P2X3.  This is to be expected as P2X3 is 
predominantly expressed on sensory neurons and very little is expressed on airway smooth 
muscle (Chen et al., 1995; Burnstock, 2008). However, as the vagal nerves were cut, this does 
not rule out a role for P2X3 in reflex induced bronchoconstriction induced by TRPV4. Finally, 
AF-353 was also shown to inhibit GSK101 induced cough in the conscious guinea pig. These 
findings tie in with previous work that showed that αβMe-ATP causes firing of nodose, but not 
jugular derived C fibres (Undem 2004). This was attributed to the fact that jugular neurons 
predominantly expressed P2X3 but nodose fibres expressed more of the P2X2/3 heterodimers 
(Kwong et al., 2008).  
To conclude, the data within this thesis has outlined a novel role for a more mechanosensitive 
ion channel in the afferent arm of airway reflexes. Activation of TRPV4 by synthetic ligands 
and by hypoosmolarity was shown to cause activation of airway specific sensory nerves both 
in vivo and in vitro through activating nodose derived Aδ airway fibres, a different mechanism 
to the well-known pro-tussive ion channels TRPV1 and TRPA1. This activation is proposed to 
be through release of ATP and subsequent activation of P2X3 present on the same subset of 
sensory neurons. In the lung, TRPV4 is likely to be acting as a cell sensor, where activators 
such as cell stretch, a hypotonic environment, or 5,6-EET, an arachidonic acid derivative, 
which are all indicative of disease conditions in the lung, lead to activation of TRPV4, and ATP 
6. Summary and Future Studies 
 
148 
 
is released as part of a cell signalling mechanism (Figure 6.1).  This is important in terms of 
airway diseases such as asthma and COPD, where patients have been shown to have 
elevated levels of ATP in the airways (Mohsenin and Blackburn, 2006; Polosa and Holgate, 
2006; Idzko et al., 2007; Lommatzsch et al., 2010) and also sensory nerve activity is 
enhanced.  
 
Therapeutically, targeting the P2X3 arm of this pathway has already shown some beneficial 
effects in the clinic, where a P2X3 antagonist AF-219, which is structurally similar to the 
antagonist AF-353 used in this thesis, significantly inhibited daytime objective cough 
frequency in patients with idiopathic chronic cough (Abdulqawi et al., 2014). However, the 
dose of the P2X3 antagonist AF-219 used (600mg twice a day) was associated with a loss of 
taste, which led to several participants leaving and also the unmasking of the study. The 
authors suggest that perhaps a lower concentration of the antagonist would bypass this side 
effect as 600mg of AF-219 shows occupancy at both homomeric P2X3 and the heterotrimeric 
P2X2/3 receptor, and it is the P2X2/3 heterodimer which has been implicated in perception of 
taste in rats and mice (Bo et al.,1999; Finger et al., 2005). However, if a TRPV4 antagonist 
was used instead, this would bypass any taste disturbance but still would potentially inhibit 
cough through blocking the release of ATP. Further it has been shown that AF-353 had no 
effect on TRPV4 mediated bronchoconstriction in the absence of a reflex arc. As TRPV4 
activation has been shown to have profound effects on both bronchoconstriction and fibre 
firing in the lung it would perhaps be advantageous to also target TRPV4 therapeutically for 
treatment in whole lung disease. However further investigation into the mechanisms of 
bronchoconstriction are required.  
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Figure 6.1: Proposed hypothesis for TRPV4 mediated ATP release and subsequent autocrine 
or paracrine activation of P2X3 
The TRPV4 ion channel is activated by a number of ligands found in the diseases airway, including a 
reduced osmolarity and arachidonic acid derivatives. This causes a change in [Ca2+]i signal which 
subsequently leads to ATP release, perhaps through activation of RhoA, which opens the Pannexin 1 
ion channel. ATP may be acting in either an autocrine or paracrine fashion. This then causes activation 
of P2X3 which leads to sensory nerve depolarisation and airway reflexes such as cough.  
 
6.2: Limitations of thesis   
There are a number of limitations to the techniques used within this thesis, some of which 
have been outlined previously.  The isolated vagus technique, although high throughput and 
readily amenable to pharmacology, is not a true measure of how events occur in vivo. 
Receptors and ion channels present on the nerve trunk may not be present in the same 
conformation as found at the nerve terminals, and the receptors and signalling proteins 
present on guinea pig and murine nerves may differ to those found in human tissue. Finally 
the vagus nerve innervates a number of midline organs and tissues alongside the lungs, 
therefore it cannot be confirmed that recordings taken are from airway specific fibres.  
These particular issues were circumvented, where possible, by repeating experiments in 
donor human vagus to ensure that any results seen are likely to be translatable to the clinic.  
Furthermore responses were repeated in airway terminating single fibres in guinea pigs and 
also in an in vivo cough model, where responses involve interactions at the nerve terminals 
and are therefore more indicative of the reflex itself. Findings were also mirrored in guinea pig 
airway specific ganglia stained with the retrograde tracer dye DiI, and also in the guinea pig in 
vivo airway terminating single fibre technique, to ensure that responses seen were airway 
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specific. However despite circumventing some issues found with the isolated vagus, these 
techniques also have mitigating issues of their own. The single fibre technique is both labour 
intensive and costly as only one fibre can be used at one time. In addition, there is currently 
no human model.  
For TRPV4 and P2X3 expression, we have used whole vagal ganglia from the guinea pig. The 
whole ganglia, along with containing neurons also contain a dense vasculature, macrophages, 
cells of dendritic phenotype, and glial cells, therefore expression levels seen may not be fully 
representative of what is seen in the neurons. This could be circumvented by utilising single 
cell PCR. This involves picking single airway labelled jugular and nodose derived neurons and 
using a specialised protocol, measuring the RNA levels of targets within these cells.  This 
technique has become fairly well established (Nassenstein et al., 2010) and would therefore 
provide a more accurate picture of TRPV4 and P2X3 expression in neurons. In addition, 
similar to the single fibre experiments, there is currently no human model of functional imaging 
of vagal ganglia neurons as they are not easily available. This is likely to be due to their 
location (behind the ear in the skull). Although human dorsal root ganglia (DRGs), which 
convey somatic sensation at the spinal level to the CNS, are more readily available, these are 
mainly neural crest derived (Eng et al., 2007). Although this is the same embryological origin 
as the jugular ganglia, the nodose ganglia are epibranchial placode derived (Nasra and Belvisi, 
2009) and therefore the DRGs may not house a fully representative subset of nerve fibres. 
The in vivo cough study is also costly both in terms of compound and number of animals 
required.  
6.3: Future work 
6.3.1: Investigate the effects of TRPV4 and P2X3 antagonists on hypoosmolar induced 
responses in vivo 
As shown in Chapter 4, hypoosmolar solutions caused firing of airway terminating Aδ-fibres, 
however due to time constraints the responses were not tested against specific antagonists. 
Alongside testing the selective TRPV4 antagonist GSK2193874, it would also be interesting 
to investigate the role of the P2X3 antagonist AF-353 as hypoosmotic responses were 
inhibited by AF-353 in vitro in the isolated vagal nerve.  A submaximal concentration of 
hypoosmotic solution (-60mOsm) would be utilised and two reproducible responses carried 
out.  The animal would then be treated with AF-353 (10mg/kg), GSK2193874 (300mg/kg) or 
appropriate vehicle for the antagonist used and responses to -60mOsm repeated and 
responses monitored.  
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Alongside investigating the effects of hypoosmolar solution in airway terminating single fibres, 
it would also be interesting to investigate the effect of hypoosmolar solutions on the cough 
response in guinea pigs. Aerosolised distilled water, a hypoosmotic solution, has been shown 
to induce cough in provocation studies in humans (Eschenbacher et al., 1984; Fuller and 
Collier, 1984). A concentration response to hypoosmotic solution would be carried out in 
guinea pigs and a submaximal concentration used against TRPV4 or P2X3 antagonists or 
appropriate vehicle to determine if the same mechanism as for TRPV4 induced responses is 
also applicable for hypoosmolar induced responses in vivo.  
6.3.2: Investigate the effects of TRPV4 and P2X3 in disease models 
All experiments within this thesis were carried out in naïve animals as it is necessary to 
understand the role of TRPV4 in the acute cough response. However, to further add to 
understanding of the role of TRPV4 in the lung it would also be important to investigate 
whether TRPV4 and P2X3 play a role in the modification of the cough response in disease 
states using in vivo model systems. Endogenous ligands of the TRPV4 ion channel are 
including arachidonic acid derivatives and osmotic stimuli (Watanabe et al., 2003; Jia et al., 
2004; Vriens et al., 2005) have been shown to be released or altered in the diseased and 
inflamed airway (Joris et al., 1993, Rolin et al., 2005, Naruyima et al., 1999). Furthermore, as 
mentioned previously, increased ATP levels have been found in the airways of patients with 
asthma and COPD (Mohsenin and Blackburn, 2006; Polosa and Holgate, 2006; Idzko et al., 
2007; Lommatzsch et al., 2010; Mortaz et al., 2010), and AF-219 was shown to inhibit chronic 
cough suggesting a role for ATP in patients with chronic cough (Abdulqawi et al., 2014). Taken 
together this would suggest that TRPV4 could play a role in the diseased airway.  
Previous work has shown that vagal nerve responses and cough responses to TRPV1 have 
been shown to be enhanced (Wortley et al., 2014) in a guinea pig cigarette smoke model 
which mimics the effects of COPD. In order to determine if TRPV4 and P2X3 responses are 
also enhanced, an in vivo model of cigarette smoke exposed guinea pigs would be used. 
Guinea pigs would be exposed to cigarette smoke for one hour twice a day for 8 days to mimic 
the inflammatory response seen in the airways in COPD. Vagal nerve tissue can then be taken 
from these animals and responses to both TRPV4 and P2X3 ligands compared to an air 
exposed control group, or alternatively a cough provocation study could be carried out 
comparing responses to cigarette smoke exposed and air exposed animals. This would allow 
the investigation of whether or not TRPV4 and P2X3 responses are enhanced under disease 
conditions caused by exposure to cigarette smoke.  
Further, as asthmatics have been shown to cough to ATP (Basoglu et al., 2005), and in guinea 
pigs, following ATP administration the number of coughs to citric acid was significantly 
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enhanced (Kamei et al., 2005), the role of TRPV4 could also be investigated in asthma-driven 
responses. A model of OVA sensitised guinea pigs could be utilised (Delescluse et al., 2012), 
where guinea pigs are sensitised with OVA or vehicle on days 0 and 7 and challenged on day 
28. Tissues and responses would be taken and monitored 10 days after challenge. Similarly 
to above, vagal nerve tissue could be taken from OVA challenged animals and responses to 
TRPV4 and P2X3 agonist compared to those of saline treated animals.  In addition, a cough 
provocation study could be carried out investigating whether or not TRPV4 mediated cough 
responses were enhanced.  
6.3.2: Investigate a Source of ATP 
In order to fully confirm that TRPV4 is causing ATP release, and to confirm the cell type 
responsible, an ATP release assay could be carried out. Neurones from the nodose ganglia, 
which are known to be activated by the TRPV4 agonist GSK101, could be isolated from all 
other cell types, including satellite cells and glial cells, and stimulated with GSK101. Following 
a set time period, the cell supernatant would be removed and ATP levels measured using an 
ATPlite luminescence detection system (Perkin Elmer, Cambridge, UK) as described in 
(Baxter et al., 2014). This assay utilises luciferase which catalyses the reaction of D-luciferin 
with the ATP present to produce oxyluciferin and light, where the amount of light is proportional 
to the amount of ATP present.  ATP release could then be determined to occur from the 
ganglia itself, or if not, from surrounding cells and tissues when activated by the TRPV4 
agonist. 
6.3.3: Investigate the effects of TRPV4 ligands on bronchoconstriction 
In Chapter 3 it was shown that firing induced by GSK101 was accompanied by a significant 
and sustained bronchoconstriction in all animals investigated which, similarly to the firing seen, 
was delayed in onset, but lasted for over 30 minutes. It has previously been shown that 4αPDD 
and hypoosmotic solutions cause bronchoconstriction in isolated human airway smooth 
muscle (Jia et al., 2004). Preliminary data has shown that this bronchoconstriction was 
mimicked in both guinea pig and human tissue, which was blocked in a concentration 
dependent manner by the TRPV4 antagonist GSK2193874 (Figure 6.2). Publications have 
attributed the contraction seen to the release of cysteinyl leukotrienes (McAlexander et al., 
2014).  
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Figure 6.2: The role of TRPV4 in bronchoconstriction 
A: The TRPV4 agonist GSK101 caused a concentration dependent increase in contraction in the guinea 
pig trachea. This was significantly inhibited by the TRPV4 antagonist GSK219 (10μM) in both guinea 
pig (B) and human (C) tissue. Data shown as mean±SEM of n=4-6 (guinea pig) and n=3 (human). * 
indicates significance at p>0.05, one way ANOVA with Dunns post-test comparing responses to vehicle, 
# indicates statistical significance at p>0.05 paired t-test.  Human donor tissue was obtained from 2 
male and 1 female donors aged 45-70 with no known respiratory disease.  
 
P2X3 is expressed predominantly on sensory nerves, and there is no reported expression in 
airway smooth muscle (Burnstock, 2008).  Furthermore, as shown in Chapter 5, GSK101 
induced contraction was not inhibited by the P2X3 antagonist AF-353 in vivo,which is expected 
as the vagus nerve was cut. However it does not rule out the role of P2X3 in reflex 
bronchoconstriction. McAlexander et al have eluded to a possible mechanism involved in 
contraction, suggesting the involvement of mast cells and subsequent release of cysteinyl 
leukotrienes which causes contraction. This was shown as GSK101 induced contraction was 
blocked by the CystLt receptor antagonist montelukast (McAlexander et al., 2014).  
Preliminary data has shown that TRPV4 does not seem to be expressed on human lung mast 
cells (Figure 6.3), indicating that the release of cysteinyl leukotrienes is not likely to be a direct 
effect of TRPV4 agonists acting on mast cells. Instead, as suggested by the slow onset of 
action, it could occur through the release of a secondary mediator. As it has been shown in 
this thesis, TRPV4 activation of sensory nerves causes ATP release, as does activation of 
epithelial cells (Baxter et al., 2014). Therefore it could be assumed that the mechanisms 
involved in bronchoconstriction could also involve the release of ATP. In order to investigate 
this further, initially ATP release could be measured from isolated human airway smooth 
muscle cells following administration of a TRPV4 agonist. In addition, expression of P2X1, 
P2X4 and P2X7 receptors have been shown on human lung mast cells (Wareham et al., 2009) 
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and their role in GSK101 induced contraction could be investigated. This will help to uncover 
the mechanism of action behind the sustained bronchoconstriction seen both in vitro and in 
vivo. 
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Figure 6.3: TRPV4 expression in Human Lung Mast Cells 
Relative expression of TRPV1 (control) and TRPV4 mRNA in human lung mast cells (HLMCs). N=3 for 
control and n=3 for FcER1.  
 
6.3.4: Clinical Studies 
The ultimate aim of this work would be to take it forward into a small proof of concept study in 
patients with chronic cough. The P2X3 antagonist AF-219 has already shown efficacy in 
patients with chronic cough, but activation of P2X3 has shown no effect on bronchospasm in 
the guinea pig.  As activation of TRPV4 causes both nerve firing and bronchoconstriction, 
targeting TRPV4 could be a more global target for the treatment of lung disease. An oral 
TRPV4 antagonist GSK2798745 is currently being used in a placebo controlled Phase 1 
clinical trial to investigate the safety, tolerability, pharmacokinetics , and pharmacodynamics 
of repeat doses of the drug in healthy controls and patients with stable heart failure (Clinical 
trial identifier: NCT02119260). If shown to be safe and well tolerated, this compound could 
also be taken forward into patients with airway disease and associated chronic cough.  
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6.4: Concluding Remarks 
The work carried out for this thesis has shown that TRPV4 causes activation of sensory nerves 
by activating nodose derived Aδ-fibres, a different mechanism to that seen with activation of 
the well-known TRP channels TRPV1 and TRPA1. This activation has been shown to be 
through release of ATP and subsequent activation of P2X3 receptors on potentially the same 
subset of nerve fibres. A role for TRPV4 in the activation of airway sensory nerves and cough 
has therefore been determined, and a possible mechanism of action has also been outlined, 
and therefore the original thesis hypothesis can be accepted. The future work that has been 
outlined above should help to further this knowledge and also uncover a potential role of 
TRPV4 in disease. 
The aim of this research was to understand the role of TRPV4 in the cough reflex and 
potentially uncover a novel therapeutic target for the treatment of cough, which is currently an 
urgent unmet medical need.  Chronic cough is associated with the inflammatory diseases 
asthma and COPD, where levels of ATP are known to be elevated (Mohsenin and Blackburn, 
2006; Polosa and Holgate, 2006; Idzko et al., 2007; Lommatzsch et al., 2010; Mortaz et al., 
2010) and patients have shown increased cough, dyspnea and chest tightness in response to 
exogenous ATP (Basoglu et al., 2005, Basoglu et al., 2015). Furthermore, there are 
polymorphisms in the TRPV4 gene which are associated with COPD (Zhu et al., 2009). Taken 
together, this indicates that elevated ATP could be a key driver in the pathogenesis of cough 
in asthma and COPD, and targeting the TRPV4 ion channel could be an attractive target for 
treatment.  
This is the first primarily mechanosensitive ion channel that has been implicated in afferent 
arm of the reflex and the cough response, and therefore antagonists may aid to treat patients 
where TRPA1 and TRPV1 antagonists are less effective.  Furthermore, through investigation 
of the mechanism of TRPV4 induced bronchoconstriction, this may uncover a novel 
mechanism of action which can be targeted in disease. Together with the implicated role of 
TRPV4 in inflammation (Baxter et al., 2014), and a recently discovered role in fibrosis 
(Rahaman et al., 2014), this would suggest a more global role for TRPV4 in the airways, and 
makes the ion channel an attractive new global therapeutic target for airway disease.  
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Appendix 
The table below outlines the chemicals used throughout this thesis. Vehicles/Diluents have 
been added where applicable. 
Drug Source Vehicle/Diluent (where 
applicable) 
 
αβ-Methylene ATP Sigma-Aldrich Distilled H20 
Acrolein Sigma-Aldrich 0.1% DMSO in Krebs 
AF-353 Afferent 
Pharmaceuticals 
0.1% DMSO in Krebs (in vitro) 
10% Polyethylene Glycol in 0.9% 
saline (in vivo) 
CaCl2 VWR - 
Capsaicin Sigma-Aldrich 0.1% DMSO in Krebs 
Citric Acid Sigma-Aldrich 0.9% saline 
Collagenase Worthington Ca2+ -free, Mg2+ -free Hank’s 
balanced salt solution 
DiI 
(DiIC18(3), 1,1'- dioctadecyl-
3,3,3',3'- 
tetramethylindocarbocyanine 
perchlorate) 
Invitrogen 2% ethanol in 0.9% saline 
Dispase II Roche Ca2+ -free, Mg2+ -free Hank’s 
balanced salt solution 
Ethanol VWR - 
F12 Invitrogen - 
Fluo–4-AM Invitrogen Extracellular Solution 
GSK1016790a Sigma-Aldrich 0.1% DMSO in Krebs (in vitro) 
0.1% DMSO in 0.9% saline (in 
vivo) 
GSK2193874 Almirall 0.1% DMSO in Krebs (in vitro) 
6% Cavitron 2Hydroxypropyl-β-
cyclodextrin in 0.9% saline (in 
vivo) 
HC030031 ChemBridge 0.1% DMSO in Krebs 
HC067047 Sigma-Aldrich 0.1% DMSO in Krebs (in vitro) 
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0.1% DMSO in 0.9% saline (in 
vivo) 
HEPES Sigma-Aldrich - 
Hyperladder IV Bioline - 
JNJ17203212 Sigma-Aldrich 0.1% DMSO in Krebs 
KCl VWR - 
KH2PO4 VWR - 
L15 Sigma-Aldrich - 
MgSO4 VWR - 
NaCl VWR - 
NaH2PO4 VWR - 
NaHCO3 VWR - 
Nuclease free water Promega - 
Papain Sigma-Aldrich Hanks Balanced Salt Solution 
PBS Sigma-Aldrich - 
Percoll Sigma-Aldrich - 
Petroleum Jelly Vaseline - 
PGD2 Sigma-Aldrich 0.1% Ethanol in Krebs 
PGE2 Sigma-Aldrich 0.1% Ethanol in Krebs 
Safeview NBS Biologicals Ltd - 
TNP-ATP Tocris - 
Tween80 Sigma-Aldrich - 
4-alpha-phorbol-12,13-
didecanoate (4αPDD) 
Tocris 0.1% DMSO in Krebs 
 
 
 
 
  
